



HAL
open science

Hydrogels of levan polysaccharide: A systematic review

Aybüke Tekin, Selay Tornacı, Defne Boyacı, Suming Li, Sonia Calligaris, Hana Maalej, Ebru Toksoy Öner

► To cite this version:

Aybüke Tekin, Selay Tornacı, Defne Boyacı, Suming Li, Sonia Calligaris, et al.. Hydrogels of levan polysaccharide: A systematic review. *International Journal of Biological Macromolecules*, 2025, 315, pp.144430. <10.1016/j.ijbiomac.2025.144430>. <hal-05370427>

HAL Id: hal-05370427

<https://hal.umontpellier.fr/hal-05370427v1>

Submitted on 18 Nov 2025

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



HAL Authorization

International Journal of Biological Macromolecules

Hydrogels of Levan Polysaccharide: A Systematic Review

--Manuscript Draft--

Manuscript Number:	IJBIOMAC-D-25-10428R1
Article Type:	Review Article
Section/Category:	Carbohydrates, Natural Polyacids and Lignins
Keywords:	Levan; Polysaccharide; Hydrogel
Corresponding Author:	Ebru Toksoy Oner Marmara University Istanbul, TURKEY
First Author:	Ebru Toksoy Oner
Order of Authors:	Ebru Toksoy Oner Aybüke Tekin Selay Tornacı Defne Boyacı Suming Li Sonia Calligaris Hana Maalej
Abstract:	<p>Levan is a fructose-based homopolysaccharide renowned for its unique properties, including exceptional adhesive strength, self-assembly capability, low viscosity, and bioactivities such as prebiotic, anti-cancer, anti-inflammatory, and anti-diabetic effects. These characteristics have created increasing interest in levan-based biomaterials over the past decade, positioning levan as a highly under-explored biopolymer for a wide range of applications, from medicine to cosmetics. As a result, levan-based hydrogels have emerged as promising biomaterials in drug delivery, tissue engineering, and cosmetic formulations, owing to their extracellular matrix-mimicking structure, tunable mechanical properties, and controlled cargo release capabilities. This review is the first to comprehensively examine the advancements in levan-based hydrogel research, systematically analyzing their biomedical applications and comparing them with other biopolymer-based hydrogels. Key questions regarding levan's potential as an alternative to established hydrogel systems are explored, highlighting areas requiring further research. By assessing trends and findings in the literature, this review provides an overview of the advantages, limitations, and prospects of levan hydrogels. Our analysis establishes a foundation for the continued development of levan-derived biomaterials, fostering broader adoption in biomedical and industrial applications.</p>
Opposed Reviewers:	
Response to Reviewers:	

Highlights

the first comprehensive review of levan-based hydrogels

analysis of state-of-the-art literature followed PRISMA protocol

hydrogel reports are limited and mainly for biomedical applications

they remain unexplored in various applications areas like food

Declaration of interests

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests:



T.C.
MARMARA UNIVERSITY
Faculty of Engineering
Department of Bioengineering



From: Prof. Ebru Toksoy Oner
Marmara University
Bioengineering Department
IBSB Research Group, Istanbul, Turkey
ORCID ID: 0000-0001-6054-8842
<http://ibsb.bioe.eng.marmara.edu.tr>
www.halomonaslevan.com

Wednesday, May 07, 2025

To: Prof. Ying Liang

Editor

International Journal of Biological Macromolecules

Central South University of Forestry and Technology,
Changsha, China

Dear Prof. Ying Liang,

Please find enclosed the revised version of our manuscript **IJBIOMAC-D-25-10428** entitled "**Hydrogels of Levan Polysaccharide: a systematic review**" which we are submitting for exclusive consideration of publication as a review article in the International Journal of Biological Macromolecules. This study represents **the first comprehensive analysis of levan-based hydrogels and their applications**.

Following the reviewers' comments, the whole manuscript underwent a comprehensive change, paragraphs were added, formats were adjusted and a new Figure was added. All the revisions made in the manuscript are marked in red. Moreover, the "Response to Reviewer's Comments" attached to this letter lists all the comments as well as our point-by-point responses. We hope to have addressed all suggestions and believe that these modifications have improved the manuscript to a great extent.

As corresponding author, on behalf of all the authors, I would like to thank you and all the reviewers for the time and effort put into careful reading and helpful commenting on our work.

Thank you again for your consideration of our work and we hope to hear from you soon.

Sincerely Yours,

Prof. Ebru Toksoy Oner
Marmara University
Industrial Biotechnology and Systems
Biology (IBSB) Research Group

Response to Reviewer's Comments

Reviewer #1:

The current manuscript reports a systematic review on hydrogels of levan polysaccharide. The obtained results could be useful information for researchers who worked in the similar field. In general, this is an interesting review.

Section 3. Since this manuscript is not about the properties of levan, it is suggested to simplify this section.

We thank Reviewer 1 for the constructive suggestions. As noted, the primary focus of this review manuscript is on levan-based hydrogels rather than levan itself. The section titled 'Why levan?' was included to provide a general overview of the key physicochemical and biological properties of levan, intended to guide researchers in developing novel hydrogel formulations. These properties may also offer additional insights depending on the application, especially when compared with hydrogel studies involving other polymers in the literature. To enhance clarity, we have revised this section as well as the rest of the manuscript to more clearly explain the relevance of these properties to hydrogel design, and we have removed or streamlined sections as appropriate.

Reviewer #2:

This manuscript deals with levan-based hydrogels. The paper gives a systematic overview of the results in this field and compares materials based on levan with hydrogels based on other polysaccharides. This new field with wide-ranging potential applications will undoubtedly be of interest to readers. Certainly, the review could be inspiring for new research.

However, the discussion could be expanded in some sections:

1. The authors used the WoS database for their search. What about other databases such as the patent database or dissertations?

Authors thank the Reviewer for this valuable comment. Firstly, the WoS search was updated during the revision from March to May 2025. While the total number of documents and their distribution among specific polysaccharides changed, the model predicted data remained the same as well as the specific percentages reported for chitosan and alginate.

A patent search was conducted using four major databases—WIPO's PATENTSCOPE, Google Patents, Espacenet (by the European Patent Office - EPO) and The Lens by querying the terms "levan" and "hydrogel" across each platform. The Lens, Google Patents and Espacenet gave a total of 7143, 4518 and 448 patent hits, respectively. A Frontpage search on Patentscope resulted in a total of four patents. Just to compare, the

same Frontpage search for "chitosan and hydrogel" and "alginate and hydrogel" yielded 2969 and 2412 hits, respectively. When these four patents were examined, "KR1020190066936 - Levan/Hap Organic-Inorganic Hybrid Filler and Method For Producing Same" and "KR1020190041272 - Medical Bio-Filler Material Using Levan Hydrogel" were granted to Korea Institute Of Ceramic Engineering And Technology in 2019 by Republic of Korea and they were related to cosmetic applications of levan, PF127 and CMC containing hydrogels. The Russian patent "RU0002815367 - Biocomposite Material Based On Natural Polysaccharides" was granted to Potapova Valentina Vladimirovna and involved a mixture of alginate and levan from *Paenibacillus polymyxa*. The final patent was also a Russian patent "RU0002819701 - Hydrogel Biocomposite Based On Bacterial Polysaccharides For Use In Tissue Engineering" issued in 2024 and involved a hydrogel composite of bacterial cellulose of *Komagataeibacter sucrofermentans* and *P. polymyxa* levan. The Cooperative Patent Classification (CPC) code A23V 2250/5068 was specific for fructans (including levan) used as food ingredients or additives in foodstuffs or non-alcoholic beverages. On the other hand, this code did not yield any hydrogel related patent hit.

The following sentences were added to the Section on state-of-the-art.

"A patent search was also conducted across four major databases, namely, World Intellectual Property Organization (WIPO)'s Patentscope, Google Patents, Espacenet (by the European Patent Office, EPO), and The Lens—using the keywords "levan" and "hydrogel." The Lens, Google Patents, and Espacenet yielded 7,143, 4,518, and 448 hits, respectively. A Frontpage search on Patentscope returned 4 results only (same search for chitosan and alginate instead of levan yielded 2969 and 2412 hits, respectively). Two Korean patents (KR1020190066936 and KR1020190041272) granted in 2019 focused on levan-based hydrogels containing PF127 and CMC for cosmetic applications [27, 28]. In 2024, two Russian patents (RU0002815367 and RU0002819701) described biocomposite hydrogels involving *Paenibacillus polymyxa*-derived levan with one combined with alginate (RU0002815367), and the other with *Komagataeibacter sucrofermentans* bacterial cellulose (RU0002819701) for tissue engineering applications. The Cooperative Patent Classification (CPC) code A23V 2250/5068, which pertains to fructans used in food applications, was identified as relevant to levan but did not yield any hydrogel-related results."

Thesis search was performed from a more general platform (Google) since each country has its own database for thesis (see <https://ndltd.org/thesis-resources/find-etds/> for the specific links). Keywords "Thesis" and "levan hydrogel" yielded only 3 relevant results all of which were from our research group, namely,

- *Halomonas* levan hydrogels for skin tissue engineering applications, SS Selvi - 2019 - search.proquest.com
- Development of Injectable Levan Hydrogels for the Treatment of Uterine Fibroids, MY Kandur - 2023 - search.proquest.com

- Levan as a Biomaterial for the Conservation of Cultural Heritage, R Sağlam - 2022 - search.proquest.com

When the Proquest data base was searched through Dissertations & Theses for "hydrogel", "levan" and "levan hydrogel", 1028, 186 and 6 results were found. These 6 were listed as follows:

- 3D Microfluidics for Environmental Pathogen Detection and Single-Cell Phenotype-To-Genotype Analysis, Zhu, Yanzhe. California Institute of Technology ProQuest Dissertations & Theses, 2020. 30555368. (acknowledgement to Axl LeVan)
- Novel, Rapid and Cost-Effective Methods for Concentration, Detection and Monitoring of Waterborne Pathogens in Resource-Limited Settings, Wu, Xunyi. California Institute of Technology ProQuest Dissertations & Theses, 2021. 30555422. (acknowledgement to Axl LeVan)
- Additive Manufacturing of 3D Functional Materials: From Surface Chemistry to Combustion-Derived Materials, Yee, Daryl W. California Institute of Technology ProQuest Dissertations & Theses, 2020. 30555434. (acknowledgement to Axl LeVan)
- Remodeling Characteristics and *in vivo* Healing of Low Viscosity Polyurethane Biocomposites for Bone Regeneration, Talley, Anne Douglas. Vanderbilt University ProQuest Dissertations & Theses, 2016. 10753468. (approved by M. Douglas LeVan, Ph.D.)
- Aqueous Aerosols in Atmospheric Chemistry and Airborne Diseases, Gu, Alan Yalun. California Institute of Technology ProQuest Dissertations & Theses, 2022. 30554081. (acknowledgement to Axl LeVan)
- The Emerging Mechanochemistry of Naphthopyran, McFadden, Molly Elizabeth. California Institute of Technology ProQuest Dissertations & Theses, 2023. 30961645. (acknowledgement to Axl LeVan)

These clearly showed that there are only very few thesis studies on levan hydrogels. I pinpoint this fact, the following sentence was added to the conclusions section:

"Despite the growing interest in levan-based hydrogels, there are only a limited number of MSc and PhD theses dedicated to this topic worldwide, highlighting a significant gap in academic research training that should be addressed through increased graduate-level investigations across institutions globally."

2. What is the regulatory framework for the introduction of hydrogels in practice?

The regulatory framework for introducing hydrogels into practice depends on their intended application—medical, cosmetic, food, or industrial. In medical and healthcare contexts, hydrogels are regulated as medical devices or drug-device combinations by authorities like the FDA in the US and under the EU Medical Device Regulation (MDR). These require classification based on risk, biocompatibility testing (e.g., ISO 10993), sterility validation, clinical evaluation, and compliance with manufacturing standards such as GMP or ISO 13485. For cosmetic uses, regulations focus on safety and proper labeling, with notification procedures like the EU's Cosmetic Products Notification Portal (CPNP). In the food sector, hydrogels must be approved as safe additives, such as GRAS substances in the US or approved E numbers in the EU. Industrial applications are generally less tightly regulated but may fall under environmental or chemical safety rules like EPA or REACH, especially if human exposure is possible.

When FDA database is searched for levan, the only relevant output is about inulin "Agave Inulin Generally Recognized as Safe (GRAS) Notice for IMAG Organic, Agave Inulin Extracted from Agave tequilana Weber var. azul" where levan is only mentioned as a structural form of fructan.

As also explained in much detail in Catoira et al. (2020), under the new European Medical Device Regulation (EU 2017/745), hydrogels—particularly those used as implantable materials—are classified as Class III medical devices, the highest risk category. This classification subjects them to strict regulatory scrutiny from the early stages of development through commercialization. Manufacturers must conduct comprehensive risk analysis and management, especially when using animal-derived materials, and compile extensive technical documentation, including clinical evaluation data. A Quality Management System (QMS), typically compliant with ISO 13485, is required, and the device must pass conformity assessments by a Notified Body. Once approved, a CE mark is granted, enabling marketing within the EU. Additionally, traceability is reinforced through the Unique Device Identification (UDI) system and the EUDAMED database. When EUDAMED database is searched for levan hydrogels, there was no relevant output.

The absence of levan hydrogels in these databases was also confirmed by a recent article that reviewed the clinical landscape of both injectable and non-injectable hydrogels, highlighting hydrogel-based medical products that have received FDA or EMA approval or are currently being investigated in active clinical trials (Clegg et al., 2024).

To emphasize these, the following paragraphs were added in the conclusions section :

" The regulatory framework for introducing hydrogels into practice depends on their intended application—medical, cosmetic, food, or industrial. In medical and healthcare contexts, hydrogels are regulated as medical devices or drug-device combinations by authorities like the FDA in the US and under the EU Medical Device Regulation (MDR). These require classification based on risk, biocompatibility testing (e.g., ISO 10993), sterility validation, clinical evaluation, and compliance with manufacturing standards such

as GMP or ISO 13485 (Catoira et al., 2020). For cosmetic uses, regulations focus on safety and proper labeling, with notification procedures like the EU's Cosmetic Products Notification Portal (CPNP). In the food sector, hydrogels must be approved as safe additives, such as GRAS substances in the US or approved E numbers in the EU. Industrial applications are generally less tightly regulated but may fall under environmental or chemical safety rules like EPA or REACH, especially if human exposure is possible.

Levan hydrogels are not currently present in major regulatory or clinical databases such as the FDA or European Database on Medical Devices (EUDAMED) and no approved or clinically investigated levan-based hydrogel products have been identified (Clegg et al., 2024). This clearly shows that they have not yet reached the stage of regulatory recognition or clinical translation despite the broader clinical interest in hydrogel technologies.

To advance the clinical and commercial translation of levan-based hydrogels, future research should prioritize comprehensive in vivo studies. While preliminary in vivo evaluations have demonstrated promising biocompatibility, the current body of evidence remains limited and insufficient to fully assess their behavior under complex physiological conditions. Systematic in vivo testing is essential to evaluate not only biocompatibility but also immunogenicity, biodegradability, mechanical stability, and therapeutic efficacy across diverse biomedical applications. Such studies are critical for meeting the safety and efficacy standards set by regulatory agencies such as the FDA and European Medicines Agency (EMA) and represent a necessary milestone before progressing to human clinical trials and market adoption. "

References :

Catoira, M.C., González-Payo, J., Fusaro, L. et al. Natural hydrogels R&D process: technical and regulatory aspects for industrial implementation. *J Mater Sci: Mater Med* 31, 64 (2020). <https://doi.org/10.1007/s10856-020-06401-w>

Clegg, J.R.; Adebowale, K.; Zhao, Z.; Mitragotri, S. Hydrogels in the clinic: An update. *Bioeng. Transl. Med.* 2024, 9, e10680.

3. Apart from biomedicine, which areas of application for levan hydrogels have the greatest potential to be developed in the future?

We thank the Reviewer for this insightful comment. While levan hydrogels have predominantly been investigated in biomedical applications, as discussed throughout the review, they also show considerable potential in other fields. For instance, their use in the food industry is discussed in Section 5.5, and their recent application in conservation science, highlighted in Section 5.6, suggests broader relevance.

To address this further, we have added the following paragraph to the manuscript to emphasize the potential of levan hydrogels in environmental applications:

“One of these emerging areas is environmental science. Levan hydrogels possess key features—such as high water absorption capacity, adjustable porosity, biodegradability, and non-toxicity—that make them suitable for environmental uses. These include their application as adsorbents in wastewater treatment and as carriers in controlled-release systems for agricultural chemicals (Dong et al., 2024). Moreover, a study by Phengnoi et al. (2019) demonstrated that blending levan with polyvinyl alcohol (PVA), a synthetic polymer with low degradability, led to increased degradation rates with higher levan content, further supporting their potential in eco-friendly materials.”

References:

Dong, Y., Ghasemzadeh, M., Khorsandi, Z., Sheibani, R., & Nasrollahzadeh, M. (2024). Starch-based hydrogels for environmental applications: A review. *International Journal of Biological Macromolecules*, 269, 131956. <https://doi.org/10.1016/j.ijbiomac.2024.131956>

Phengnoi, P., Thongmee, K., Tiptipakorn, S., Boekfa, B., & Kuttiyawong, K. (2019). Biodegradation of Levan Polymer / Poly (Lactic Acid) (PLA) blend. *IOP Conference Series Materials Science and Engineering*, 526(1), 012025. <https://doi.org/10.1088/1757-899x/526/1/012025>

4. It is known that levan (as well as some other polysaccharides) has certain disadvantages in the production of hydrogels, such as weak mechanical properties, fast degradation time and susceptibility to microbial contamination.

What strategy is used to overcome these shortcomings?

Authors thank the Reviewer for highlighting this important point. It is indeed recognized that native levan, like many natural polysaccharides, faces challenges such as limited mechanical strength, rapid degradation, and vulnerability to microbial contamination when used in hydrogel formulations. Also, the uncharged nature of levan prevents it from forming a stable hydrogel on its own. This can lead to poor mechanical properties and rapid degradation. To address these issues, several strategies have been employed. One common approach is the chemical or physical crosslinking of levan with other polymers—both natural and synthetic—such as polyvinyl alcohol (PVA), chitosan, or gelatin, which improves the structural integrity and mechanical properties of the resulting hydrogels (see Table 1 and relevant sections in the manuscript. Additionally, blending levan with polymers that possess antimicrobial activity or incorporating antimicrobial agents (e.g., silver nanoparticles or essential oils) can mitigate contamination risks. The degradation rate can also be modulated by adjusting the degree of crosslinking, molecular weight of levan, or by forming composite networks that provide controlled stability. These modifications aim to tailor levan-based hydrogels for specific applications, enhancing their performance without compromising their biocompatibility.

The following paragraphs have been added to the manuscript.

“This self-assembly behavior contributes to the formation of 3D networks, which are characteristic of hydrogels, while maintaining low viscosity in solution. Although levan's low viscosity is advantageous for injectable hydrogel systems, it can also hinder the development of mechanically strong and stable hydrogels. This limitation can be addressed by optimizing reaction conditions to relax the self-assembled structures, employing chemical crosslinking, or forming composite hydrogels.”

“Furthermore, the inherently fast biodegradation rate of levan can be tuned by chemical modifications or by integrating it into composite hydrogels, allowing for better control over its stability and degradation kinetics in various application environments. “

Reviewer #3:

Tekin et al. presented an interesting manuscript about hydrogels of levan polysaccharide, an emerging field because of the interesting properties of this biopolymer as authors have stated in the manuscript. Some revisions should be done before publishing at IJBM.

- Authors should include a figure that explains the differences between hydrogels crosslinking (physical or chemical), and what is the role of levan in each case.

Following this valuable suggestion, the following Figure was added to the manuscript as Figure 2 and related context was discussed.




Figure 2. Physically and chemically crosslinked levan-based hydrogels (Created with Canva.com).

- More information about hydrogels should be included in the introduction. Perhaps after line 78, before presenting the objective of the work.

Following paragraph was added to the text for a better explanation and more information about hydrogels

"Compared to rigid scaffolds or dry polymeric systems, polysaccharide-based hydrogels offer flexibility, soft structure, high porosity, and water-holding capacity that promote cell viability, proliferation, matrix remodeling, and better resemblance to the native living tissue. In the formation of hydrogels, the use of polysaccharides that contain different chemical groups or whose chemical modifications are relatively easier allows both chemical and physical crosslinking. Thus, depending on the requirements and the area of use, it is possible to obtain chemically, mechanically, and dimensionally stable hydrogels formed with covalent bonds or to obtain hydrogels that do not require crosslinkers and whose preparation process is easier and faster. Due to their extracellular matrix-mimicking properties, biocompatibility, flexible synthesis methods, and suitable physical properties, they have found broad applications as artificial soft tissue biomaterials in various biomedical fields, such as biosensors, and tissue engineering and regenerative medicine [6, 7]. Furthermore, with a smart hydrogel approach, polysaccharide-based hydrogels can be tuned to respond to environmental stimuli such as pH, temperature, electrical and magnetic fields, ionic strength or light and can change some of their properties such as their wettability, degradability, swelling, and mechanical or surface properties. These tunable properties making them attractive especially for smart drug delivery systems and personalized medicine [8, 9]."

- page 3, After numerical analysis (papers published about hydrogels) Authors should explain why there are only 21 papers related with levan hydrogels if you compare with other polysaccharides. The reason is, mainly, levan viscosity. Authors should deepen on this property.

As the Reviewer rightly noted, there are currently very few publications specifically focused on levan hydrogels. Although the levan polymer has been known for over a century (Toksoy Öner et al., 2016), it remained largely overlooked until the early 2000s, when the number of publications on levan began to increase significantly. This surge in interest is primarily due to advances in addressing the high production cost of levan—a major limiting factor in its wider application. Numerous researchers have tackled this challenge, and today, several high-yield production platforms exist for both microbial and enzymatic levan. These developments have been discussed in depth in the Book of Fructans (J. Combie, E. Toksoy Öner, Fructan Production Processes, The Book of Fructans (2023), pp. 187–199. <https://doi.org/10.1016/b978-0-323-85410-8.00009-0>) as well as in the conclusions section of this manuscript.

The inherently low viscosity of levan, often perceived as a drawback, can actually be advantageous in microbial production systems, where it helps maintain stable culture rheology even at high product concentrations—as observed with xanthan. Moreover, this low viscosity results from levan's self-assembling behavior, which under controlled conditions can be harnessed in the design of smart delivery systems. A paragraph elaborating on the viscosity and self-assembly behavior of levan has been added to Section 3.

Reference:

E. Toksoy Öner, J. Hernández, J. Combie, Review of levan polysaccharide: from a century of past experiences to future prospects, *Biotechnol. Adv.* 34 (2016) 827–844.

- section 3, maybe viscosity issues can be explained here as well.

Thanks to Reviewer for this constructive addition. The required section was added to section 3.

“This self-assembly behavior contributes to the formation of 3D networks, which are characteristic of hydrogels, while maintaining low viscosity in solution. Although levan's low viscosity is advantageous for injectable hydrogel systems, it can also hinder the development of mechanically strong and stable hydrogels. This limitation can be addressed by optimizing reaction conditions to relax the self-assembled structures, employing chemical crosslinking, or forming composite hydrogels. ”

- sections 3.1, 3.2, 3.3., 3.4 explains the current uses of levan, because of its properties, but they do not explain why these properties can be used to create hydrogels. Authors should reinforce this part of the review.

As also noted above, the primary focus of this review manuscript is on levan-based hydrogels rather than levan itself. The section titled 'Why levan?' was included to provide a general overview of the key physicochemical and biological properties of levan, intended to guide researchers in developing novel hydrogel formulations. These properties may also offer additional insights depending on the application, especially when compared with hydrogel studies involving other polymers in the literature. To enhance clarity, we have revised this section as well as the rest of the manuscript to more clearly explain the relevance of these properties to hydrogel design, and we have removed or streamlined sections as appropriate.

- section 4. Authors should clarify that "there is not a paper that presents levan-hydrogel only formed by levan". All papers combined levan with other polysaccharide or they use a crosslinker. This issue has to be addressed properly.

The authors thank the Reviewer for this very important point. Indeed, similar to dextran, native levan is an uncharged and highly water-soluble polymer that cannot form stable hydrogels in its unmodified form due to the absence of charged groups and insufficient intermolecular interactions required for three-dimensional network formation. Therefore, hydrogel formation with levan typically necessitates structural modification and/or chemical or physical crosslinking. To clarify this point, the following sentence has been added to the main text: "Due to its uncharged nature and water solubility, native levan does not readily form stable hydrogels without chemical or physical crosslinking or prior structural modification."

- section 4 must be extended. Authors should explain here why polymer (or fructans) functionalization is important. Some paragraphs about fructan functionalization to create hydrogels are needed.

Authors would like to thank the Reviewer for this important point. Following the suggestion, Section 4 has been extended and one Figure (Figure 2) was added to illustrate the discussed items.

The added paragraphs are as follows :

" Chemical crosslinking involves the formation of covalent bonds between polymer chains, either directly or via low-molecular-weight crosslinkers, resulting in hydrogels with enhanced long-term stability and mechanical strength. In contrast, physical crosslinking relies on non-covalent interactions, often leading to heterogeneous polymer networks and hydrogels that are structurally less stable and mechanically brittle. Nevertheless, physically crosslinked hydrogels formed via weak interactions, such as ionic or electrostatic interactions, hydrophobic interactions, hydrogen bonding, or van der Waals forces, can exhibit advantageous properties, including self-healing capability and responsiveness to external stimuli [99].

The choice of cross-linking method depends on the physicochemical properties of the polymer. Due to its uncharged nature and water solubility, native levan does not readily form stable hydrogels without chemical or physical crosslinking or prior structural modification. Therefore, either levan or its chemical derivatives are mixed with other polymers to promote physical crosslinking, or chemical crosslinkers are used to establish covalent bonds and enhance hydrogel stability. Furthermore, the inherently fast biodegradation rate of levan can be tuned by chemical modifications or by integrating it into composite hydrogels, allowing for better control over its stability and degradation kinetics in various application environments.

In literature, there are reports on physically linked levan hydrogels such as injectable levan/ CMC /Pluronic F127 blends [27, 28]. In both studies, it was stated that there is hydrophobic association and hydrogen bonding between levan, Pluronic F127, and CMC, and especially that the poly(ethylene oxide) group of Pluronic F127 interacts with levan, and therefore levan is necessary for physical crosslinking. In another study, ionically crosslinked levan/gellan blends were examined, and it was hypothesized that under alkaline conditions, gellan interacts with levan via ionic crosslinking between hydroxyl and carboxyl groups to form a hydrogel network [29]. On the other hand, relatively more studies used chemical crosslinking to obtain better mechanical stability, including photo-polymerized methacrylated *Bacillus* levan [34] or chitosan crosslinked oxidized *Bacillus* levan [36]. In these studies, functional groups were introduced into levan to facilitate its reaction with crosslinkers or other polymers. For instance, methacrylate-modified levan enables covalent bonding with photoinitiated crosslinkers such as lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) or Irgacure 2959 [34]. Similarly, the incorporation of aldehyde groups through oxidation allows levan to form Schiff base linkages with amine-containing polymers like chitosan [36]. However, there are also examples in which unmodified levan has been directly employed to form chemically crosslinked hydrogels such as glutaraldehyde crosslinked *Zymomonas* levan/PVA [35], and BDDE crosslinked *Halomonas* levan [37 - 42]. Figure 2 illustrates various types of chemically and physically crosslinked levan-based hydrogels while Figure 3 gives the classification of levan hydrogels.

"

- Table 1, *Z. mobilis* example, 3rd row, should be expressed as: Levan/PVA crosslinked glutaraldehyde

The suggested correction was made in Table 1.

- Conclusion. Authors should include as future research, the importance of carry out *in vivo* experiments, due to the lack of knowledge, as an essential milestone to deliver these hydrogels to market.

The authors thank the Reviewer for this insightful comment highlighting the importance of *in vivo* studies as a critical step toward clinical and commercial translation of levan-based hydrogels. We have revised the conclusion to better reflect this point and emphasize the necessity of further *in vivo* experimentation. The following paragraph was added to the conclusions section:

"To advance the clinical and commercial translation of levan-based hydrogels, future research should prioritize comprehensive *in vivo* studies. While preliminary *in vivo* evaluations have demonstrated promising biocompatibility, the current body of evidence remains limited and insufficient to fully assess their behavior under complex physiological

conditions. Systematic *in vivo* testing is essential to evaluate not only biocompatibility but also immunogenicity, biodegradability, mechanical stability, and therapeutic efficacy across diverse biomedical applications. Such studies are critical for meeting the safety and efficacy standards set by regulatory agencies such as the FDA and European Medicines Agency (EMA) and represent a necessary milestone before progressing to human clinical trials and market adoption."

Minor typos:

We are grateful to reviewers for their careful audits. All minor typos have been corrected as listed and highlighted with red in the main text.

+ line 172, "a crucial"

+ NaOH and CaCl₂ in Table 1

+ Uppercase for pNIPA in Table 1

+ line 487, "combined" was replaced with "incorporated"

+ All bacteria names in the text were written following the universal standards including those pointed by the Reviewer (line 524, line 560, line 568, line 608, line 615, line 645)

Hydrogels of Levan Polysaccharide: A Systematic Review

Aybüke Tekin^a, Selay Tornacı^a, Defne Boyacı^b, Suming Li^c, Sonia Calligaris^d, Hana Maalej^e,
Ebru Toksoy Öner^{a*}

^a IBSB, Marmara University, Department of Bioengineering, Istanbul, Turkey

^b Uskudar American Academy, 34664, Uskudar, Istanbul, Turkey

^c Institut Européen des Membranes, UMR CNRS 5635, Université de Montpellier, France

^d Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine,
Udine, 33100, Italy

^e Laboratory of Biodiversity and Valorization of Arid Areas Bioresources (BVBA),
LR16ES36, Faculty of Sciences of Gabes, University of Gabes, Gabes 6072, Tunisia

*Corresponding author. E-mail: ebru.toksoy@marmara.edu.tr

Abstract

Levan is a fructose-based homopolysaccharide renowned for its unique properties, including exceptional adhesive strength, self-assembly capability, low viscosity, and bioactivities such as prebiotic, anti-cancer, anti-inflammatory, and anti-diabetic effects. These characteristics have created increasing interest in levan-based biomaterials over the past decade, positioning levan as a highly under-explored biopolymer for a wide range of applications, from medicine to cosmetics. As a result, levan-based hydrogels have emerged as promising biomaterials in drug delivery, tissue engineering, and cosmetic formulations, owing to their extracellular matrix-mimicking structure, tunable mechanical properties, and controlled cargo release capabilities. This review is the first to comprehensively examine the advancements in levan-based hydrogel research, systematically analyzing their biomedical applications and comparing them with other biopolymer-based hydrogels. Key questions regarding levan's potential as an alternative to established hydrogel systems are explored, highlighting areas requiring further research. By assessing trends and findings in the literature, this review provides an overview of the advantages, limitations, and prospects of levan hydrogels. Our analysis establishes a foundation for the continued development of levan-derived biomaterials, fostering broader adoption in biomedical and industrial applications.

Keywords

Levan; Polysaccharide; Hydrogel; Biocompatibility; Biomaterials; Tissue Engineering

39

1. Introduction

40 Throughout history, significant milestones in humanity have been marked by
41 discoveries in human physiology, diseases and treatments. However, the search for solutions
42 to health problems dates back even further, as people have always relied on natural or
43 synthetic materials from their environment to facilitate wound healing, repair damaged tissues
44 and organs, and even enhance food preservation and safety [1]. Today, with increasing clinical
45 and industrial needs, there is a growing demand for materials, devices, and techniques not
46 only for diagnosing and treating diseases but also for ensuring safety, improving food quality,
47 extending shelf life, and enhancing health benefits [2,3]. Biomedical and food sciences have
48 emerged as multidisciplinary fields in response to these needs, aiming to improve human
49 health by addressing genetic, environmental, and dietary factors. The size of the biotechnology
50 market, which includes both biocompatible and functional, natural or synthetic materials that
51 meet the definition of "biocompatibility", is expected to increase from 1.75 trillion to
52 approximately 4.61 trillion USD from 2025 to 2034 [4]. This trend indicates growing interest in
53 the biomedical, food and cosmetic sectors, as well as in the development of biomaterials for
54 diverse applications.

55 Polysaccharides, the most common biocompatible polymers in nature, have been used
56 throughout human history for their nutritional and healing properties due to their structural and
57 functional characteristics that make them multifunctional bioactive materials [5]. Today, they
58 are widely utilized not only in diagnosis, regenerative medicine, gene therapy, drug targeting,
59 and tissue engineering, but also in food and nutrition sectors for enhancing food texture,
60 stability, and bioavailability, as well as for their prebiotic and health-promoting effects.
61 Polysaccharide-based hydrogels are three-dimensional colloidal solids that retain water in their
62 3D network structure. Compared to rigid scaffolds or dry polymeric systems, polysaccharide-
63 based hydrogels offer flexibility, soft structure, high porosity, and water-holding capacity that
64 promote cell viability, proliferation, matrix remodeling, and better resemblance to the native
65 living tissue. In hydrogel formation, polysaccharides with diverse functional groups enable both
66 chemical and physical crosslinking. Depending on application, this allows for the development
67 of covalently bonded hydrogels with enhanced chemical, mechanical, and dimensional
68 stability, as well as crosslinker-free hydrogels that are easier and faster to prepare [6]. Due to
69 their extracellular matrix-mimicking properties, biocompatibility, flexible synthesis methods,
70 and suitable physical properties, they have found broad applications as artificial soft tissue
71 biomaterials in various biomedical fields, such as controlled drug and cargo release,
72 biosensors, and tissue engineering and regenerative medicine [6, 7]. Furthermore, with a smart
73 hydrogel approach, polysaccharide-based hydrogels can be tuned to respond to environmental
74 stimuli such as pH, temperature, electrical and magnetic fields, ionic strength or light and can
75 change some of their properties such as their wettability, degradability, swelling, and
76 mechanical or surface properties. These tunable properties make them attractive especially
77 for smart drug delivery systems and personalized medicine [8, 9]. While chitosan [10], dextran
78 [11], and alginate [12] are common natural polysaccharides used in hydrogel formulations,
79 levan-based hydrogels have recently gained increasing attention in health-related applications
80 [13]. Levan, a natural homopolysaccharide of fructose, has been part of the human diet for
81 centuries. However, compared to inulin-type fructans, which have a well-established market
82 market as prebiotics, our knowledge of levan remains limited [14,15]. Despite this, levan's
83 remarkable properties, such as biocompatibility, biodegradability, antioxidant, immune
84 boosting, prebiotic, heparin-mimicking, anti-aging, and cryoprotectant effects, have piqued
85 scientific interest, leading to extensive research on its production, derivatives, and levan-based

86 biomaterials [16,17,18]. Challenges such as high production costs and limited commercial
87 availability, have hindered its widespread industrial use, promoting research into new
88 production systems [19]. This has led to the discovery of more affordable methods for
89 producing levan, opening up new avenues for its used in cosmetics, medicine,
90 pharmaceuticals, and the food sector [20]. However, further research is still needed before
91 levan can become a widely used product in these fields.

92 This review systematically examines trends and research on levan-based hydrogels and their
93 applications in various biomedical fields, such as drug delivery, tissue engineering, and
94 cosmetics. Several key questions are addressed, including why levan is an ideal biomaterial
95 for biomedical applications, whether levan-based hydrogels can compete with other
96 biomaterial-based hydrogels, and which sectors have extensively researched them. The
97 literature is compared with other biomaterial-based hydrogels, revealing the advantages and
98 limitations of levan-based hydrogels in various applications. This review aims to provide a solid
99 foundation for future research and development in levan-based hydrogel and biomaterial
100 applications.

101

102 **2. State-of-the art**

103 In order to gain insight into the current literature on levan-based hydrogels, a systematic
104 review was conducted following the Preferred Reporting Items for Systematic Reviews and
105 Meta-Analyses (PRISMA) protocol. The search strategy involved querying Scopus,
106 ScienceDirect, and other journal websites using keywords such as “Levan”, “Levan hydrogels”,
107 and “hydrogel”. No date or language restrictions were applied. To explore the sector-specific
108 uses, additional keywords, such as "drug delivery", "tissue engineering", "cosmetics", and
109 “food industry” were incorporated. From an initial set of 141 records, screening identified 15
110 relevant documents, after removing duplicates and out-of-scope articles. Further, a search on
111 the Web of Science (WoS) database revealed a total of 124,017 documents related to
112 hydrogels as of May 2025. Starting from the first studies with silica gels in 1946, the number
113 of documents increased exponentially after the 2000s, and according to the best model fit, a
114 total of 20,236 documents will be published in 2025 alone and an additional 182,458 reports
115 by the end of 2030. When the search was narrowed down to specific polysaccharides by
116 adding keywords, the total number of documents was 16,639 (chitosan), 13,508 (alginate),
117 8,884 (cellulose), and 6,666 (hyaluronic acid), followed by starch (1,946), dextran (1,837),
118 pectin (990), and xanthan (836). On the other hand, adding "levan" as a keyword reduced the
119 total number of documents to 21 that were only less than 0.02% of all hydrogel documents and
120 many orders of magnitude less than common polysaccharides like chitosan (13.4%) or alginate
121 (10.9%). While one of these 21 documents only cited levan and hence was discarded, another
122 one was a review article on the recent advancements in pharma and healthcare applications
123 of exopolysaccharide composites where authors also considered levan as a promising
124 biopolymer and briefly discussed a few levan-based biomaterials in a short paragraph [21].
125 The remaining 19 research articles also included those from the previous search, and they
126 were screened for their relevance. The first mention of levan as a hydrogel component
127 appeared in Castillo and López-Munigua’s 2004 study, which focused on the enzymatic
128 synthesis of high molecular weight levan by *Bacillus subtilis* levansucrase, resulting in a highly
129 viscous levan precipitate resembling a hydrogel [22]. Other early studies highlighted levan’s
130 hydrogel-like properties in *B. subtilis* biofilms [23] and *Erwinia tasmaniensis*-produced levan,
131 which formed sticky hydrogels at high concentrations [24]. The hydrogel’s swelling behavior

132 was also explored in enzymatically synthesized levan from *Erwinia amylovora* levansucrase
133 [25]. Another interesting study on encapsulating *Gluconobacter oxydans* cells in poly(vinyl
134 alcohol) (PVA) hydrogels reported interactions of the polymer network with bacterial
135 extracellular polysaccharide (EPS) components including levan as well as acetan, cellulose,
136 and dextran [26].

137 In 2018, Choi et al. introduced the first physically crosslinked levan hydrogels using
138 *Zymomonas mobilis* levan mixed with Pluronic F127 and carboxymethylcellulose (CMC) [27].
139 The group further incorporated hydroxyapatite to improve the hydrogel's injectability,
140 biocompatibility, and long-acting anti-wrinkle efficacy [28]. Similarly, blends of gellan and
141 *Erwinia herbicola* levan were ionically crosslinked to create shear-thinning hydrogels for tissue
142 engineering [29]. Other studies explored the use of *E. herbicola* levan mixed with CBD oil to
143 form sponges (rather than hydrogels) for wound healing applications [30]. Likewise, Maria et
144 al. (2021) reported that a *Bacillus* levan isolated from honey showed the capacity to form
145 emulsion hydrogels with omega-3 polyunsaturated fatty acids (PUFA) from ray liver oil and
146 chia oil [31].

147 In 2017, the first covalent use of levan in a hydrogel structure was reported, where
148 carboxymethylated derivative of levan from *Halomonas smyrnensis*, *Halomonas* levan, was
149 employed as a cross-linker for temperature-responsive N-isopropyl acrylamide (pNIPA)
150 hydrogels [32]. Then, another group used the same procedure to obtain short
151 carboxymethylated *Zymomonas* levan, attached catechol, and then synthesized hydrogels
152 with high adhesivity [33].

153 Further advancements included the photochemical crosslinking of methacrylated
154 *Bacillus* levan to form covalent hydrogels, which were characterized for their structural and
155 mechanical features, biodegradability, and cytocompatibility [34]. These studies were followed
156 by the use of glutaraldehyde crosslinked *Zymomonas* levan/PVA hydrogels as pathogen-
157 capturing filters [35], chitosan crosslinked oxidized *Bacillus* levan hydrogels loaded with
158 curcumin for wound dressing applications [36], as well as 1,4-butanediol diglycidyl ether
159 (BDDE) crosslinked *Halomonas* levan hydrogels for controlled release of Amphotericin B
160 (AmB) [37], Resveratrol [38], *Plantago lanceolata* extracts [39], and as cryoprotectants for
161 probiotic bacteria [40]. These BDDE/*Halomonas* levan hydrogels were also integrated with
162 polyacrylamide to obtain interpenetrating hydrogel networks for uses in the conservation of
163 cultural heritage [41]. Most recently, these hydrogels also showed promise in guided bone
164 regeneration [42].

165 A patent search was also conducted across four major databases, namely, World
166 Intellectual Property Organization (WIPO)'s Patentscope, Google Patents, Espacenet (by the
167 European Patent Office, EPO), and The Lens—using the keywords "levan" and "hydrogel."
168 The Lens, Google Patents, and Espacenet yielded 7,143, 4,518 and 448 hits, respectively. A
169 Frontpage search on Patentscope returned 4 results only (same search for chitosan and
170 alginate instead of levan yielded 2,969 and 2,412 hits, respectively). Two Korean patents
171 (KR1020190066936 and KR1020190041272) granted in 2019 focused on levan-based
172 hydrogels containing PF127 and CMC for cosmetic applications [27, 28]. In 2024, two Russian
173 patents (RU0002815367 and RU0002819701) described biocomposite hydrogels involving
174 *Paenibacillus polymyxa*-derived levan with one combined with alginate (RU0002815367), and
175 the other with *Komagataeibacter sucrofermentans* bacterial cellulose (RU0002819701) for
176 tissue engineering applications. The Cooperative Patent Classification (CPC) code A23V

177 2250/5068, which pertains to fructans used in food applications, was identified as relevant to
178 levan but did not yield any hydrogel-related results.

179

180

181 **3. Why levan?**

182 Levan is a versatile, non-structural homopolysaccharide composed primarily of
183 fructose units linked by β -2,6 glycosidic bonds, with different degrees of branching at the β -
184 2,1 position. This unique structure allows levan to be synthesized naturally by a range of
185 microorganisms, including archaea, fungi, bacteria, and a few plants [43]. Due to the difficulty
186 of extracting levan from plants in large quantities, most of the levan used in current studies is
187 derived from microbial sources through cloning levan-related genes [44, 45].

188 Levan has several properties that make it extremely useful for use as a hydrogel
189 formulation in a variety of applications. First, it is an amphiphilic polymer soluble in both water
190 and oil, but insoluble in most organic solvents, except dimethyl sulfoxide (DMSO). Such
191 solubility profile gives levan the ability to self-assemble in water into densely packed spheres
192 with a diameter of 25-250 nm, resulting in a low viscosity of its aqueous solutions [46]. This
193 self-assembly behavior contributes to the formation of 3D networks, which are characteristic
194 of hydrogels, while maintaining low viscosity in solution. Although levan's low viscosity is
195 advantageous for injectable hydrogel systems, it can also hinder the development of
196 mechanically strong and stable hydrogels. This limitation can be addressed by optimizing
197 reaction conditions to relax the self-assembled structures, employing chemical crosslinking, or
198 forming composite hydrogels.


199 Another important feature of levan is its suitability for chemical derivatization methods,
200 such as sulfation, phosphonation, and oxidation [47]. Chemically-modified levan derivatives
201 exhibit distinct properties, such as the anticoagulant activity of sulfated *Halomonas* levan [48]
202 or the enhanced anticarcinogenic activity of oxidized *Halomonas* levan [49], which may
203 support the design of hydrogels with diverse properties tailored for specific applications.
204 Besides, a distinguishing feature of levan compared to other bioactive polymers is its
205 remarkable adhesive strength. This is due to the high number of interactions, such as hydrogen
206 bonds, Van der Waals forces, and interactions between the abundant hydroxyl groups within
207 the structure, which contribute to levan's strong adhesion properties [50]. This adhesive
208 strength is especially significant in the context of microbial biofilms, where levan serves not
209 only as a crucial structural component to protect the microbial community but also as a nutrient
210 reservoir, enabling survival under nutrient-deprived conditions [51].

211 There is growing interest in the use of bioactive polymers in hydrogel design across
212 diverse fields, from biomedicine to the food industry. Unlike traditional hydrogels that primarily
213 serve as passive carriers, these polymers can actively interact with biological systems, thereby
214 enhancing the material's functionality and biocompatibility depending on the application.
215 Levan, with its wide range of bioactivities, holds significant potential to confer additional
216 therapeutic or functional benefits when incorporated into hydrogel systems. Figure 1
217 summarizes various bioactivities of levan polysaccharide with the state of the art literature
218 discussed in the following sections.

219

220

221
222
223
224
225



226
227
228
229

Figure 1. Bioactivities of Levan polymer (Created with Canva.com).

230 3.1. *Levan as a Potential Prebiotic*

231 Prebiotics are non-digestible food ingredients that promote the growth or activity of
232 beneficial microbes in the body. Their degradation products, short-chain fatty acids (SCFAs),
233 have gained attention for influencing the microbiota and general health, including effects
234 beyond the gastrointestinal system [52, 53, 54]. In a study conducted with fructans of different
235 molecular weights, it was observed that high molecular weight levan was more effective than
236 low molecular weight fructooligosaccharides in terms of increasing the production of SCFAs
237 and contributing to the diversity of the intestinal microbiota [55]. For prebiotics to be used by
238 the beneficial microbiota, they must reach the colon without being digested in the upper
239 intestine [56]. Fructans, which meet this requirement, differ from glucans in that they are only
240 metabolized by the colon microbiota [51, 57]. Today, inulin-type fructans are the most
241 researched group for their effects on microbiota, immunity, and intestinal barrier function [58].
242 Although levan is less researched, there are studies on levan as a potential prebiotic [15, 59].
243 It has been reported that when chicken [59], pigs [60], or rats [61] were fed with levan, breast
244 meat and feed ratio increased, ammonia levels decreased, digestive abilities improved, and
245 beneficial bacteria were abundant. There are even studies where levans' prebiotic activity was
246 higher than inulin. For example, levan produced from *Erwinia* sp. significantly enhanced
247 microbial community growth compared to inulin, likely due to its higher degree of

248 polymerization (DP), which allowed for prolonged persistence in the colon [62]. Moreover,
249 levan from *Streptococcus salivarius* had higher or similar prebiotic activity scores against four
250 probiotic bacteria compared to inulin [63] while levan from *Bacillus siamensis* and *Bacillus*
251 *velezensis* supported the growth of *Streptococcus thermophilus* DKT-3 better than inulin [64].

252

253 3.2. *Anti-diabetic and Anti-obesogenic Activity of Levan*

254 Levan, unlike glucans such as cellulose and starch, is broken down into fructose rather
255 than glucose, making it a potentially more suitable option for diabetic patients [65]. Dahech et
256 al. (2011) demonstrated that orally administered levan reduced hyperglycemia and oxidative
257 stress in diabetic rats, also protecting against hepatic and pancreatic toxicity [66]. Further
258 studies reported that levan supplementation lowered blood sugar and serum cholesterol
259 levels—critical factors in diabetes management [67, 68, 69]. Moreover, in obese rats on a
260 high-fat diet, levan suppressed diet-induced obesity and hyperlipidemia, reducing total
261 cholesterol while increasing HDL levels [70]. Additionally, a combination of levan and
262 fermented ginseng was shown to reduce hyperlipidemia, fat accumulation, body weight gain,
263 and improve glucose homeostasis and leptin resistance [71]. These findings highlight the
264 biotherapeutic potential of levan in improving diabetes, diabetes-related metabolic
265 syndromes, and obesity.

266

267 3.3. *Anti-cancer, Antioxidant and Antiviral Activities of Levan*

268 Cancer, characterized by uncontrolled cell growth due to DNA mutations, remains a
269 significant health challenge due to the diversity in tumor types and treatment responses,
270 prompting growing interest in natural agents alongside traditional therapies like chemotherapy
271 and radiotherapy [72, 73]. Levan is one of the natural polymers that have been extensively
272 studied for their anticancer potential across various cancer types where the structural
273 properties of levan, such as its chain length and degree of branching, were found to play a
274 crucial role in its anticancer efficacy [74]. Recently, nanoparticles coated with *Zymomonas*
275 levan (Np-Lev) have shown significant antiproliferative activity against breast cancer and
276 melanoma cells [75], while levan combined with doxorubicin significantly reduced expression
277 of cancer-related genes in hepatocellular carcinoma cells [74]. Moreover, the combined use of
278 bacterial levan and benzimidazole derivative (BMPE) exhibited notable antimetastatic effects
279 in a triple-negative breast cancer mouse model via immunomodulation and redox regulation
280 [76].

281 Oxidative stress, caused by excessive accumulation of reactive oxygen species (ROS),
282 can result in cellular damage such as DNA disruption, protein misfolding, lipid peroxidation,
283 and membrane dysfunction, which in turn are associated with diseases like type 2 diabetes,
284 cardiovascular and neurodegenerative disorders, and ischemia [77]. In this context, levan has
285 been shown to effectively suppress peroxidation, donate electrons, and terminate free radical
286 chain reactions, acting as a potent antioxidant [78]. Studies have demonstrated that levan
287 derived from *Bacillus* strains and its sulfated forms possess strong antioxidant properties [64,
288 79, 80]. Similarly, levan isolated from *Acetobacter xylinum* and *Leuconostoc mesenteroides*
289 cultures have also been reported to exhibit strong antioxidant and anti-inflammatory effects
290 [44, 81].

291 Viruses with their complex structures and historical impact on pandemics, have driven

292 increased interest in antiviral agents, particularly following the global COVID-19 pandemic.
293 Levan has been studied for its antiviral properties, with *Bacillus* levan shown to affect
294 respiratory HPA1, H5N1, and enteric adenovirus type 40 [82]. More recently, same researchers
295 found that crude, dialyzed, and sulfated derivatives of levan produced from *Enterococcus*
296 *faecalis* cultures showed antiviral activity against Newcastle disease virus (NDV) [83].

297

298

299 3.4. Immunomodulatory Activity of Levan

300 The immune system plays a crucial role in defending against infections and cancer and
301 understanding its mechanisms is essential for recognizing its role in diseases, interactions with
302 other systems, and the development of new therapeutic strategies [84]. While traditional
303 treatments like corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are
304 commonly used to suppress inflammation [85], their long-term use is limited by significant side
305 effects [86], driving research into more selective and natural treatment approaches for immune
306 modulation with fewer adverse effects [87, 88].

307 There are numerous reports in the literature on the immunomodulatory activity of levan
308 polysaccharides from various sources, but only a few of them have investigated the related
309 molecular mechanism [89]. *In vivo* oral administration of *B. subtilis* natto levan was found to
310 reduce the serum level of ovalbumin-specific Immunoglobulin E (IgE), modulate the T helper
311 2 (Th2) cell response, and pattern recognition was found to be mediated by Toll-like receptor
312 (TLR) 4 [90]. TLR4 are receptors that recognize conserved pathogen-associated molecular
313 patterns (PAMPs) and thus constitute the first line of defense [91]. In addition, they recognize
314 lipopolysaccharide (LPS) glycolipids found in the outer membranes of both commensal and
315 pathogenic Gram-negative bacteria [92, 93]. A recent study showed that LPS is the actual
316 molecular determinant of the immunomodulatory property of levan toward TLR4 receptor-
317 expressing innate immune cells [94].

318 Some studies provide a better understanding of the changes in the immunomodulatory
319 properties of structurally different levan produced from different sources. For example, while
320 levan produced from *L. mesenteroides* increased the levels of interleukin-4 (IL-4), an important
321 anti-inflammatory cytokine [81], levan obtained from *Paenibacillus bovis* sp. did not cause any
322 modulation in IL-4 levels [95]. In addition, levan of different molecular weights from the same
323 species has been observed to have different effects on inflammation-related pathways. For
324 example, levan from *B. subtilis* altered iNOS, COX-2 gene expression [96] and nitric oxide
325 (NO) production [97] in RAW264.7 macrophages depending on molecular weight. Moreover, a
326 relatively recent study used methacrylated levan as a bio-ink for 3D bioprinting of bone tissue
327 scaffolds. In addition to good bioprintability, the samples supported the expression of the anti-
328 inflammatory marker CD206 [98]. These results suggest that the inherent immunomodulatory
329 effect may make levan an ideal polymer for hydrogels in tissue repair and regeneration
330 applications, as it will reduce the possibility of rejection by the body.

331

332 4. Synthesis of Levan-based hydrogels


333 Properties of hydrogels such as mechanical strength, self-healing ability, swelling
334 capacity, and biodegradability depend on cross-linking processes. Hydrogel synthesis is
335 generally achieved through chemical or physical crosslinking methods. Chemical crosslinking

336 involves the formation of covalent bonds between polymer chains, either directly or via low-
 337 molecular-weight crosslinkers, resulting in hydrogels with enhanced long-term stability and
 338 mechanical strength. In contrast, physical crosslinking relies on non-covalent interactions,
 339 often leading to heterogeneous polymer networks and hydrogels that are structurally less
 340 stable and mechanically brittle. Nevertheless, physically crosslinked hydrogels formed via
 341 weak interactions, such as ionic or electrostatic interactions, hydrophobic interactions,
 342 hydrogen bonding, or van der Waals forces, can exhibit advantageous properties, including
 343 self-healing capability and responsiveness to external stimuli [99].

344 The choice of cross-linking method depends on the physicochemical properties of the
 345 polymer. Due to its uncharged nature and water solubility, native levan does not readily form
 346 stable hydrogels without chemical or physical crosslinking or prior structural modification.
 347 Therefore, either levan or its chemical derivatives are mixed with other polymers to promote
 348 physical crosslinking, or chemical crosslinkers are used to establish covalent bonds and
 349 enhance hydrogel stability. Furthermore, the inherently fast biodegradation rate of levan can
 350 be tuned by chemical modifications or by integrating it into composite hydrogels, allowing for
 351 better control over its stability and degradation kinetics in various application environments.

352 In literature, there are reports on physically linked levan hydrogels such as injectable
 353 levan/ CMC /Pluronic F127 blends [27, 28]. In both studies, it was stated that there is
 354 hydrophobic association and hydrogen bonding between levan, Pluronic F127, and CMC, and
 355 especially that the poly(ethylene oxide) group of Pluronic F127 interacts with levan, and
 356 therefore levan is necessary for physical crosslinking. In another study, ionically crosslinked
 357 levan/gellan blends were examined, and it was hypothesized that under alkaline conditions,
 358 gellan interacts with levan via ionic crosslinking between hydroxyl and carboxyl groups to form
 359 a hydrogel network [29]. On the other hand, relatively more studies used chemical crosslinking
 360 to obtain better mechanical stability, including photo-polymerized methacrylated *Bacillus* levan
 361 [34] or chitosan crosslinked oxidized *Bacillus* levan [36]. In these studies, functional groups
 362 were introduced into levan to facilitate its reaction with crosslinkers or other polymers. For
 363 instance, methacrylate-modified levan enables covalent bonding with photoinitiated
 364 crosslinkers such as lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) or Irgacure 2959
 365 [34]. Similarly, the incorporation of aldehyde groups through oxidation allows levan to form
 366 Schiff base linkages with amine-containing polymers like chitosan [36]. However, there are
 367 also examples in which unmodified levan has been directly employed to form chemically
 368 crosslinked hydrogels such as glutaraldehyde crosslinked *Zymomonas* levan/PVA [35], and
 369 BDDE crosslinked *Halomonas* levan [37 - 42]. Figure 2 illustrates various types of chemically
 370 and physically crosslinked levan-based hydrogels while Figure 3 gives the classification of
 371 levan hydrogels.

372
 373
 374
 375
 376
 377
 378
 379



380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417

Figure 2. Physically and chemically crosslinked levan-based hydrogels (Created with Canva.com).

The good biocompatibility of hydrogels under physiological conditions, their degradability, and the low toxicity of the formed degradation products are important issues in the selection of the crosslinking agent [99]. Although hydrogels with good mechanical stability are formed by chemical crosslinking, crosslinking agents are generally synthetic and can cause toxic effects [100]. In a related study, levan was used to crosslink pNIPA hydrogels as an alternative to bis-acrylamide (BAAm), aiming to eliminate its potential toxic effects [32].

So far, mostly BDDE crosslinked levan hydrogels are reported where the formation of covalent bonds occurs as a result of the reaction between the epoxide groups of BDDE and the primary hydroxyl groups on the levan backbone. However, in a recent review by Wojtkiewicz et al. (2024) [101], it was noted that long-term use of BDDE-crosslinked hydrogels can lead to tissue hardening and redness in the application area after several years, potentially due to BDDE itself or its byproducts released during hydrogel disintegration, as indicated by clinical findings. On the other hand, physical crosslinking offers a valuable alternative to avoid the potential risks associated with chemical methods.




Figure 3. Classification of levan-based hydrogels (Created with Canva.com)

418

5. Applications of Levan Hydrogels

419

420 Levan-based hydrogels have emerged as promising biomaterials in various biomedical
 421 applications, particularly in drug delivery systems, tissue engineering, and regenerative
 422 medicine, as well as in cosmetics. Their unique physicochemical properties, including
 423 biocompatibility, biodegradability, and stimuli-responsiveness, make them suitable candidates
 424 for controlled and targeted drug release, offering improved stability, bioavailability, and efficacy.
 425 In Table 1 are summarized the key findings on levan-based hydrogels in various sectors to
 426 provide a general overview of their diverse applications.

427

428 **Table 1.** Hydrogels of Levan

Source of Levan	Hydrogel structure	Application	Reference
<i>Bacillus subtilis</i>	Levan was methacrylated and then photo-polymerized	Mechanically stable, slightly degradable and cytocompatible gels suitable as starting materials in common additive manufacturing processes like bioprinting or stereolithography	[34]
	Levan was oxidized with sodium metaperiodate and then mixed with chitosan for the gelation	Bio- and hemo-compatible drug delivery system and wound dressing material with sustained curcumin release	[36]
<i>Erwinia herbicola</i>	Levan/gellan blends crosslinked ionically with NaOH and CaCl ₂	Shear-thinning properties showed high potential of levan-gellan hydrogel for its use as an injectable material in medical and cosmetic industries	[29]
<i>Halomonas elongata</i>	BDDE crosslinked levan hydrogels loaded with liposomes containing <i>Plantago lanceolata</i> L. Extracts	Biocompatible and biodegradable levan-based herbal liposome-loaded hydrogels for acute wound healing	[39]
<i>Halomonas smyrnensis</i>	Hydrolyzed, carboxylated and then methacrylated levan crosslinked with <i>N</i> -isopropyl acrylamide (NIPA)	Thermoresponsive levan/pNIPA hydrogels for the controlled release of 5-ASA for the treatment of inflammatory bowel diseases	[32]
	BDDE crosslinked levan hydrogels	Amphotericin B release for exerting antifungal activity against <i>Candida albicans</i>	[37]
	Hydrolyzed and	Controlled release of resveratrol	[38]

	phosphonated levan crosslinked with BDDE	for skin tissue engineering	
	Levan, acrylamide and methylene-bis-acrylamide solution crosslinked with BDDE and Ammonium persulfate	IPN-based Levan/PA hydrogels for conservation of cultural heritage	[41]
	Hydrolyzed levan cross-linked with BDDE	Levan hydrogels for guided bone regeneration and bone tissue engineering	[42]
	Pluronic F127/CMC/levan mixture	Injectable hydrogels to be used as an alternative to hyaluronic acid (HA) based dermal fillers in soft tissue augmentation	[27]
	Hydroxyapatite containing Pluronic F127/CMC/levan hydrogels	<i>In vivo</i> stability of the composite hydrogel was enhanced with high anti-wrinkle efficacy maintained for 8 weeks and showing high collagen production	[28]
Zymomonas mobilis	Levan/PVA crosslinked with glutaldehyde	Virus capture efficiency of levan-PVA hydrogels was higher than that of commercial cotton swabs	[35]
	Catechol conjugated carboxymethylated levan hydrogels via oxidation-induced catechol/quinone (covalent) and Fe ³⁺ -(non-covalent) mediated coordinative crosslinking	Levan-catechol conjugate hydrogel for wound healing applications	[33]

429

430 5.1. Pharmaceutical Applications

431 Direct clinical use of active pharmaceutical ingredients (APIs) “as is” is limited since
432 drugs are sensitive chemicals and are adversely affected by body conditions (pH, temperature,
433 enzymes, etc.), low bioavailability, and low absorption [102]. Therefore, delivery systems that
434 transport therapeutics to relevant sites in the body in a controlled manner are necessary for
435 effective drug delivery. Traditional drug delivery systems require high and continuous doses
436 due to untargeted distribution and uncontrolled release of the drug. This is contrary to keeping
437 the plasma drug concentration above the minimum effective concentration (MEC) and below
438 the toxic concentration and may cause side effects [103]. There is increasing interest in
439 controlled and targeted drug delivery systems (DDS), designed to release the correct dose of
440 a therapeutic agent directly to the desired site and within the required period. These systems
441 maximize the effectiveness of the therapeutic agent and minimize possible side effects [104].

442 The conventional DDS methods, like oral tablets and injections, often suffer from limitations
443 like poor bioavailability, systemic side effects, and the need for frequent administration [105].
444 Advanced drug delivery systems have been developed to overcome these challenges, and so
445 many new options, such as liposomes, nanoparticles, microneedles, polymeric carriers, and
446 hydrogels offering unique advantages, improve health care day by day [106]. Among them,
447 hydrogels have gained considerable attention due to their cross-linked hydrophilic polymer
448 network that can retain large amounts of water. When loaded with drugs, they can hold the
449 drug inside and gradually release it in a controlled manner due to their porous structure and
450 swelling properties [107]. Nowadays, more specific versions of hydrogels, such as stimuli (pH,
451 temperature, enzymes, etc.) responsive, injectable, or nanogels, are being designed, thus
452 rapidly progressing towards more efficient and effective drug delivery systems [108,109].

453 The use of levan-based drug delivery systems may overcome, to a great extent, the
454 challenges of the conventional modes of drug administration. So far, various drugs have been
455 loaded into levan-based-drug delivery systems for targeted and controlled delivery. After levan
456 polysaccharide was first reported to be suitable for delivering peptides, proteins, and
457 macromolecular drugs [110], *Halomonas* levan was used for controlled release of vancomycin
458 [111], curcumin [112], paclitaxel [113], and resveratrol [114]. Additionally, levan derived from
459 *Bacillus licheniformis* has demonstrated high potential as a pharmaceutical excipient in topical
460 drug formulations [115]. Recent studies include *B. subtilis* levan-based nanoparticles loaded
461 with the antiretroviral drug - dolutegravir for potential use in HIV treatment [116] and levan-
462 shelled hydrophobic silica nanoclusters encapsulating doxorubicin as an ultrasound-
463 responsive drug delivery system for cancer treatment [117]. These studies reveal that levan is
464 a promising polymer for drug delivery strategies, not only as a carrier but also with its
465 bioactivity.

466 When designing drug delivery systems, some important issues should be considered.
467 The first one is the ability to provide targeted delivery. Hydrogels have been demonstrated as
468 the ideal pharmaceutical carrier in biomedicine due to their high porosity and water content
469 through their unique three-dimensional (3D) crosslinked network structure [118]. Stimuli-
470 responsive hydrogels, also known as smart or intelligent hydrogels, have become the most
471 studied systems for drug delivery [119]. They are able to respond to environmental changes
472 like temperature, pH, or magnetic fields, controlling not only drug administration but also the
473 timing and release profiles, with their sol-gel phase transition behavior influenced by their
474 sensor characteristics and surrounding conditions [120].

475 Examples of levan-based-stimuli-responsive hydrogels include thermoreactive
476 levan/N-isopropyl acrylamide (levan/pNIPA) hydrogels for controlled release of 5-
477 aminosalicylic acid (5-ASA) used in the treatment of inflammatory bowel diseases. Osman et
478 al. (2017) used methacrylated, hydrolyzed, and carboxymethylated forms of *Halomonas* levan
479 as crosslinkers to prepare levan-pNIPA hydrogel for the first time [32]. The biocompatibility of
480 the obtained hydrogels with L929 cells was evaluated, and data showed that the
481 biocompatibility was improved with higher levan percentage in hydrogels. Also, when different
482 concentrations and temperatures were tested, addition of levan brought the volume phase
483 transition temperature closer to the human body temperature.

484 Every drug delivery system, including hydrogels, has a limited residence time in the
485 targeted release region. This is between 2-5 hours for the stomach and 2-6 hours for the small
486 intestine, and at the end of this period, the content is transferred to the next step of the system,
487 such as the colon. Therefore, it is important to test how much and how quickly a hydrogel will

488 release the encapsulated drug. Since it is known that the type and content of crosslinker used
489 in hydrogel production change the drug release characteristics, the levan/pNIPA hydrogel
490 system [32] was compared with the same system where chitosan was used as a crosslinker
491 instead of levan [121]. It is observed that both hydrogels released approximately 90% of the
492 drug in 2 hours under the same conditions (37 °C, pH 7.4). Both hydrogels can release an
493 effective amount of the drug in a sufficient time. However, while 100% of the drug was released
494 in 4 hours in the chitosan hydrogel, this period was 6 hours in the levan hydrogel. This
495 difference can be attributed to the pH-sensitive structure of chitosan, suggesting that levan
496 may be a good alternative for medications that need to be released over a longer period.

497 The second important point to consider when designing drug-delivery hydrogels is the
498 swelling capacity. The reason is the high influence of swelling on drug loading efficiency (DLE)
499 and drug encapsulation efficiency (DEE), which are mandatory for an adequate drug delivery
500 system. It is worth noting that the swelling capacity of a hydrogel depends on the polymer used
501 and the degree of cross-linking. While high crosslinking causes lower water absorption
502 capacity, lower crosslinking degree leads to lower mechanical stability [38,122]. So, the
503 optimum cross-linking degree should be selected for enhanced drug delivery. Another essential
504 factor influencing swelling is the pH of the environment. Therefore, in a study by Demici et al.
505 (2020) to estimate swelling capacity, tests were performed with selected hydrogels that have
506 an optimum polymer/crosslinker ratio (*Halomonas* levan/BDDE) in different solutions [37]. The
507 results showed that the swelling capacity of the hydrogels was pH dependent, higher pH
508 leading to higher swelling, and the maximum equilibrium degree was reached in 1 hour.
509 Antifungal and cytotoxicity tests also revealed the high potential of levan hydrogels in the
510 transport of pH-sensitive drugs such as amphotericin B (AmB) [37].

511 The third and possibly most crucial factor is the biocompatibility of the drug delivery
512 system. Hydrogels, especially those produced from natural polymers, are known as
513 biocompatible since they are not toxic or injurious and do not cause immunological rejection in
514 living tissues [107]. Considering the need for more systematic studies on levan-based
515 hydrogels to widen their use in drug delivery systems and biomedical applications, chemically
516 modified forms were used to synthesize biocompatible hydrogels. Recently, levan produced
517 by *H. smyrnensis* and its hydrolyzed and phosphonated derivatives crosslinked with BDDE
518 were produced for the first time for resveratrol delivery [38]. Results revealed the superior *in*
519 *vitro* biocompatibility of levan hydrogels with a human keratinocyte cell line (HaCaT).
520 Additionally, cell attachment to phosphonated hydrogels was higher since phosphonate groups
521 affect cellular attachment via mimicking protein-protein and protein-natural polymer
522 interactions [123]. This finding proved that hydrogels produced from chemically modified forms
523 of levan polymer have superior potential in the pharmaceutical and cosmetic industries.

524

525 5.2. *Levan Hydrogels in Tissue Engineering*

526 Tissue engineering (TE), a rapidly growing field, is used to substitute diseased or
527 damaged tissues with functional ones, aiming to restore or enhance the function of the affected
528 tissues. Nowadays, hydrogels, due to their unique properties, have become an integral part
529 of tissue engineering, especially in enhancing tissue function and promoting cell growth,
530 differentiation, and regeneration [124,125]. When selecting biomaterials to form hydrogels,
531 several factors need to be considered, including mechanical properties, biocompatibility,
532 gelation time and swelling capacity [126]. The understanding that natural polymers, especially

533 polysaccharides, have the potential to meet these properties positions levan as an attractive
534 candidate for tissue engineering applications.

535 The first study on the synthesis of photo-crosslinkable levan derivatives and their use
536 for hydrogel production was reported by Berg et al. (2018) [34]. Levan from *B. subtilis* was
537 chemically modified via methacrylation with glycidyl methacrylate (GMA), methacrylic
538 anhydride (MAA), or 2-isocyanatoethyl methacrylate (IEM) and then photo-polymerized in the
539 presence of different photoinitiator systems and irradiation units. The resulting hydrogels were
540 mechanically stable and cytocompatible. Furthermore, it was shown that changing the type of
541 crosslinker and the crosslinking density altered the degradation rate of the hydrogels, thus
542 making these gels suitable candidates for both drug delivery and tissue engineering
543 applications. Considering the complexity and high cost of materials used in tissue engineering
544 in terms of preparation and application processes, there is a high need for new-generation
545 biomaterials that can be produced at low cost, have high bioactivity, and are sustainable [127].
546 The increasing use of natural polymers such as gelatin, hyaluronic acid, etc., in tissue
547 engineering applications has encouraged researchers to explore the potential of levan in this
548 area [128]. In a recent study, levan hydrogels were incorporated with Bio-Oss®, a traditional
549 xenograft used in guided bone regeneration applications (GPR), at different ratios. The results
550 showed that, in addition to higher biocompatibility, levan containing hydrogels exhibited higher
551 new bone formation, osteoblast density, and new vessel formation compared to the group
552 containing only Bio-Oss® [42].

553

554 5.3. *Applications in Wound Healing*

555 Wounds, which are pathological cases caused by various diseases and physical-
556 chemical damages, are classified as acute or chronic depending on the type of damage and
557 the duration of the healing process [129]. Wound healing is a complex biological process that
558 involves the coordination of various tissues and cell types, such as fibroblasts and
559 keratinocytes, to repair damaged skin or other tissues. Wound dressing materials play a critical
560 role in accelerating the healing process by providing an optimal environment for tissue
561 regeneration [130, 131]. A suitable and effective wound dressing material should possess key
562 properties, including biocompatibility, non-toxicity or non-allergenicity, mechanical strength, air
563 permeability, moisture retention, antimicrobial activity, and ease of removal [132, 133].
564 Conventional wound dressings often fail to meet these requirements, making biopolymer-
565 based hydrogels a promising alternative due to their morphological similarity to the
566 extracellular matrix and ability to mimic natural tissue structures [134, 135, 136, 137, 138].

567 Levan has gained attention for its wound healing potential. Its anti-inflammatory,
568 antibacterial and high adhesive properties, contribute significantly to tissue repair [139]. Levan
569 can support cell proliferation, particularly of fibroblasts and keratinocytes, which are essential
570 for wound closure and immune response regulation [140, 141]. Additionally, levan can enhance
571 the mechanical stability of wound healing systems, promoting faster recovery. As proof of that,
572 *Bacillus mojavensis* Levan-PVA nanofibers have been shown to accelerate wound healing due
573 to the water-holding properties of levan combined with the film-forming ability of PVA [142].
574 Increasing levan-PVA concentration further enhances tensile strength and cell viability, leading
575 to better healing outcomes [143] showed increasing levan-PVA concentration causes higher
576 tensile strength and improved cell viability. In addition, porous microbial levan-based sponges
577 loaded with cannabis oil (Lev@CBDs) exhibited a suitable swelling ratio and enough thermal
578 stability to use even after being exposed to harsh conditions for a long period. Also, produced

579 sponges exhibited antibacterial activity against *Staphylococcus aureus* and *Pseudomonas*
580 *aeruginosa*, the two most known bacteria that cause infection in wound areas [30]. In addition
581 to its bioactivity on the wound area, levan can also be used as a natural reducing and coating
582 material for microelement nanoparticles (NPs) [144] due to the presence of -OH groups on the
583 polymer chains [145].

584 In some cases, using more than one polymer for the synthesis of hydrogels called
585 hydrogel composites is preferred to obtain an effective drug delivery system, as they offer
586 excellent properties of contained biomaterials, which other drug delivery systems cannot
587 quickly achieve for the controlled release of drugs to specific sites. Basically, by cross-linking
588 through covalent bonding/ionic interactions/hydrogen bonding of levan with other polymers,
589 hydrogels with increased structural integrity can be formed. To improve wound healing, the
590 oxidized form of levan from *B. subtilis* was crosslinked with chitosan by Veerepandian et al.
591 (2023) [36]. Schiff's base reaction between oxidized levan and chitosan leads to formation of
592 hydrogels without need for an initiator such as UV light or chemical cross-linkers, making
593 hydrogels more biocompatible and suitable for wound healing. All the hydrogels had highly
594 interconnected porous networks due to the large number of functional groups in the structure
595 of levan and chitosan that help cell attachment, proliferation, and nutrient transfer. The
596 hydrogels showed better thermal stability than neat levan, and the presence of chitosan made
597 the swelling behavior of hydrogels pH-dependent (pH 2.6). The results from the
598 hemocompatibility tests via direct and indirect methods showed non-significant differences
599 compared to the control group. In another study, levan-catechol conjugate (LC) was
600 synthesized by combining the carboxyl group of CM-levan with the amino group of dopamine
601 using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) chemistry. This
602 conjugation improves the produced hydrogels' water-proof ability as well as fast swelling over
603 the first 30 min of incubation, which makes these hydrogels good candidates for wound healing
604 applications. Furthermore, the increased blood clotting rate, low endotoxin levels, and faster
605 wound closure in the SD rat model compared to the control suggested that it can be used as
606 a biomedical adhesive in wound healing process [33]. Moreover, the wound healing efficacy of
607 the composite material developed by loading herbal liposomes into levan-based hydrogel
608 structures was investigated by Altıntaş and Çelik (2023) [39]. Hydrogel structures were
609 developed for the first time with levan produced by *Halomonas elongata* 153B halophilic
610 bacteria for wound healing. Extracts from *P. lanceolata* L., commonly known as a wound herb,
611 which has cell regeneration ability and anti-bacterial activity in the wound area, were obtained.
612 Then, extract-loaded liposomes were prepared, and were loaded into the levan-based
613 hydrogels for controlled release into the wound area. The wound healing efficacy of the herbal
614 liposome-loaded levan-based hydrogel was evaluated in an *in vitro* wound model. Results
615 indicated that the developed hydrogels are a promising therapeutic approach for the healing
616 of acute wounds [39].

617

618 5.4. Cosmetics

619 The skin, which is the largest organ of the body, has the basic functions of protecting
620 the body from pathogens and external environmental elements (radiation, impact, heat, etc.)
621 and maintaining homeostasis by maintaining body temperature and humidity [146]. Cosmetic
622 substances such as lotions, creams, masks, etc. are generally products used to maintain or
623 improve the current condition and can be produced from various raw materials [147]. However,
624 some cosmetic products contain several ingredients like parabens, which can harm the skin

625 and hair [148]. Recently, natural products are rapidly gaining attention due to their
626 biocompatibility, sustainability, and high contribution to skin health. Cosmetic product users
627 are more interested in skin and environment-friendly, biodegradable ingredients instead of
628 synthetic additives. For this reason, bioactive formulations are widely available in skincare,
629 haircare, and personal care items [149]. Levan, on the other hand, has remarkable properties
630 such as skin whitening, moisturizing, and reduction of skin irritants [150, 151].

631 While the selection of raw materials used in cosmetic formulas varies depending on
632 which area they will be applied in, today the cosmetic industry is showing much more interest
633 in hydrogel-based cosmetic products due to their properties such as biocompatibility, elasticity,
634 and the ability to hold excess water [152, 153, 154]. Hydrogels, which can be used to help
635 restore skin elasticity, softness, and moisture, can also facilitate drug penetration by loosening
636 the skin barrier [155]. Synthetic polymers and biopolymers are widely used in commercially
637 available cosmetic products. Biodegradable polymers, especially polysaccharides, have been
638 attracting much attention of scientists looking for new compounds with cosmetic properties
639 because they can be eliminated by normal metabolic pathways and do not cause toxicity and
640 accumulation in the body [156, 157].

641 The variety of properties of levan mentioned above makes it a useful and safe
642 biomaterial for cosmetics. In the literature, lots of research showed the suitability of using levan
643 in cosmetics. For example, the stimulation of human fibroblasts and keratinocytes by *Z. mobilis*
644 levan [158], as well as a whitening agent by inhibition of melanin production [159]. Lewińska
645 et al. (2022) [160] developed tonic, gel, and cream formulations containing surfactin-stabilized
646 *B. subtilis* levan nanoparticles (NP) and nanoemulsion (NE) nanosystems. They reported that
647 these formulations improved skin hydration, elasticity, wrinkle depth, and also skin
648 discoloration. In addition, levan, which also met the requirement of non-toxicity, did not show
649 cytotoxicity on human dermal fibroblasts (NHDF) [161]. In *in vitro* experiments with *Halomonas*
650 levan and its derivatives, increased cell proliferation, skin barrier function, and rapid wound
651 healing ability were observed [139]. In addition, the cosmetic product needs to maintain its
652 stability for a long time when the approximate period of use is evaluated. Da Silva et al. (2022)
653 [162] reported the maintenance of moisturizing, antioxidant activity, and stability of the product
654 consisting of *B. subtilis* natto levan and almond oil for 3 months. In a study, carboxymethyl
655 levan (CML)-hEGF nanoparticles designed to overcome the low stability of human epidermal
656 growth factor (hEGF) maintained over 100% cell proliferation activity for 6 weeks [163]. This is
657 one of the important studies supporting the potential use of levan as a cosmeceutical because
658 hEGF is a signaling molecule that stimulates the growth and motility of keratinocytes and
659 fibroblasts in epithelial tissues [164]. Moreover, in a study aimed at enhancing the effects of
660 levan with biocompatible actives such as natural compounds and vitamins, levan was
661 combined with natural compounds such as aloe vera extract, avocado oil, and vitamin E [165].
662 The cosmeceutical formulations were non-toxic and completely vegan, as well as showing
663 good stability. Another study also showed that levan-containing digestive extract reduces the
664 irritating effect of ionic surfactants and is therefore a suitable ingredient for the formulation of
665 harmless body wash cosmetics [166].

666 Soft tissue fillers are applications developed as an alternative to plastic surgery due to
667 reasons such as low life risk, fast recovery time, and instant effect. The material used for an
668 effective application should be biocompatible, non-allergenic, and stable [167, 168]. Fillers are
669 essentially divided into two categories: non-biodegradable and biodegradable, according to
670 the properties of the raw material used [169]. Non-biodegradable fillers are less tolerated in
671 the body than biodegradable ones and therefore can cause serious side effects. Hyaluronic

672 acid (HA) fillers are approved by Food and Drug Administration (FDA) and known for providing
673 the ideal features mentioned today and dominate the sector [167]. Choi [27] developed an
674 injectable levan-based hydrogel for use as a dermal filler for soft tissue augmentation and
675 reported that this system could be an alternative to hyaluronic acid (HA)-based dermal fillers.
676 The injectable hydrogels were formed by combining Pluronic F127, CMC, and levan derived
677 from *Z. mobilis* with hydrophobic and non-covalent interactions. The levan hydrogel and HA-
678 based hydrogels were tested in an animal disease model both *in vitro* and *in vivo*. Rheological
679 results showed that the elastic modulus of levan-based hydrogel (~6 kPa) was higher than that
680 of the HA-based hydrogel (~2.8 kPa), and the interconnected porous structures were similar
681 to each other. In addition, no cytotoxicity was observed in human adult dermal fibroblasts
682 (hADF) in the levan-treated group, and enhanced cell proliferation was observed. Since
683 collagen synthesis is another important factor in enhancing the anti-wrinkle effect [170],
684 hydrogels were also evaluated for their ability to improve collagen synthesis. hADF cells
685 treated with levan showed higher expression of the type I collagen gene and improved anti-
686 wrinkle efficacy in the wrinkle mouse model compared to HA. Later, by adding hydroxyapatite
687 to the prepared hydrogels, their *in vivo* stability was extended to maintain the anti-wrinkle effect
688 [28]. Levan hydrogel was biocompatible and stable longer *in vivo* than Pluronic F127 or HA,
689 indicating that levan has high potential as a new material for effective dermal filler compared
690 to HA *in vivo*. Therefore, levan-based dermal fillers are an up-and-coming, low-cost alternative
691 to overpriced HA-based hydrogels. Additionally, due to its surface morphology, thermal
692 behavior, rheological properties, and gel-forming features, enzymatically produced *E.*
693 *amylovora* levan was also proposed as a promising candidate for cosmeceutical applications
694 [25]. In this study, levan and other commercial hydrogels, such as carrageenan and guar gum,
695 showed similar rheological behavior, similar porous network microstructure, and endothermic
696 temperature.

697 Normally, shear-thinning hydrogels are mostly ideal for use in the cosmetic industry;
698 however, chemical modification, which is usually applied for synthesis, causes high gelation
699 time and chemical toxicity. Nair and Choudhury [29] produced levan/gellan composite
700 hydrogels using levan from the *E. herbicola* solution and low acyl gellan polysaccharide, aiming
701 to eliminate the problems caused by chemical modification by using natural polysaccharides.
702 The results showed that the composite hydrogels exhibited remarkable mechanical properties
703 and easy injectability. In addition, it was observed that when the ratio of levan or gellan
704 polysaccharide in the composite hydrogels was increased, the swelling percentage also
705 increased due to free hydroxyl groups compared to hydrogels consisting of equal amounts of
706 each polysaccharide [171]. In addition, it was shown that the hydrogels had 97% water
707 retention capacity and sufficient cross-linking with strong structures, revealing the significant
708 potential of levan-gellan hydrogel for use as an injectable material in the medical and cosmetic
709 industries.

710

711 5.5. Potential Applications in Food Science

712 Levan-based hydrogels hold significant promise in the food industry due to their natural
713 origin, biocompatibility, and functional properties such as antioxidant, antidiabetic, and anti-
714 obesogenic activity. Different authors proposed the use of levan in association with other
715 biopolymers to form films feasible as edible coatings. For instance, levan-gellan gum [172],
716 levan-chitosan [173], levan-vanillin [174], and oxidized levan-gelatin [175] films have been
717 proposed as a coating to be applied on the surface of food products to improve their shelf life.

718 Moreover, the gelling properties of levan could be exploited for the design of functional
719 foods with improved overall acceptability while delivering prebiotic levan. Being levan, able to
720 form hydrogels, its usage in all gel-based foods could be tested. However, to this aim, it would
721 be fundamental to have a deep understanding of structure-function relationships at different
722 lengths of scales (from nano to micro and macro scale). Today, the possible interactions of
723 levan with other biopolymers, such as proteins or other carbohydrates, in complex food
724 systems are still underexplored but highly demanded for the design of novel sustainable food
725 with designed health-improving capacity. In this context, Hundschell et al. (2022) [176] studied
726 the influence of levan on the thermally induced gel formation of β -lactoglobulin. The presence
727 of levan increased the water-binding capacity of the gel network. Besides, some studies
728 elucidated the structuring ability of levan produced by microbial fermentation in bread. The
729 exopolysaccharide levan is reported to be able to impact the bread quality [177]. *B. subtilis*
730 levan produced from coconut inflorescence extract was studied not only for its technological
731 properties but also as a sweetener [178]. The possibility of exploiting levan also as an
732 alternative and innovative sweetener is particularly interesting in the attempt to reduce the use
733 of artificial non-nutritive sweeteners, such as saccharin, cyclamate, and aspartame.
734 Considering both the health and technological functionalities of levan, it seems to be an ideal
735 polymer that can be used in many areas, from packaging to the food industry, as an ingredient
736 in many food formulations.

737 Furthermore, thinking about the possibility of converting hydrogels into oleogels, i.e.,
738 oil-based gels with macroscopic properties mimicking those of solid fats [179, 180], or into
739 aerogels, i.e., highly porous materials designed as delivery systems [181], it cannot be
740 underestimated the possibility to use levan hydrogels in the field of oleogelation or
741 aerogelation.

742

743 5.6. Other Applications

744 To minimize the health, economic, and social damage that epidemics can cause, it is
745 important to detect and capture the pathogens that cause them as soon as possible and many
746 strategies are applied in today's literature. Some of these are magnetic nanoparticles (MNPs)
747 for the detection of various infectious diseases [182], superparamagnetic iron oxide
748 nanoparticles (SPIONs) functionalized with peptides obtained from salivary protein, a
749 mesoporous PDMS sponge for foodborne pathogens [183], magnetic beads (MB) coated with
750 specific molecules for pathogen detection from blood samples [184], and a silk protein-based
751 microbial trap [185]. It is known that carbohydrates on the mucosal tissue surface act as
752 receptors for pathogens during infection and prevent invasion by preventing pathogens from
753 passing through the cell membrane [186]. With this approach, carbohydrate materials that will
754 be designed by taking inspiration from a natural process may be useful as pathogen trappers.
755 Li et al. (2011) [187] used carbohydrate-functional chitosan nanofibers to capture the influenza
756 virus. Moreover, carbohydrate-enriched graphene sheets [188] and glycosylated stimuli-
757 responsive polyacrylamide microspheres with AgNPs [189] not only selectively encapsulated
758 pathogens but also enabled the killing of captured bacteria.

759 Kim et al. (2020) [35] proposed hydrogels made of levan produced from *Z. mobilis* and
760 glutaraldehyde poly(vinyl alcohol) (PVA) as influenza virus capture and recovery materials. The
761 approach that levan would promote virus capture by effectively interacting with the lectin,
762 hemagglutinin and nucleoprotein (NP) of the virus was confirmed by RT-PCR and ELISA tests.
763 According to the results, the virus capture efficiency of levan-PVA hydrogels was higher than

764 commercial cotton swabs due to the lack of the lectin binding function of PVA alone. To test
765 the capture capacity of levan hydrogels in different transmission routes, the authors also
766 produced bioaerosols containing influenza viruses and tested their capture with a filter material
767 containing the hydrogels. RT-PCR analyses showed that levan hydrogels increased the
768 capture of virus droplets compared to the control group. This study showed that levan-based
769 hydrogels could be simple and cost-effective materials for pathogen capture and recovery.

770 Another interesting application is the use of levan hydrogels in conservation science.
771 Cultural heritages play a major role in ensuring the historical, social, and economic integrity of
772 the society. Even traditional restoration methods applied to protect them from destructive
773 environmental factors such as temperature, light, microorganisms, and erosion can damage
774 the heritage [190]. On the other hand, in recent years, new methods have been developed to
775 overcome the limitations of traditional restoration techniques and materials, and the interest in
776 sustainable, environmentally friendly, and non-toxic systems has increased. Recently, the
777 application of materials science and nanoscience to the preservation of works of art has led to
778 the development of advanced cleaning systems and approaches that are transforming the
779 preservation of cultural heritage [191]. The first suggestion of gels with their ability to provide
780 appropriate protection and cleaning due to the osmotic balance and flexibility they provide
781 [192], followed by the production of more advanced and responsive gels [193], inorganic
782 nanomaterials [194], microemulsions [195], biocomposite films [196], hybrids such as fibroin-
783 nanocellulose composite [197] and chitosan-based coatings [198] are among the materials
784 used in studies carried out to protect cultural heritage today, and it is noteworthy that
785 carbohydrates are frequently used in this sector due to their outstanding properties.

786 Based on the many important properties of levan-based hydrogels, a study was
787 conducted to investigate the potential use of levan polysaccharides in areas other than health
788 services, such as conservation. Saglam et al. (2023) [41] investigated the potential use of IPN-
789 based enzymatic levan-polyacrylamide hydrogels (EL-PA) in paper protection applications.
790 According to the results of hydrogel characterization in terms of structural, morphological,
791 rheological, and swelling kinetics, EL-PA hydrogels have larger specific surface areas
792 compared to PA-gel, and this is one of the properties sought in surface coating applications
793 [199]. In addition, in the FTIR analysis performed on the paper sample previously coated with
794 hydrogel, as a result of the separation of the hydrogel, only typical bands associated with
795 cellulose were observed, suggesting that the hydrogels successfully removed the
796 contaminants on the paper surface. The results showed that levan-based hydrogels have high
797 potential in conservation science thanks to their biocompatibility and easy applicability [41].

798

799 **6. Conclusion and Future Perspectives**

800 As the demand for natural, economical, biocompatible, and biodegradable materials
801 continues to rise, levan has emerged as a promising polysaccharide with a wide range of
802 applications in various fields, from medicine to cosmetics. Its properties, such as adhesive
803 strength, self-assembly, low viscosity, and its bioactivity, ranging from prebiotic and anti-cancer
804 to anti-inflammatory and anti-diabetic, distinguished it from other polysaccharides, making it a
805 polymer of significant interest for further research and development [15, 17]. Levan-based
806 hydrogels, with their 3D network structures, have proven to be ideal materials for biomedical
807 applications due to their superior biocompatibility, biodegradability, and nontoxicity.
808 Furthermore, Levan derivatives, such as methacrylated, phosphonated, and oxidized levan,

809 have shown potential as parent materials for hydrogel production. These hydrogels have
810 already been explored for applications in drug delivery, tissue engineering, cosmetics, and
811 beyond. However, challenges remain, including high production costs of levan and variability
812 in its properties, such as molecular weight, chain length, and branching patterns which depend
813 on the producing organisms and production conditions. These issues must be addressed to
814 optimize levan-based hydrogels for broader industrial applications [45].

815 In this systematic review, the physicochemical and functional properties of levan
816 polymers as ideal hydrogel raw materials are examined, together with the wide range of usage
817 areas of existing hydrogels from drug delivery to conservation science. In addition, in some
818 sections, an objective perspective is provided by comparing the hydrogel structures that are
819 currently accepted as gold standards with levan-based hydrogels. In light of the studies
820 conducted on levan hydrogels to date and in drug delivery, tissue engineering, cosmetics, and
821 other different fields, it can be expected that the potential usage areas of these hydrogels will
822 increase even more in the future. One of these emerging areas is environmental science.
823 Levan hydrogels possess key features—such as high water absorption capacity, adjustable
824 porosity, biodegradability, and non-toxicity—that make them suitable for environmental uses.
825 These include their application as adsorbents in wastewater treatment and as carriers in
826 controlled-release systems for agricultural chemicals [200]. Moreover, a study by Phengnoi et
827 al. (2019) [201] demonstrated that blending levan with polyvinyl alcohol (PVA), a synthetic
828 polymer with low degradability, led to increased degradation rates with higher levan content,
829 further supporting their potential in eco-friendly materials.

830 Despite the competitive properties of levan-based hydrogels with other natural polymer
831 hydrogels currently used, unfortunately, this is a relatively new field and there are still not
832 enough studies in the literature, only a handful of patents have been issued. Although most
833 studies have been in the fields focused on drug delivery and tissue engineering, hydrogel
834 studies in these areas are still insufficient.

835 A recently published article presenting a comprehensive bibliometric analysis of
836 hydrogel research suggested that future applications of hydrogels will predominantly focus on
837 wound healing, drug delivery, cell encapsulation, bioprinting, tissue engineering, electronic
838 devices, and environmental applications. Notably, in the field of drug delivery, the development
839 of responsive sustained-release nanocarriers, intelligent drug delivery systems, and targeted
840 delivery approaches are expected to be significant trends [202]. Also, in their analysis, “wound
841 healing”, “3D printing”, “antibacterial”, “strain”, “adhesive”, “tough”, “strain sensor”, and
842 “inflammation” were identified as hot spots.

843 Moving forward, levan-based hydrogels need to be developed further to enhance their
844 functionality and applicability. One important avenue of research is the investigation of levan’s
845 interaction with both synthetic and natural materials used in hydrogel production. The
846 properties of composite hydrogels, formed by combining levan with other materials, also
847 warrant further study.

848 The regulatory framework for introducing hydrogels into practice depends on their
849 intended application—medical, cosmetic, food, or industrial. In medical and healthcare
850 contexts, hydrogels are regulated as medical devices or drug-device combinations by
851 authorities like the FDA in the US and under the EU Medical Device Regulation (MDR). These
852 require classification based on risk, biocompatibility testing (e.g., ISO 10993), sterility
853 validation, clinical evaluation, and compliance with manufacturing standards such as GMP or

854 ISO 13485 [203]. For cosmetic uses, regulations focus on safety and proper labeling, with
855 notification procedures like the EU's Cosmetic Products Notification Portal (CPNP). In the food
856 sector, hydrogels must be approved as safe additives, such as GRAS substances in the US or
857 approved E numbers in the EU. Industrial applications are generally less tightly regulated but
858 may fall under environmental or chemical safety rules like EPA or REACH, especially if human
859 exposure is possible.

860 Levan hydrogels are not currently present in major regulatory or clinical databases such
861 as the FDA or European Database on Medical Devices (EUDAMED) and no approved or
862 clinically investigated levan-based hydrogel products have been identified [204]. This clearly
863 shows that they have not yet reached the stage of regulatory recognition or clinical translation
864 despite the broader clinical interest in hydrogel technologies. To advance the clinical and
865 commercial translation of levan-based hydrogels, future research should prioritize
866 comprehensive *in vivo* studies. While preliminary *in vivo* evaluations have demonstrated
867 promising biocompatibility, the current body of evidence remains limited and insufficient to fully
868 assess their behavior under complex physiological conditions. Systematic *in vivo* testing is
869 essential to evaluate not only biocompatibility but also immunogenicity, biodegradability,
870 mechanical stability, and therapeutic efficacy across diverse biomedical applications. Such
871 studies are critical for meeting the safety and efficacy standards set by regulatory agencies
872 such as the FDA and European Medicines Agency (EMA) and represent a necessary milestone
873 before progressing to human clinical trials and market adoption.

874 Despite the growing interest in levan-based hydrogels, there are only a limited number
875 of MSc and PhD theses dedicated to this topic worldwide, highlighting a significant gap in
876 academic research training that should be addressed through increased graduate-level
877 investigations across institutions globally. In conclusion, while levan hydrogels currently show
878 significant promise in several biomedical applications, their full potential has yet to be realized.
879 Future research will likely expand their use, not just as bioactive delivery systems, but also in
880 more diverse and functional areas, benefiting from their natural, biocompatible, and versatile
881 properties.

882

883 **Acknowledgements**

884 The authors sincerely acknowledge the financial support from the Partnership for Research
885 and Innovation in the Mediterranean Area (PRIMA) under the Valostones project. ETO also
886 gratefully acknowledges support from The Scientific and Technological Research Council of
887 Turkey (TÜBİTAK) through project 123N067.

888

889 **Declaration of generative AI and AI-assisted technologies in the writing** 890 **process**

891 During the preparation of this work the author(s) used ChatGPT in order to improve readability
892 and language of the work. After using this tool/service, the author(s) reviewed and edited the
893 content as needed and take(s) full responsibility for the content of the published article. Any
894 use of generative AI in this manuscript adheres to ethical guidelines for use and
895 acknowledgement of generative AI in academic research.

896

897 **References**

- 898 [1] B. Balakrishnan, P.A. Hassan, A.K. Tyagi, An introduction to biomaterials, *Engineered*
899 *Biomaterials: Progress and Prospects.* (2023) 1–57.
900 https://doi.org/10.1142/9789811272011_0001.
- 901 [2] S. Todros, M. Todesco, A. Bagno, Biomaterials and Their Biomedical Applications: From
902 Replacement To Regeneration, Processes. 9 (2021) 1949. <https://doi.org/10.3390/pr9111949>.
- 903 [3] M. Ansari, A. Darvishi, A review of the current state of natural biomaterials in wound healing
904 applications, *Front. in Bioeng. and Biotechnol.* 12 (2024) 1309541.
905 <https://doi.org/10.3389/fbioe.2024.1309541>.
- 906 [4] P. Research, Biotechnology Market Size to Worth Around USD 4.25 Trillion by 2033.
907 <https://www.precedenceresearch.com/biotechnology-market>, 2024 (accessed 10 February
908 2025).
- 909 [5] I. Benalaya, G. Alves, J. Lopes, L.R. Silva, A review of natural polysaccharides: Sources,
910 characteristics, properties, food, and pharmaceutical applications, *Int. J. Mol. Sci.* 25(2) (2024)
911 1322. <https://doi.org/10.3390/ijms25021322>.
- 912 [6] Q. Yang, J. Peng, H. Xiao, X. Xu, Z. Qian, Polysaccharide hydrogels: Functionalization,
913 construction and served as scaffold for tissue engineering, *Carbohydr. Polym.* 278 (2022)
914 118952. <https://doi.org/10.1016/j.carbpol.2021.118952>.
- 915 [7] P.M. Junaid, A.H. Dar, K.K. Dash, S. Rohilla, R. Islam, R. Shams, V.K. Pandey, S.
916 Srivastava, P. S. Panesar, S. Zaidi, Polysaccharide-based hydrogels for microencapsulation of
917 bioactive compounds: A review, *J. Agric. Food Res.* 15 (2024) 101038.
918 <https://doi.org/10.1016/j.jafr.2024.101038>.
- 919 [8] M.U.A. Khan, G.M. Stojanović, M.F.B. Abdullah, A. Dolatshahi-Pirouz, H.E. Marei, N.
920 Ashammakhi, A. Hasan, Fundamental properties of smart hydrogels for tissue engineering
921 applications: A review, *Int. J. Biol. Macromol.* 254 (2024) 127882.
922 <https://doi.org/10.1016/j.ijbiomac.2023.127882>.
- 923 [9] A. Bordbar-Khiabani, M. Gasik, Smart hydrogels for advanced drug delivery systems, *Int.*
924 *J. Mol. Sci.* 23 (2022) 3665. <https://doi.org/10.3390/ijms23073665>.
- 925 [10] D. Tahir, A. Ardiansyah, H. Heryanto, E.E.M. Noor, M.A. Mohamed, Chitosan-based
926 hydrogels: A comprehensive review of transdermal drug delivery, *Int. J. Biol. Macromol.* 298
927 (2025) 140010. <https://doi.org/10.1016/j.ijbiomac.2025.140010>.
- 928 [11] N. Maqbool, Z. Ali, S. Batool, M.U. Rehman, A.H. Alamri, A.A. Fatease, A.A. Lahiq, S.T.
929 Alsharif, F.U. Din, Improved wound care via novel dextran and boric acid loaded wound healing
930 gel in excision mice wound model, *J. Drug Deliv. Sci. Technol.* (2025) 106586.
931 <https://doi.org/10.1016/j.jddst.2024.106586>.
- 932 [12] J. Singh, N. Vishavnath, V. Sharma, B. Singh, Development of agar-alginate marine
933 polysaccharides-based hydrogels for agricultural applications to reduce environmental
934 hazards, *Int. J. Biol. Macromol.* 295 (2025) 139659.
935 <https://doi.org/10.1016/j.ijbiomac.2025.139659>.
- 936 [13] Akan G. & Toksoy Öner E. (2021) Gel Properties of Microbial Polysaccharides. In: Oliveira
937 J., Radhouani H., Reis R.L. (eds) *Polysaccharides of Microbial Origin.* Springer, Cham.
938 https://doi.org/10.1007/978-3-030-35734-4_34-1.

- 939 [14] D. Ni, S. Zhang, X. Liu, Y. Zhu, W. Xu, W. Zhang, W. Mu, Production, effects, and
940 applications of fructans with various molecular weights, *Food Chem.* 437 (2024) 137895.
941 <https://doi.org/10.1016/j.foodchem.2023.137895>.
- 942 [15] E. Toksoy Öner, J. Hernández, J. Combie, Review of levan polysaccharide: from a century
943 of past experiences to future prospects, *Biotechnol. Adv.* 34 (2016) 827–844.
944 <https://doi.org/10.1016/j.biotechadv.2016.05.002>.
- 945 [16] B. Veerapandian, S. Krishnan, S. Sivaraman, A. Immanuel, S.R. Shanmugam, E.T. Öner,
946 P. Venkatachalam, V. Ulaganathan, *Bacillus* spp. as microbial factories for levan and
947 fructooligosaccharide production – Recent trends, *Int. J. Biol. Macromol.* (2025) 252.
948 <https://doi.org/10.1016/j.ijbiomac.2025.140252>.
- 949 [17] E.T. Öner, Levan as a Functional Polymer for Biomedical Applications, In Elsevier eBooks.
950 (2023) pp. 257–274. <https://doi.org/10.1016/b978-0-323-85410-8.00008-9>.
- 951 [18] S. Tornacı, M. Erginer, B. Gökalsın, A. Aysan, M. Çetin, M. Sadauki, N. Fındıklı, S. Genç,
952 C. Sesal, E. Toksoy Öner, Investigating the cryoprotective efficacy of fructans in mammalian
953 cell systems via a structure-functional perspective, *Carbohydr. Polym.* 328 (2024) 121704.
954 <https://doi.org/10.1016/j.carbpol.2023.121704>.
- 955 [19] E.C. de Siqueira, E. Toksoy Öner, Co-production of levan with other high-value
956 bioproducts: A Review, *Int. J. Biol. Macromol.* 235 (2023) 123800.
957 <https://doi.org/10.1016/j.ijbiomac.2023.123800>.
- 958 [20] M. González-Torres, F. Hernández-Rosas, N. Pacheco, J. Salinas-Ruiz, J.A. Herrera-
959 Corredor, R. Hernández-Martínez, Levan production by *Suhomyces kilbournensis* using
960 sugarcane molasses as a carbon source in submerged fermentation, *Molecules* 29(5) (2024)
961 1105. <https://doi.org/10.3390/molecules29051105>.
- 962 [21] V. Ahuja, A.K. Bhatt, J.R. Banu, V. Kumar, G. Kumar, Y.-H. Yang, S.K. Bhatia, Microbial
963 Exopolysaccharide Composites in Biomedicine and Healthcare: Trends and Advances,
964 *Polymers* 15 (2023) 1801. <https://doi.org/10.3390/polym15071801>.
- 965 [22] E. Castillo, A. López–Munguía, Synthesis of levan in water–miscible organic solvents, *J.*
966 *Biotechnol.* 114 (2004) 209–217. <https://doi.org/10.1016/j.jbiotec.2004.06.003>.
- 967 [23] N. Ido, A. Lybman, S. Hayet, D.N. Azulay, M. Ghayeb, S. Liddawieh, L. Chai, *Bacillus*
968 *subtilis* biofilms characterized as hydrogels. insights on water uptake and water binding in
969 biofilms, *Soft Matter* 16(26) (2020) 6180–6190. <https://doi.org/10.1039/d0sm00581a>.
- 970 [24] C. Charoenwongphaibun, C. Lorthongpanich, P. Septham, K. Wangpaiboon, P. Panpetch,
971 R. Pichyangkura, T. Charoenwongpaiboon, K. Kuttiyawong, Synthesis of Cationic Quaternized
972 Nanolevan Derivative for Small Molecule and Nucleic Acid Delivery, *Gels* 9(3) (2023) 188.
973 <https://doi.org/10.3390/gels9030188>.
- 974 [25] J. Peng, W. Xu, D. Ni, W. Zhang, T. Zhang, C. Guang, W. Mu, Preparation of a novel water-
975 soluble gel from *Erwinia amylovora* levan, *Int. J. Biol. Macromol.* 122 (2019) 469–478.
976 <https://doi.org/10.1016/j.ijbiomac.2018.10.093>.
- 977 [26] V.K. Truong, C.M. Bhadra, A.J. Christofferson, I. Yarovsky, M. Al Kobaisi, C.J. Garvey, O.N.
978 Ponamoreva, S.V. Alferov, V.A. Alferov, P.G. Tharushi Perera, D.H. Nguyen, R. Buividas, S.
979 Juodkakis, R.J. Crawford, E.P. Ivanova, Three-dimensional organization of self-encapsulating
980 *Gluconobacter oxydans* bacterial cells, *ACS Omega* 2(11) (2017) 8099–8107.
981 <https://doi.org/10.1021/acsomega.7b01282>.

- 982 [27] W.I. Choi, Y. Hwang, A. Sahu, K. Min, D. Sung, G. Tae, J.H. Chang, An injectable and
983 physical levan-based hydrogel as a dermal filler for soft tissue augmentation, *Biomater. Sci.*
984 6(10) (2018) 2627–2638. <https://doi.org/10.1039/c8bm00524a>.
- 985 [28] Y. Hwang, J.S. Lee, H. An, H. Oh, D. Sung, G. Tae, W.I. Choi, Hydroxyapatite-embedded
986 levan composite hydrogel as an injectable dermal filler for considerable enhancement of
987 biological efficacy, *J. Ind. Eng. Chem.* 104 (2021) 491–499.
988 <https://doi.org/10.1016/j.jiec.2021.08.040>.
- 989 [29] R. Nair, A.R. Choudhury, Synthesis and rheological characterization of a novel shear
990 thinning levan gellan hydrogel, *Int. J. Biol. Macromol.* 159 (2020) 922–930.
991 <https://doi.org/10.1016/j.ijbiomac.2020.05.119>.
- 992 [30] R. Hama, A. Ulziibayar, J.W. Reinhardt, T. Watanabe, J. Kelly, T. Shinoka, Recent
993 developments in biopolymer-based hydrogels for tissue engineering applications,
994 *Biomolecules* 13 (2023) 280. <https://doi.org/10.3390/biom13020280>.
- 995 [31] S.V. María, G.D.C. Katia, A. Florencia, M.L. María, G. Gerardo, V. Nancy, R.C. Mariana,
996 Biopolymer production by bacteria isolated from native stingless bee honey, *Scaptotrigona*
997 *jujuyensis*, *Food Biosci.* 42 (2021) 101077. <https://doi.org/10.1016/j.fbio.2021.101077>
- 998 [32] A. Osman, E. Toksoy Öner, M.S. Eroglu, Novel levan and pNIPA temperature sensitive
999 hydrogels for 5-ASA controlled release, *Carbohydr. Polym.* 165 (2017) 61–70.
1000 <https://doi.org/10.1016/j.carbpol.2017.01.097>.
- 1001 [33] A. Osman, E. Lin, D.S. Hwang, A sticky carbohydrate meets a mussel adhesive: Catechol-
1002 conjugated levan for hemostatic and wound healing applications, *Carbohydr. Polym.* 299
1003 (2022) 120172. <https://doi.org/10.1016/j.carbpol.2022.120172>.
- 1004 [34] A. Berg, E. Toksoy Öner, J. Combie, B. Schneider, R. Ellinger, J. Weisser, R. Wyrwa, M.
1005 Schnabelrauch, Formation of new, cytocompatible hydrogels based on photochemically
1006 crosslinkable levan methacrylates, *Int. J. Biol. Macromol.* 107 (2018) 2312–2319.
1007 <https://doi.org/10.1016/j.ijbiomac.2017.10.120>.
- 1008 [35] S.-J. Kim, P.K. Bae, M. Choi, J.O. Keem, Y. Shin, Fabrication and Application of Levan–
1009 PVA Hydrogel for Effective Influenza Virus Capture, *ACS Appl. Mater. Interfaces* 12 (2020)
1010 29103–29109. <https://doi.org/10.1021/acsami.0c08333>.
- 1011 [36] B. Veerapandian, T.K.R. Selvaraj, S.R. Shanmugam, K.K. Sarwareddy, K.P. Mani, P.
1012 Venkatachalam, In-vitro drug release and stability assessment of tailored levan–chitosan
1013 biocomposite hydrogel, *Iran. Polym. J.* (2023) 1–13. <https://doi.org/10.1007/s13726-023-01229-x>.
- 1015 [37] T. Demirci, M. Erginer Hasköylü, M.S. Eroğlu, J. Hemberger, E. Toksoy Öner, Levan-based
1016 hydrogels for controlled release of Amphotericin B for dermal local antifungal therapy of
1017 Candidiasis, *Eur. J. Pharm. Sci.* 145 (2020) 105255.
1018 <https://doi.org/10.1016/j.ejps.2020.105255>.
- 1019 [38] S.S. Selvi, M. Erginer Hasköylü, S. Genç, E. Toksoy Öner, Synthesis and characterization
1020 of levan hydrogels and their use for resveratrol release, *J. Bioact. Compat. Polym.* 36(6) (2021)
1021 464–480. <https://doi.org/10.1177/08839115211055725>.
- 1022 [39] Ö.E. Altıntaş, P.A. Çelik, Levan-based bioactive hydrogels containing herbal liposome in
1023 treating acute wounds, *J. Bioact. Compat. Polym.* 38 (2023) 437–457.
1024 <https://doi.org/10.1177/08839115231198528>.

- 1025 [40] M. Yavuz, M. Erginer, C. Kasavi, E. Toksoy Öner, Enhanced preservation of viability and
1026 species stratification in *Lactocaseibacillus* group using levan-fortified skim milk as a
1027 cryoprotectant during freeze-drying, *Food Sci. Biotechnol.* (2024).
1028 <https://doi.org/10.1007/s10068-024-01802-x>.
- 1029 [41] R.O. Saglam, S.U. Yıldırım, F.N. Oktar, S. Genc, G. Erdem, E.T. Oner, Synthesis and
1030 characterization of interpenetrating network (IPN) based levan-polyacrylamide hydrogels and
1031 their application in conservation of Cultural Heritage, *J. Cult. Herit.* 64 (2023) 255–265.
1032 <https://doi.org/10.1016/j.culher.2023.10.013>.
- 1033 [42] C.Y. Akkulah, M. Erginer, A. Cumbul, O. Kirtel, F. Bayram, E. Toksoy Öner, Enhanced
1034 effects of levan hydrogels and bovine grafts on guided bone regeneration: In-vitro and in-vivo
1035 analysis, *Int. J. Biol. Macromol.* 292 (2025) 139129.
1036 <https://doi.org/10.1016/j.ijbiomac.2024.139129>.
- 1037 [43] O. Kirtel, M. Menéndez, M. Versluys, W. Van den Ende, L. Hernández, E. Toksoy Öner,
1038 Levansucrase from *Halomonas smyrnensis* AAD6T: first halophilic GH-J clan enzyme
1039 recombinantly expressed, purified, and characterized, *Appl. Microbiol. Biotechnol.*
1040 102(21)(2018) 9207–9220. <https://doi.org/10.1007/s00253-018-9311-z>.
- 1041 [44] R. Srikanth, G. Siddartha, C.H.S.S. Sundhar Reddy, B.S. Harish, M. Janaki Ramaiah, K.B.
1042 Uppuluri, Antioxidant and anti-inflammatory levan produced from *Acetobacter xylinum*
1043 NCIM2526 and its statistical optimization, *Carbohydr. Polym.* 123 (2015) 8–16.
1044 <https://doi.org/10.1016/j.carbpol.2014.12.079>.
- 1045 [45] J. Combie, E. Toksoy Öner, Fructan Production Processes, *The Book of Fructans* (2023)
1046 187–199. <https://doi.org/10.1016/b978-0-323-85410-8.00009-0>.
- 1047 [46] G. Gojgic-Cvijovic, D. Jakovljevic, B. Loncarevic, N. Todorovic, M. Pergal, J. Ciric, K. Loos,
1048 V. Beskoski, M. Vrvic, Production of levan by *Bacillus licheniformis* NS032 in sugar beet
1049 molasses-based medium, *Int. J. Biol. Macromol.* 121 (2018) 142–151.
1050 <https://doi.org/10.1016/j.ijbiomac.2018.10.019>.
- 1051 [47] O. Kirtel, E.T. Öner, Levan polysaccharide for biomedical applications, *Soft Matter Biomed.*
1052 *Appl.* (2021) 134–154. <https://doi.org/10.1039/9781839161124-00134>.
- 1053 [48] M. Erginer, A. Akcay, B. Coskuncan, T. Morova, D. Rende, S. Bucak, N. Baysal, R. Özişik,
1054 M.S. Eroğlu, M. Agirbasli, E. Toksoy Öner, Sulfated levan from *Halomonas smyrnensis* as a
1055 bioactive, heparin-mimetic glycan for cardiac tissue engineering applications, *Carbohydr.*
1056 *Polym.* 149 (2016) 289–296. <https://doi.org/10.1016/j.carbpol.2016.04.092>.
- 1057 [49] H.K. Sarilmiser, E. Toksoy Öner, Investigation of anti-cancer activity of linear and
1058 aldehyde-activated levan from *Halomonas smyrnensis* AAD6T, *Biochem. Eng. J.* 92 (2014)
1059 28–34. <https://doi.org/10.1016/j.bej.2014.06.020>.
- 1060 [50] J. Combie, E.T. Öner, From healing wounds to resorbable electronics, Levan can fill
1061 bioadhesive roles in scores of Markets, *Bioinspir. Biomim.* 14(1) (2018) 011001.
1062 <https://doi.org/10.1088/1748-3190/aaed92>.
- 1063 [51] M. Versluys, O. Kirtel, E. Toksoy Öner, W. Van den Ende, The Fructan Syndrome:
1064 Evolutionary Aspects and Common Themes Among Plants and Microbes, *Plant Cell Environ.*
1065 41(1) (2017) 16–38. <https://doi.org/10.1111/pce.13070>.

- 1066 [52] S. Yoo, S. Jung, K. Kwak, J. Kim, The Role of Prebiotics in Modulating Gut Microbiota:
1067 Implications for Human Health, *International Journal of Molecular Sciences*. 25(9) (2024) 4834.
1068 <https://doi.org/10.3390/ijms25094834>.
- 1069 [53] D. Davani-Davari, M. Negahdaripour, I. Karimzadeh, M. Seifan, M. Mohkam, S. Masoumi,
1070 A. Berenjian, Y. Ghasemi, Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical
1071 Applications, *Foods* 8(3) (2019) 92. <https://doi.org/10.3390/foods8030092>.
- 1072 [54] M. Arapović, L. Puljić, N. Kajić, B. Kartalović, K. Habschied, K. Mastanjević, New insights
1073 in prebiotic utilization: A systematic review, *Processes* 12(5) (2024) 867.
1074 <https://doi.org/10.3390/pr12050867>.
- 1075 [55] Y. Xiao, Q. Zhao, D. Ni, X. Zhang, W. Hao, Q. Yuan, W. Xu, W. Mu, D. Wu, X. Wu, S.
1076 Wang, Polymerization of dietary fructans differentially affects interactions among intestinal
1077 microbiota of colitis mice, *The ISME J.* (2025). <https://doi.org/10.1093/ismejo/wrae262>.
- 1078 [56] Y. Jia, Y. Liu, Y. Wu, F. Ren, H. Liu, From Diet to microbiota: How fruits and vegetables
1079 influence gut microbiota, *Int. J. Food Sci. Technol.* 60(1) (2025).
1080 <https://doi.org/10.1093/ijfood/vvae008>.
- 1081 [57] S.S. Selvi, E. Eminagic, M.Y. Kandur, E. Ozcan, C. Kasavi, E.T. Toksoy Öner, Ch. 10 -
1082 Research and Production of Microbial Polymers for Food Industry, in: G. Molina, V.K. Gupta,
1083 B.N. Singh, N. Gathergood (Eds.), *Bioprocessing for Biomolecules Production*, 2019, pp. 211–
1084 231, ISBN 1119434327, 9781119434320.
- 1085 [58] L. Li, Z. Qiu, Y. Qiao, X. Bai, W. Zhu, Z. Li, Z. Zheng, Immunomodulatory effects of inulin-
1086 type fructans from *Arctium Lappa* L. by targeting gut microbiota and their metabolites, *Food*
1087 *Chem.* 467 (2025) 142308. <https://doi.org/10.1016/j.foodchem.2024.142308>.
- 1088 [59] P. Zhao, J. Wang, I. Kim, Evaluation of dietary fructan supplementation on growth
1089 performance, nutrient digestibility, meat quality, fecal microbial flora, and fecal noxious gas
1090 emission in finishing pigs, *J. Anim. Sci.* 91(11) (2013) 5280–5286.
1091 <https://doi.org/10.2527/jas.2012-5393>.
- 1092 [60] X.J. Lei, Y.M. Kim, J.H. Park, D.H. Baek, C.M. Nyachoti, I.H. Kim, Effects of levan-type
1093 fructan on growth performance, nutrient digestibility, diarrhea scores, faecal shedding of total
1094 lactic acid bacteria and coliform bacteria, and faecal gas emission in weaning pigs, *J. Sci. Food*
1095 *Agric.* 98(4) (2017) 1539–1544. <https://doi.org/10.1002/jsfa.8625>.
- 1096 [61] A.A. Hamdy, N.A. Elattal, M.A. Amin, A.E. Ali, N.M. Mansour, G.E. Awad, A.R.H. Farrag,
1097 M.A. Esawy, *In vivo* assessment of possible probiotic properties of *Bacillus subtilis* and
1098 prebiotic properties of levan, *Biocatal. Agric. Biotechnol.* 13 (2018) 190–197.
1099 <https://doi.org/10.1016/j.bcab.2017.12.001>.
- 1100 [62] C. Liu, S. Kolida, D. Charalampopoulos, R.A. Rastall, An evaluation of the prebiotic
1101 potential of microbial levans from *Erwinia* sp. 10119, *J. Funct. Foods* 64 (2020) 103668.
1102 <https://doi.org/10.1016/j.jff.2019.103668>.
- 1103 [63] J. Ju, S. Heo, H. Kim, M. Jo, S. Jeon, D. Park, C. Kim, B. Oh, Selective production of two
1104 prebiotic extracellular polysaccharides from an oral probiotic lactic acid bacterium,
1105 *Streptococcus salivarius* SY511, *LWT* 198 (2024) 116051.
1106 <https://doi.org/10.1016/j.lwt.2024.116051>.

- 1107 [64] R. Wannasutta, S. Laopeng, S. Yuensuk, S. McCloskey, N. Riddech, W. Mongkolthanaruk,
1108 Biopolymer-Levan Characterization in *Bacillus* Species Isolated from Traditionally Fermented
1109 Soybeans (Thua Nao), ACS Omega (2025). <https://doi.org/10.1021/acsomega.4c09641>.
- 1110 [65] P. Zambelli, L. Tamborini, S. Cazzamalli, A. Pinto, S. Arioli, S. Balzaretti, F.J. Plou, L.
1111 Fernandez-Arrojo, F. Molinari, P. Conti, D. Romano, An efficient continuous flow process for
1112 the synthesis of a non-conventional mixture of fructooligosaccharides, Food Chem. 190 (2016)
1113 607–613. <https://doi.org/10.1016/j.foodchem.2015.06.002>.
- 1114 [66] I. Dahech, K.S. Belghith, K. Hamden, A. Feki, H. Belghith, H. Mejdoub, Antidiabetic activity
1115 of levan polysaccharide in alloxan-induced diabetic rats, Int. J. Biol. Macromol. 49(4) (2011)
1116 742–746. <https://doi.org/10.1016/j.ijbiomac.2011.07.007>.
- 1117 [67] K.S. Belghith, I. Dahech, K. Hamden, A. Feki, H. Mejdoub, H. Belghith, Hypolipidemic
1118 effect of diet supplementation with bacterial levan in cholesterol-fed rats, Int. J. Biol. Macromol.
1119 50(4) (2012) 1070–1074. <https://doi.org/10.1016/j.ijbiomac.2012.02.024>.
- 1120 [68] S. Bahroudi, B. Shabanpour, J. Combie, A. Shabani, M. Salimi, Levan Exerts Health
1121 Benefit Effect through Alteration in Bifidobacteria Population, Iranian Biomed. J. 24(1) (2020)
1122 54–59. <https://doi.org/10.29252/ibj.24.1.54>.
- 1123 [69] W. Ahmad, A. Nasir, S. Prakash, A. Hayat, M.U. Rehman, S. Khaliq, K. Akhtar, M.A. Anwar,
1124 N. Munawar, *In vitro* and *in vivo* interventions reveal the health benefits of levan-type
1125 exopolysaccharide produced by a fish gut isolate *Lactobacillus reuteri* FW2, Life 15(1) (2025)
1126 89. <https://doi.org/10.3390/life15010089>.
- 1127 [70] S.A. Kang, K. Hong, K. Jang, S. Kim, K.H. Lee, B.I. Chang, C. Kim, R. Choue, Anti-obesity
1128 and hypolipidemic effects of dietary levan in high fat diet-induced obese rats, J. Microbiol.
1129 Biotechnol. 14 (2004) 796–804.
- 1130 [71] J.S. Oh, S.R. Lee, K.T. Hwang, G.E. Ji, The anti-obesity effects of the dietary combination
1131 of fermented red ginseng with levan in high fat diet mouse model, Phytother. Res. 28(4) (2013)
1132 617–622. <https://doi.org/10.1002/ptr.5042>.
- 1133 [72] J. Wang, Y. Jiang, Natural compounds as anticancer agents: Experimental evidence,
1134 World J. Exp. Med. 2(3) (2012) 45. <https://doi.org/10.5493/wjem.v2.i3.45>.
- 1135 [73] P. Marino, G. Pepe, M.G. Basilicata, V. Vestuto, S. Marzocco, G. Autore, A. Procino, I.M.
1136 Gomez-Monterrey, M. Manfra, P. Campiglia, Potential role of natural antioxidant products in
1137 oncological diseases, Antioxidants 12 (2023) 704. <https://doi.org/10.3390/antiox12030704>.
- 1138 [74] W.A. Wahab, H.I. Shafey, K.F. Mahrous, M.A. Esawy, S.A. Saleh, Coculture of bacterial
1139 levans and evaluation of its anti-cancer activity against hepatocellular carcinoma cell lines, Sci.
1140 Rep. 14 (2024). <https://doi.org/10.1038/s41598-024-52699-9>.
- 1141 [75] A.T. De Aguiar Silva, I.D.L. Cavalcanti, M. De Araújo Sobral, G.M. De Souza Lima, O.D.L.
1142 Pessoa, N.S.S. Magalhães, C.G.O. Coimbra, M.C. De Britto Lira Nogueira, Development of
1143 levan-coated PIBCA nanoparticles and their antiproliferative activity against MDA-MB-231 and
1144 B16F10 cells, Colloids Surf. A 670 (2023) 131567.
1145 <https://doi.org/10.1016/j.colsurfa.2023.131567>.
- 1146 [76] H. Shawky, D.B. Fayed, S.S.A. El-Karim, H. Rezk, M.A. Esawy, E.K. Farrag,
1147 Immunotherapeutic effects of de novo benzimidazole derivative and prebiotic bacterial levan
1148 against triple-negative breast tumors by harnessing the immune landscape to intercept the

- 1149 oncogenic transcriptome, *Int. J. Biol. Macromol.* 289 (2024) 138844.
1150 <https://doi.org/10.1016/j.ijbiomac.2024.138844>.
- 1151 [77] S. Chen, Q. Li, H. Shi, F. Li, Y. Duan, Q. Guo, New insights into the role of mitochondrial
1152 dynamics in oxidative stress-induced diseases, *Biomed. Pharm.* 178 (2024) 117084.
1153 <https://doi.org/10.1016/j.biopha.2024.117084>.
- 1154 [78] G. Mummaleti, C. Sarma, S. Yarrakula, R. Urla, H. Gazula, Production, properties and
1155 applications of levan polysaccharide, *Food Hum.* 100369 (2024).
1156 <https://doi.org/10.1016/j.foohum.2024.100369>.
- 1157 [79] A.M. Abdel-Fattah, A.M. Gamal-Eldeen, W.A. Helmy, M.A. Esawy, Antitumor and
1158 antioxidant activities of levan and its derivative from the isolate *Bacillus subtilis* NRC1aza,
1159 *Carbohydr. Polym.* 89 (2012) 314–322. <https://doi.org/10.1016/j.carbpol.2012.02.041>.
- 1160 [80] I. Dahech, B. Harrabi, K. Hamden, A. Feki, H. Mejdoub, H. Belghith, K.S. Belghith,
1161 Antioxidant effect of nondigestible levan and its impact on cardiovascular disease and
1162 atherosclerosis, *Int. J. Biol. Macromol.* 58 (2013) 281–286.
1163 <https://doi.org/10.1016/j.ijbiomac.2013.04.058>.
- 1164 [81] O. Taylan, M.T. Yilmaz, E. Dertli, Partial characterization of a levan type exopolysaccharide
1165 (EPS) produced by *Leuconostoc mesenteroides* showing immunostimulatory and antioxidant
1166 activities, *Int. J. Biol. Macromol.* 136 (2019) 436–444.
1167 <https://doi.org/10.1016/j.ijbiomac.2019.06.078>.
- 1168 [82] M.A. Esawy, E.F. Ahmed, W.A. Helmy, N.M. Mansour, W.M. El-Senousy, M.M. El-Safty,
1169 Production of levansucrase from novel honey *Bacillus subtilis* isolates capable of producing
1170 antiviral levans, *Carbohydr. Polym.* 86 (2011) 823–830.
1171 <https://doi.org/10.1016/j.carbpol.2011.05.035>.
- 1172 [83] A.A. Gamal, A.M. Hashem, M.M. El-Safty, R.A. Soliman, M.A. Esawy, Evaluation of the
1173 antiviral activity of *Enterococcus faecalis* Esawy levan and its sulfated form, *Biocatal. Agric.*
1174 *Biotechnol.* 28 (2020) 101735. <https://doi.org/10.1016/j.bcab.2020.101735>.
- 1175 [84] K. Foo, D. Roofeh, Inflammatory diseases, in: N. Liao, J. Mahan, S. Misra, R. Scherzer, J.
1176 Schiller (Eds.), *Pediatric Rotations*, Springer, Cham, 2024. https://doi.org/10.1007/978-3-031-59873-9_26.
- 1177
- 1178 [85] Y. Sharma, M. Arora, K. Bala, The potential of immunomodulators in shaping the future of
1179 healthcare, *Deleted J.* 1 (2024) 1–1. <https://doi.org/10.1007/s44337-024-00029-3>.
- 1180 [86] M. Strzelec, J. Detka, P. Mieszczak, M.K. Sobocińska, M. Majka, Immunomodulation—a
1181 general review of the current state-of-the-art and new therapeutic strategies for targeting the
1182 immune system, *Front. Immunol.* 14 (2023). <https://doi.org/10.3389/fimmu.2023.1127704>.
- 1183 [87] M. Arfeen, A. Srivastava, N. Srivastava, R.A. Khan, S.A. Almahmoud, H.A. Mohammed,
1184 Design, classification, and adverse effects of NSAIDs: A review on recent advancements,
1185 *Bioorg. Med. Chem.* 112 (2024) 117899. <https://doi.org/10.1016/j.bmc.2024.117899>.
- 1186 [88] Y. Qian, J. Ding, R. Zhao, Y. Song, J. Yoo, H. Moon, S. Koo, J.S. Kim, J. Shen, Intrinsic
1187 immunomodulatory hydrogels for chronic inflammation, *Chem. Soc. Rev.* (2024).
1188 <https://doi.org/10.1039/d4cs00450g>.
- 1189 [89] I.D. Young, D. Latousakis, N. Juge, The immunomodulatory properties of β -2,6 fructans:
1190 A comprehensive review, *Nutrients* 13 (2021) 1309. <https://doi.org/10.3390/nu13041309>.

1191 [90] Q. Xu, T. Yajima, W. Li, K. Saito, Y. Ohshima, Y. Yoshikai, Levan (β -2,6-fructan), a major
1192 fraction of fermented soybean mucilage, displays immunostimulating properties via Toll-like
1193 receptor 4 signaling: induction of interleukin-12 production and suppression of T-helper type 2
1194 response and immunoglobulin E production, *Clin. Exp. Allergy* 36 (2006) 94-101.
1195 <https://doi.org/10.1111/j.1365-2222.2006.02401.x>.

1196 [91] M. Molteni, S. Gemma, C. Rossetti, The role of toll-like receptor 4 in infectious and
1197 noninfectious inflammation, *Mediators Inflamm.* (2016) 1-9.
1198 <https://doi.org/10.1155/2016/6978936>.

1199 [92] B.W. Simpson, M.S. Trent, Pushing the envelope: LPS modifications and their
1200 consequences, *Nat. Rev. Microbiol.* 17 (2019) 403-416. <https://doi.org/10.1038/s41579-019-0201-x>.

1202 [93] E. Gerber-Tichet, F.P. Blanchet, K. Majzoub, E.J. Kremer, Toll-like receptor 4 – a
1203 multifunctional virus recognition receptor, *Trends Microbiol.* 33 (2024) 34-47.
1204 <https://doi.org/10.1016/j.tim.2024.07.001>.

1205 [94] I.D. Young, S.A. Nepogodiev, I.M. Black, G. Le Gall, A. Wittmann, D. Latousakis, T.
1206 Visnapuu, P. Azadi, R.A. Field, N. Juge, N. Kawasaki, Lipopolysaccharide associated with β -
1207 2,6 fructan mediates TLR4-dependent immunomodulatory activity *in vitro*, *Carbohydr. Polym.*
1208 277 (2022) 118606. <https://doi.org/10.1016/j.carbpol.2021.118606>.

1209 [95] X. Xu, C. Gao, Z. Liu, J. Wu, J. Han, M. Yan, Z. Wu, Characterization of the levan produced
1210 by *Paenibacillus bovis* sp. nov. BD3526 and its immunological activity, *Carbohydr. Polym.* 144
1211 (2016) 178-186. <https://doi.org/10.1016/j.carbpol.2016.02.049>.

1212 [96] P. Aramsangtienchai, W. Raksachue, S. Pechroj, K. Srisook, The immunomodulatory
1213 activity of levan in RAW264.7 macrophage varies with its molecular weights, *Food Biosci.* 53
1214 (2023) 102721. <https://doi.org/10.1016/j.fbio.2023.102721>.

1215 [97] P. Aramsangtienchai, T. Kongmon, S. Pechroj, K. Srisook, Enhanced production and
1216 immunomodulatory activity of levan from the acetic acid bacterium, *Tanticharoenia*
1217 *sakaeratensis*, *Int. J. Biol. Macromol.* 163 (2020) 574-581.
1218 <https://doi.org/10.1016/j.ijbiomac.2020.07.001>.

1219 [98] Y.O. Waidi, V.S. Wagh, S. Mishra, S. Jhunjhunwala, S.G. Dastager, K. Chatterjee, Vat-
1220 Based 3D-bioprinted scaffolds from photocurable bacterial levan for osteogenesis and
1221 immunomodulation, *Biomacromolecules* (2025). <https://doi.org/10.1021/acs.biomac.4c01264>.

1222 [99] C.N. Munyiri, E.S. Madivoli, J. Kisato, J. Gichuki, P.G. Kareru, Biopolymer based
1223 hydrogels: crosslinking strategies and their applications, *Int. J. Polym. Mater. Polym. Biomater.*
1224 74 (2025) 625-640. <https://doi.org/10.1080/00914037.2024.2356603>.

1225 [100] S. Maiti, B. Maji, H. Yadav, Progress on green crosslinking of polysaccharide hydrogels
1226 for drug delivery and tissue engineering applications, *Carbohydr. Polym.* 326 (2023) 121584.
1227 <https://doi.org/10.1016/j.carbpol.2023.121584>.

1228 [101] M. Wojtkiewicz, A. Stachura, B. Roszkowski, N. Winiarska, K. Kazimierska, K. Stachura,
1229 Are we overlooking harms of BDDE-cross-linked dermal fillers? A scoping review, *Aesthet.*
1230 *Plast. Surg.* (2024). <https://doi.org/10.1007/s00266-024-01995-0>.

1231 [102] S. Adepu, S. Ramakrishna, Controlled drug delivery systems: Current status and future
1232 directions, *Molecules* 26 (2021) 5905. <https://doi.org/10.3390/molecules26195905>.

- 1233 [103] M. Hamidi, M.S. Tabatabaei, M. Moslehi, M. Barati, Introduction to novel drug delivery
1234 systems, *Novel Drug Delivery Systems* (2024) 1–34.
1235 <https://doi.org/10.1002/9781119852476.ch1>.
- 1236 [104] U.E. Ewii, A.L. Onugwu, V.C. Nwokpor, I. Akpaso, T.E. Ogbulie, B. Aharanwa, C. Chijioke,
1237 N. Verla, C. Ihome, C. Ujowundu, C. Anyiam, A.A. Attama, Novel drug delivery systems: Insight
1238 into self-powered and nano-enabled drug delivery systems, *Nano TransMed* 3 (2024) 100042.
1239 <https://doi.org/10.1016/j.ntm.2024.100042>.
- 1240 [105] A.C. Anselmo, S. Mitragotri, An overview of clinical and commercial impact of drug
1241 delivery systems, *J. Controlled Release* 190 (2014) 15–28.
1242 <https://doi.org/10.1016/j.jconrel.2014.03.053>.
- 1243 [106] R. Sharma, S. Kumar, R. Malviya, B.G. Prajapati, D. Puri, S. Limmatvapirat, P.
1244 Sriamornsak, Recent advances in biopolymer-based mucoadhesive drug delivery systems for
1245 oral application, *J. Drug Delivery Sci. Technol.* 91 (2024) 105227.
1246 <https://doi.org/10.1016/j.jddst.2023.105227>.
- 1247 [107] N.H. Thang, T.B. Chien, D.X. Cuong, Polymer-based hydrogels applied in drug delivery:
1248 An overview, *Gels* 9 (2023) 523. <https://doi.org/10.3390/gels9070523>.
- 1249 [108] Y. Guo, M. Wang, Y. Zhang, Z. Zhao, J. Li, Advanced hydrogel material for colorectal
1250 cancer treatment, *Drug Delivery* 32 (2024) 1. <https://doi.org/10.1080/10717544.2024.2446552>.
- 1251 [109] X. Xuan, Y. Li, X. Xu, Z. Pan, Y. Li, Y. Luo, L. Sun, Three-dimensional printable magnetic
1252 hydrogels with adjustable stiffness and adhesion for magnetic actuation and magnetic
1253 hyperthermia applications, *Gels* 11 (2025) 67. <https://doi.org/10.3390/gels11010067>.
- 1254 [110] A.D. Sezer, H. Kazak, E. Toksoy Öner, J. Akbuğa, Levan-based nanocarrier system for
1255 peptide and protein drug delivery: Optimization and influence of experimental parameters on
1256 the nanoparticle characteristics, *Carbohydr. Polym.* 84 (2011) 358–363.
1257 <https://doi.org/10.1016/j.carbpol.2010.11.046>.
- 1258 [111] A.D. Sezer, H. Kazak Sarılmışer, E. Rayaman, A. Çevikbaş, E. Toksoy Öner, J. Akbuğa,
1259 Development and characterization of vancomycin-loaded levan-based microparticulate system
1260 for drug delivery, *Pharm. Dev. Technol.* 22 (2017) 627–634.
1261 <https://doi.org/10.3109/10837450.2015.1116564>.
- 1262 [112] F. Bahadori, Z. Eskandari, N. Ebrahimi, M.S. Bostan, M.S. Eroğlu, E.T. Oner,
1263 Development and optimization of a novel PLGA-Levan based drug delivery system for
1264 curcumin, using a quality-by-design approach, *Eur. J. Pharm. Sci.* 138 (2019) 105037.
1265 <https://doi.org/10.1016/j.ejps.2019.105037>.
- 1266 [113] E.C. Mutlu, F. Bahadori, M.S. Bostan, H.K. Sarilmiser, E. ToksoyOner, M.S. Eroğlu,
1267 *Halomonas* levan-coated phospholipid based nano-carrier for active targeting of A549 lung
1268 cancer cells, *Eur. Polym. J.* 144 (2020) 110239.
1269 <https://doi.org/10.1016/j.eurpolymj.2020.110239>.
- 1270 [114] E. Cinan, S. Cesur, M. Erginer Haskoylu, O. Gunduz, E. Toksoy Öner, Resveratrol-loaded
1271 levan nanoparticles produced by electrohydrodynamic atomization technique, *Nanomaterials*
1272 11 (2021) 2582. <https://doi.org/10.3390/nano11102582>.
- 1273 [115] I. Pantelić, M. Lukić, G. Gojgić-Cvijović, D. Jakovljević, I. Nikolić, D.J. Lunter, R. Daniels,
1274 S. Savić, *Bacillus licheniformis* levan as a functional biopolymer in topical drug dosage forms:

1275 From basic colloidal considerations to actual pharmaceutical application, *Eur. J. Pharm. Sci.*
1276 142 (2020) 105109. <https://doi.org/10.1016/j.ejps.2019.105109>.

1277 [116] S.L. Sadhana, K.P. Dharshini, D.R. Devi, V.H.B. Naryanan, B. Veerapandian, R. Luo, J.
1278 Yang, S.R. Shanmugam, V. Ponnusami, M. Brzezinski, Y. Zheng, Investigation of levan-derived
1279 nanoparticles of dolutegravir: A promising approach for the delivery of anti-HIV drug as milk
1280 admixture, *J. Pharm. Sci.* 113 (2024) 2513–2523. <https://doi.org/10.1016/j.xphs.2024.05.019>.

1281 [117] Y.H. Song, H.M. Cho, Y.C. Ryu, B.H. Hwang, J.H. Seo, Electro-sprayable levan-coated
1282 nanoclusters and ultrasound-responsive drug delivery for cancer therapy, *ACS Appl. Mater.*
1283 *Interfaces* 16 (2024) 21509–21521. <https://doi.org/10.1021/acsami.3c18774>.

1284 [118] T. Ho, C. Chang, H. Chan, T. Chung, C. Shu, K. Chuang, T. Duh, M. Yang, Y. Tyan,
1285 Hydrogels: Properties and applications in biomedicine, *Molecules* 27 (2022) 2902.
1286 <https://doi.org/10.3390/molecules27092902>.

1287 [119] Y. Li, X. Ding, H. Hu, F. Xu, Stimulus-responsive polysaccharide-based hydrogels: From
1288 design to biomedical applications, *Precision Med. Eng.* 1 (2024) 100001.
1289 <https://doi.org/10.1016/j.preme.2024.100001>.

1290 [120] I.S. Protsak, Y.M. Morozov, Fundamentals and advances in stimuli-responsive hydrogels
1291 and their applications: A review, *Gels* 11 (2025) 30. <https://doi.org/10.3390/gels11010030>.

1292 [121] M.S. Bostan, M. Senol, T. Cig, I. Peker, A.C. Goren, T. Ozturk, M.S. Eroglu, Controlled
1293 release of 5-aminosalicylic acid from chitosan based pH and temperature sensitive hydrogels,
1294 *Int. J. Biol. Macromol.* 52 (2012) 177–183. <https://doi.org/10.1016/j.ijbiomac.2012.09.018>.

1295 [122] H. Nasution, H. Harahap, N.F. Dalimunthe, M.H.S. Ginting, M. Jaafar, O.O.H. Tan, H.K.
1296 Aruan, A.L. Herfananda, Hydrogel and effects of crosslinking agent on cellulose-based
1297 hydrogels: A review, *Gels* 8 (2022) 568. <https://doi.org/10.3390/gels8090568>.

1298 [123] R.A. Gemeinhart, C.M. Bare, R.T. Haasch, E.J. Gemeinhart, Osteoblast-like cell
1299 attachment to and calcification of novel phosphonate-containing polymeric substrates, *J.*
1300 *Biomed. Mater. Res. Part A* 78A (2006) 433–440. <https://doi.org/10.1002/jbm.a.30788>.

1301 [124] A. Revete, A. Aparicio, B.A. Cisterna, J. Revete, L. Luis, E. Ibarra, E.A.S. González, J.
1302 Molino, D. Reginensi, Advancements in the use of hydrogels for regenerative medicine:
1303 Properties and biomedical applications, *Int. J. Biomater.* 2022 (2022) 1–16.
1304 <https://doi.org/10.1155/2022/3606765>.

1305 [125] S. Dutta, P. Bansal, Hydrogel-based bio-inks: Current progress and future directions in
1306 3D printing, *Indian J. Chem. Technol.* (2025). <https://doi.org/10.56042/ijct.v32i1.12274>.

1307 [126] F. Ali, I. Khan, J. Chen, K. Akhtar, E.M. Bakhsh, S.B. Khan, Emerging fabrication
1308 strategies of hydrogels and its applications, *Gels* 8 (2022) 205.
1309 <https://doi.org/10.3390/gels8040205>.

1310 [127] M.P. Ferraz, An overview on the big players in bone tissue engineering: Biomaterials,
1311 scaffolds and cells, *Int. J. Mol. Sci.* 25(7) (2024) 3836. <https://doi.org/10.3390/ijms25073836>.

1312 [128] S. Pramanik, S. Kharche, N. More, D. Ranglani, G. Singh, G. Kapusetti, Natural
1313 biopolymers for bone tissue engineering: A brief review, *Eng. Regener.* 4(2) (2023) 193–204.
1314 <https://doi.org/10.1016/j.engreg.2022.12.002>.

1315 [129] C. Ding, X. Liu, S. Zhang, S. Sun, J. Yang, G. Chai, N. Wang, S. Ma, Q. Ding, W. Liu,
1316 Multifunctional hydrogel bioscaffolds based on polysaccharide to promote wound healing: A

- 1317 review, Int. J. Biol. Macromol. 259 (2024) 129356.
1318 <https://doi.org/10.1016/j.ijbiomac.2024.129356>.
- 1319 [130] G. Sandri, S. Rossi, M.C. Bonferoni, C. Caramella, F. Ferrari, Electrospinning
1320 technologies in wound dressing applications, in: *Therapeutic Dressings and Wound Healing*
1321 *Applications*, Wiley, 2020, pp. 315–336. <https://doi.org/10.1002/9781119433316.ch14>.
- 1322 [131] M.G. Nur, M. Rahman, T.M. Dip, M.H. Hossain, N.B. Hossain, S. Baratchi, R. Padhye, S.
1323 Houshyar, Recent advances in bioactive wound dressings, *Wound Repair Regen.* 33(1)
1324 (2024). <https://doi.org/10.1111/wrr.13233>.
- 1325 [132] M. Farahani, A. Shafiee, Wound healing: From passive to smart dressings, *Adv.*
1326 *Healthcare Mater.* 10(16) (2021). <https://doi.org/10.1002/adhm.202100477>.
- 1327 [133] S. Kaya, S. Derman, Properties of ideal wound dressing, *Ankara Univ. Eczacilik Fak.*
1328 *Dergisi* 47(3) (2023) 5. <https://doi.org/10.33483/jfpau.1253376>.
- 1329 [134] R. Hama, J.W. Reinhardt, A. Ulziibayar, T. Watanabe, J. Kelly, T. Shinoka, Recent tissue
1330 engineering approaches to mimicking the extracellular matrix structure for skin regeneration,
1331 *Biomimetics* 8(1) (2023) 130. <https://doi.org/10.3390/biomimetics8010130>.
- 1332 [135] A. Gaspar-Pintiliescu, A. Stanciuc, O. Craciunescu, Natural composite dressings based
1333 on collagen, gelatin and plant bioactive compounds for wound healing: A review, *Int. J. Biol.*
1334 *Macromol.* 138 (2019) 854–865. <https://doi.org/10.1016/j.ijbiomac.2019.07.155>.
- 1335 [136] J. Su, J. Li, J. Liang, K. Zhang, J. Li, Hydrogel preparation methods and biomaterials for
1336 wound dressing, *Life* 11(10) (2021) 1016. <https://doi.org/10.3390/life11101016>.
- 1337 [137] M.L. Del Prado-Audelo, I.H. Caballero-Florán, N. Mendoza-Muñoz, D. Giraldo-Gomez,
1338 J. Sharifi-Rad, J.K. Patra, M. González-Torres, B. Florán, H. Cortes, G. Leyva-Gómez, Current
1339 progress of self-healing polymers for medical applications in tissue engineering, *Iran. Polym.*
1340 *J.* 31 (2022) 7–29. <https://doi.org/10.1007/s13726-021-00943-8>.
- 1341 [138] B.F. Far, L. Jameie, P. Taromi, R. Nahavndi, E. Jamshidi, Dermal and oral wound healing,
1342 in: *ACS Symp. Ser.* (2025) 297–329. <https://doi.org/10.1021/bk-2025-1497.ch009>.
- 1343 [139] C. Sturzoiu, M. Petrescu, B. Galateanu, M. Anton, C. Nica, G.I. Simionca, G. Stoian,
1344 *Zymomonas mobilis* levan is involved in metalloproteinases activation in healing of wounded
1345 and burned tissues, *Sci. Pap. Anim. Sci. Biotechnol.* 44(1) (2011) 453–458.
- 1346 [140] M. Erginer, B. Gökalsin, S. Tornaci, C. Sesal, E.T. Öner, Exploring the potential of
1347 *Halomonas* levan and its derivatives as active ingredients in cosmeceutical and skin
1348 regenerating formulations, *Int. J. Biol. Macromol.* 240 (2023) 124418.
1349 <https://doi.org/10.1016/j.ijbiomac.2023.124418>.
- 1350 [141] E. Peled, S. Tornaci, I. Zlotver, A. Dubnika, E.T. Öner, A. Sosnik, First transcriptomic
1351 insight into the reprogramming of human macrophages by levan-type fructans, *Carbohydr.*
1352 *Polym.* 320 (2023) 121203. <https://doi.org/10.1016/j.carbpol.2023.121203>.
- 1353 [142] A. Haddar, E. Ben Ayed, A. Sila, J.-L. Putaux, A. Bougatef, S. Boufi, Hybrid levan–
1354 Ag/AgCl nanoparticles produced by UV-irradiation: Properties, antibacterial efficiency, and
1355 application in bioactive poly(vinyl alcohol) films, *RSC Adv.* 11(62) (2021) 38990–39003.
1356 <https://doi.org/10.1039/d1ra07852f>.
- 1357 [143] N. Ismayilova, M.K. Zia, H.S. Akkaya, S. Ulag, Y. Guldorum, E.T. Öner, E. Ince,
1358 Development and Evaluation of Fucoidan-Loaded Electrospun Polyvinyl Alcohol/Levan

- 1359 Nanofibers for Wound Dressing Applications, *Biomimetics* 9(9) (2024) 1–14.
1360 <https://doi.org/10.3390/biomimetics9090508>.
- 1361 [144] O.M. Bondarenko, A. Ivask, A. Kahru, H. Vija, T. Titma, M. Visnapuu, U. Joost, K. Pudova,
1362 S. Adamberg, T. Visnapuu, T. Alamäe, Bacterial polysaccharide levan as stabilizing, non-toxic
1363 and functional coating material for microelement-nanoparticles, *Carbohydr. Polym.* 136 (2016)
1364 710–720. <https://doi.org/10.1016/j.carbpol.2015.09.093>.
- 1365 [145] Á. González-Garcinuño, R. Masa, M. Hernández, Á. Domínguez, A. Tabernero, E.M. Del
1366 Valle, Levan-Capped Silver Nanoparticles for Bactericidal Formulations: Release and Activity
1367 Modelling, *Int. J. Mol. Sci.* 20(6) (2019) 1502. <https://doi.org/10.3390/ijms20061502>.
- 1368 [146] R.D. Kasai, D. Radhika, S. Archana, H. Shanavaz, R. Koutavarapu, D.Y. Lee, J. Shim, A
1369 review on hydrogels classification and recent developments in biomedical applications, *Int. J.*
1370 *Polym. Mater. Polym. Biomater.* 72(13) (2022) 1059–1069.
1371 <https://doi.org/10.1080/00914037.2022.2075872>.
- 1372 [147] S. Mitura, A. Sionkowska, A. Jaiswal, Biopolymers for hydrogels in cosmetics: review, *J.*
1373 *Mater. Sci. Mater. Med.* 31 (2020) 50. <https://doi.org/10.1007/s10856-020-06390-w>.
- 1374 [148] S.K. Bhatia, P.S. Panesar, S. Mehariya, *Microbial Exopolysaccharides: Production and*
1375 *applications*, CRC Press (2024).
- 1376 [149] J.K. Liu, Natural products in cosmetics, *Nat. Prod. Bioprospect.* 12(1) (2022) 40.
- 1377 [150] M.E. Hasköylü, E.T. Öner, Fructans in Personal Care Products, in: *The Book of Fructans*
1378 (2023) 275–294. Academic Press.
- 1379 [151] K.H. Kim, C.B. Chung, Y.H. Kim, K.S. Kim, C.S. Han, C.H. Kim, Cosmeceutical properties
1380 of levan produced by *Zymomonas mobilis*, *J. Cosmet. Sci.* 56 (2005) 395–406.
- 1381 [152] M.E. Parente, A.O. Andrade, G. Ares, F. Russo, Á. Jiménez-Kairuz, Bioadhesive
1382 hydrogels for cosmetic applications, *Int. J. Cosmet. Sci.* 37 (2015) 511–518.
1383 <https://doi.org/10.1111/ics.12227>.
- 1384 [153] E. Manousi, A. Chatzitaki, E. Vakirlis, C. Karavasili, D.G. Fatouros, Development and *in*
1385 *vivo* evaluation of 3D printed hydrogel patches for personalized cosmetic use based on skin
1386 type, *J. Drug Deliv. Sci. Technol.* 92 (2023) 105306.
1387 <https://doi.org/10.1016/j.jddst.2023.105306>.
- 1388 [154] M.A. Waqar, N. Mubarak, A.M. Khan, F. Shaheen, M.A. Mustafa, T. Riaz, Recent
1389 advances in polymers, preparation techniques, applications, and future perspectives of
1390 hydrogels, *Int. J. Polym. Mater.* 1–20 (2024). <https://doi.org/10.1080/00914037.2024.2335163>.
- 1391 [155] M. Tamimi, S. Bagheri-Khoulenjani, R. Narain, S. Rajabi, Hydrogels for wound dressing,
1392 in: Elsevier eBooks (2025) 531–562. <https://doi.org/10.1016/b978-0-443-16168-1.00019-2>.
- 1393 [156] Q. Wu, N. Cheng, D. Fang, H. Wang, F. Rahman, H. Hao, Y. Zhang, Recent advances
1394 on application of polysaccharides in cosmetics, *Deleted J.* 1(1) (2024) 100004.
1395 <https://doi.org/10.1016/j.jdsct.2024.100004>.
- 1396 [157] B.G. Prajapati, S.R. Shah, S. Singh, Natural Biopolymer, Smart Ways of Biomaterial
1397 Designing Synthesis and Characterization: Prospects of Enhanced Application From Labs to
1398 Clinics, 63 (2025).

- 1399 [158] K.H. Kim, C.B. Chung, Y.H. Kim, K.S. Kim, C.S. Han, C.H. Kim, Cosmeceutical properties
1400 of levan produced by *Zymomonas mobilis*, *Int. J. Cosmet. Sci.* 28(3) (2006) 231.
1401 <https://doi.org/10.1111/j.1467-2494.2006.00314.2.x>.
- 1402 [159] F. Masayo, T. Takayuki, Beautifully Whitening Agent, JP2006052146A (2006), Patent,
1403 February 23.
- 1404 [160] A. Lewińska, M. Domżał-Kędzia, M. Łukaszewicz, Self-assembly levan, as a natural
1405 active bio-nanocarrier, *Sustainable Chem. Pharm.* 31 (2022) 100936.
1406 <https://doi.org/10.1016/j.scp.2022.100936>.
- 1407 [161] M. Domżał-Kędzia, A. Lewińska, A. Jaromin, M. Weselski, R. Pluskota, M. Łukaszewicz,
1408 Fermentation parameters and conditions affecting levan production and its potential
1409 applications in cosmetics, *Bioorg. Chem.* 93 (2019) 102787.
1410 <https://doi.org/10.1016/j.bioorg.2019.02.012>.
- 1411 [162] R.T. Da Silva, G.T. Bersaneti, B.G. Bigotto, V.A.I. Silveira, A.A.S.G. Lonni, D. Borsato,
1412 M.A.P.C. Celligoi, Development of a facial biocosmetic containing levan, almond, and
1413 cinnamon oils with antioxidant and moisturizing properties, *Acta Sci. Biol. Sci.* 44 (2022)
1414 e58869. <https://doi.org/10.4025/actascibiolsci.v44i1.58869>.
- 1415 [163] H. Ko, B.H. Sung, M. Kim, H.J. Park, J. Sohn, J. Bae, Dual-functional carboxymethyl
1416 levan-based protein carrier for cosmeceutical application of human epidermal growth factor,
1417 *Int. J. Biol. Macromol.* 229 (2022) 181–187. <https://doi.org/10.1016/j.ijbiomac.2022.12.278>.
- 1418 [164] M.A. Seeger, A.S. Paller, The roles of growth factors in keratinocyte migration, *Adv.*
1419 *Wound Care* 4(4) (2014) 213–224. <https://doi.org/10.1089/wound.2014.0540>.
- 1420 [165] J.K. Helenas, G.T. Bersaneti, R.T. Da Silva, B.G. Bigotto, A.A.S.G. Lonni, D. Borsato, C.
1421 Baldo, M.A.P.C. Celligoi, Development of facial cosmetic formulations using microbial levan in
1422 association with plant-derived compounds using simple lattice design, *Braz. Arch. Biol.*
1423 *Technol.* 66 (2022). <https://doi.org/10.1590/1678-4324-2023220275>.
- 1424 [166] T. Wasilewski, A. Seweryn, D. Pannert, K. Kierul, M. Domżał-Kędzia, Z. Hordyjewicz-
1425 Baran, M. Łukaszewicz, A. Lewińska, Application of Levan-Rich Digestate Extract in the
1426 Production of Safe-to-Use and Functional Natural Body Wash Cosmetics, *Molecules* 27(9)
1427 (2022) 2793. <https://doi.org/10.3390/molecules27092793>.
- 1428 [167] A. Fallacara, E. Durini, S. Vertuani, S. Manfredini, Hyaluronic acid fillers in soft tissue
1429 regeneration, *Facial Plast. Surg.* 33(01) (2017) 87–96. <https://doi.org/10.1055/s-0036-1597685>.
- 1431 [168] D. Hamrah, B. Aleman, Injectable soft tissue fillers and their use in facial rejuvenation,
1432 in: Springer eBooks (2024) 301–313. https://doi.org/10.1007/978-3-031-47307-4_42.
- 1433 [169] D. Cassuto, G. Bellia, C. Schiraldi, An overview of soft tissue fillers for cosmetic
1434 dermatology: From filling to regenerative medicine, *Clin. Cosmet. Investig. Dermatol.* 14 (2021)
1435 1857–1866. <https://doi.org/10.2147/ccid.s276676>.
- 1436 [170] X. He, X. Gao, Y. Guo, W. Xie, Research progress on bioactive factors against skin aging,
1437 *Int. J. Mol. Sci.* 25(7) (2024) 3797. <https://doi.org/10.3390/ijms25073797>.
- 1438 [171] A.M. Romyantsev, A. Pan, S.G. Roy, P. De, E.Y. Kramarenko, Polyelectrolyte gel swelling
1439 and conductivity vs counterion type, cross-linking density, and solvent polarity,
1440 *Macromolecules* 49(17) (2016) 6630–6643. <https://doi.org/10.1021/acs.macromol.6b00911>.

1441 [172] N. Agarwal, N. Jyoti, M. Thakur, B.B. Mishra, S.P. Singh, Preparation and characterization
1442 of biodegradable films based on levan polysaccharide blended with gellan gum, Environ.
1443 Technol. Innov. 31 (2023) 103231. <https://doi.org/10.1016/j.eti.2023.103231>.

1444 [173] Y. Wang, Z. Zhou, Y. Han, Levan-chitosan blend films: Preparation, structural, physical
1445 properties and application in pork packaging, Int. J. Biol. Macromol. 217 (2022) 624–632.
1446 <https://doi.org/10.1016/j.ijbiomac.2022.07.049>.

1447 [174] M. Xu, L. Zhang, Y. Zeng, Z. Zhou, Y. Han, Preparation and characterization of Levan
1448 composite film incorporating vanillin for use as a potential edible coating for peony seed oil,
1449 Int. J. Biol. Macromol. (2024) 138732. <https://doi.org/10.1016/j.ijbiomac.2024.138732>.

1450 [175] W. Hong, H. Xiao, Z. Zhang, M. Xu, Z. Yi, Z. Zhou, Y. Han, A composite film of oxidized
1451 levan crosslinked with gelatin: Strong hydrophobic and mechanical properties and effective
1452 preservation of fresh mozzarella cheese, Int. J. Biol. Macromol. 284 (2024) 137701.
1453 <https://doi.org/10.1016/j.ijbiomac.2024.137701>.

1454 [176] C.S. Hundschell, J. Brühhan, T. Anzmann, R. Kohlus, A.M. Wagemans, Influence of levan
1455 on the thermally induced gel formation of β -lactoglobulin, Gels 8(4) (2022) 228.
1456 <https://doi.org/10.3390/gels8040228>.

1457 [177] T. Ua-Arak, F. Jakob, R.F. Vogel, Fermentation pH modulates the size distributions and
1458 functional properties of *Gluconobacter albidus* TMW 2.1191 levan, Front. Microbiol. 8 (2017)
1459 807. <https://doi.org/10.3389/fmicb.2017.00807>.

1460 [178] G. Mummaleti, C. Sarma, S.K. Kalakandan, H. Gazula, V. Sivanandham, A. Anandharaj,
1461 Characterization of levan produced from coconut inflorescence sap using *Bacillus subtilis* and
1462 its application as a sweetener, LWT 154 (2021) 112697.
1463 <https://doi.org/10.1016/j.lwt.2021.112697>.

1464 [179] F. Ciuffarin, S. Plazzotta, K. Rondou, F. Van Bockstaele, K. Dewettinck, L. Manzocco, S.
1465 Calligaris, Oil structuring using whey protein-based cryogel particles: Effect of gelation pH and
1466 feasibility as an ingredient in low-saturated fat cocoa spreads, Food Res. Int. 196 (2024)
1467 115029. <https://doi.org/10.1016/j.foodres.2024.115029>.

1468 [180] S. Plazzotta, S. Calligaris, L. Manzocco, Innovative bioaerogel-like materials from fresh-
1469 cut salad waste via supercritical-CO₂-drying, Innov. Food Sci. Emerg. Technol. 47 (2018) 485–
1470 492.

1471 [181] L. De Berardinis, S. Plazzotta, M. Magnan, L. Manzocco, Hybrid aerogels of spirulina
1472 and whey proteins as novel cellular solids, LWT 213 (2024) 117078.
1473 <https://doi.org/10.1016/j.lwt.2024.117078>.

1474 [182] B.H. Elwakil, M.H. Elsabrouty, N. Yousef, M. El-Khatib, Functionalized magnetic
1475 nanosystems for the detection and control of infectious diseases, Elsevier eBooks (2024) 475–
1476 503. <https://doi.org/10.1016/b978-0-443-19012-4.00017-5>.

1477 [183] S. Azinheiro, K. Kant, M. Shahbazi, A. Garrido-Maestu, M. Prado, L. Dieguez, A smart
1478 microfluidic platform for rapid multiplexed detection of foodborne pathogens, Food Control 114
1479 (2020) 107242. <https://doi.org/10.1016/j.foodcont.2020.107242>.

1480 [184] S. David, R. Munteanu, A. Tițoiu, I. Petcu, I. Cernat, C. Leancu, M. Gheorghiu, E.
1481 Gheorghiu, Direct, rapid detection of pathogens from urine samples, Materials 15(21) (2022)
1482 7640. <https://doi.org/10.3390/ma15217640>.

- 1483 [185] S. Wu, J. Chen, H. Wu, Biofabricating a silk scaffold as a functional microbial trap, ACS
1484 Biomater. Sci. Eng. 6(12) (2020) 7041–7050.
1485 <https://doi.org/10.1021/acsbiomaterials.0c01232>.
- 1486 [186] K. Kato, A. Ishiwa, The role of carbohydrates in infection strategies of enteric pathogens,
1487 Trop. Med. Health 43(1) (2014) 41–52. <https://doi.org/10.2149/tmh.2014-25>.
- 1488 [187] X. Li, P. Wu, G.F. Gao, S. Cheng, Carbohydrate-functionalized chitosan fiber for influenza
1489 virus capture, Biomacromolecules 12(11) (2011) 3962–3969.
1490 <https://doi.org/10.1021/bm200970x>.
- 1491 [188] Z. Qi, P. Bharate, C. Lai, B. Ziem, C. Böttcher, A. Schulz, F. Beckert, B. Hatting, R.
1492 Mülhaupt, P.H. Seeberger, R. Haag, Multivalency at interfaces: Supramolecular carbohydrate-
1493 functionalized graphene derivatives for bacterial capture, release, and disinfection, Nano Lett.
1494 15(9) (2015) 6051–6057. <https://doi.org/10.1021/acs.nanolett.5b02256>.
- 1495 [189] J.K. Ajish, P.N. Rao, S. Bhakta, S. Kota, K.A. Kumar, Glycosylated stimuli-responsive
1496 polyacrylamide microspheres with in-situ formed AgNPs for bacterial capture, detection and
1497 killing, Colloids Surf. A Physicochem. Eng. Asp. 696 (2024) 134305.
1498 <https://doi.org/10.1016/j.colsurfa.2024.134305>.
- 1499 [190] D. Chelazzi, P. Baglioni, From nanoparticles to gels: A breakthrough in art conservation
1500 science, Langmuir 39(31) (2023) 10744–10755.
1501 <https://doi.org/10.1021/acs.langmuir.3c01324>.
- 1502 [191] N. Khaksar-Baghan, A. Koochakzai, Y. Hamzavi, An overview of gel-based cleaning
1503 approaches for art conservation, Heritage Sci. 12(1) (2024). [https://doi.org/10.1186/s40494-](https://doi.org/10.1186/s40494-024-01369-0)
1504 [024-01369-0](https://doi.org/10.1186/s40494-024-01369-0).
- 1505 [192] A. Burnstock, R. Wolbers, Cleaning painted surfaces: Aqueous methods, Stud. Conserv.
1506 46(3) (2001) 221. <https://doi.org/10.2307/1506812>.
- 1507 [193] E. Carretti, M. Bonini, L. Dei, B.H. Berrie, L.V. Angelova, P. Baglioni, R.G. Weiss, New
1508 frontiers in materials science for art conservation: Responsive gels and beyond, Acc. Chem.
1509 Res. 43(6) (2010) 751–760. <https://doi.org/10.1021/ar900282h>.
- 1510 [194] D. Chelazzi, G. Poggi, Y. Jaidar, N. Toccafondi, R. Giorgi, P. Baglioni, Hydroxide
1511 nanoparticles for cultural heritage: Consolidation and protection of wall paintings and
1512 carbonate materials, J. Colloid Interface Sci. 392 (2012) 42–49.
1513 <https://doi.org/10.1016/j.jcis.2012.09.069>.
- 1514 [195] D. Chelazzi, R. Giorgi, P. Baglioni, Microemulsions, micelles, and functional gels: How
1515 colloids and soft matter preserve works of art, Angew. Chem. Int. Ed. 57(25) (2017) 7296–
1516 7303. <https://doi.org/10.1002/anie.201710711>.
- 1517 [196] G. Infurna, G. Cavallaro, G. Lazzara, S. Milioto, N.T. Dintcheva, Bionanocomposite films
1518 containing halloysite nanotubes and natural antioxidants with enhanced performance and
1519 durability as promising materials for cultural heritage protection, Polymers 12(9) (2020) 1973.
1520 <https://doi.org/10.3390/polym12091973>.
- 1521 [197] C. Cianci, D. Chelazzi, G. Poggi, F. Modi, R. Giorgi, M. Laurati, Hybrid fibroin-
1522 nanocellulose composites for the consolidation of aged and historical silk, Colloids Surf. A
1523 Physicochem. Eng. Asp. 634 (2021) 127944. <https://doi.org/10.1016/j.colsurfa.2021.127944>.

1524 [198] C.H.M. Camargos, G. Poggi, D. Chelazzi, P. Baglioni, C.A. Rezende, Protective coatings
1525 based on cellulose nanofibrils, cellulose nanocrystals, and lignin nanoparticles for the
1526 conservation of cellulosic artifacts, *ACS Appl. Nano Mater.* 5(9) (2022) 13245–13259.
1527 <https://doi.org/10.1021/acsanm.2c02968>.

1528 [199] S. Croll, Surface roughness profile and its effect on coating adhesion and corrosion
1529 protection: A review, *Prog. Org. Coat.* 148 (2020) 105847.
1530 <https://doi.org/10.1016/j.porgcoat.2020.105847>.

1531 [200] Y. Dong, M. Ghasemzadeh, Z. Khorsandi, R. Sheibani, M. Nasrollahzadeh, Starch-based
1532 hydrogels for environmental applications: A review, *Int. J. Biol. Macromol.* 269 (2024) 131956.
1533 <https://doi.org/10.1016/j.ijbiomac.2024.131956>.

1534 [201] P. Phengnoi, K. Thongmee, S. Tiptipakorn, B. Boekfa, K. Kuttiyawong, Biodegradation of
1535 levan polymer / poly(lactic acid) (PLA) blend, *IOP Conf. Ser. Mater. Sci. Eng.* 526 (2019)
1536 012025. <https://doi.org/10.1088/1757-899X/526/1/012025>.

1537 [202] Z.-Z. Yuan, Y.-Z. Fan, S.-J. Cheng, F.-J. Wei, J. Gao, C.-X. Wang, B.-S. Song, S.-L. Tan,
1538 S.-L. Gao, J.-J. Kang, Y. Liu, S.-H. Li, A bibliometric analysis of hydrogel research in various
1539 fields: The trends and evolution of Hydrogel Application, *J. Nanobiotechnol.* 23(1) (2025)
1540 <https://doi.org/10.1186/s12951-025-03090-x>.

1541 [203] M.C. Catoira, J. González-Payo, L. Fusaro, et al., Natural hydrogels R&D process:
1542 technical and regulatory aspects for industrial implementation, *J. Mater. Sci. Mater. Med.* 31
1543 (2020) 64. <https://doi.org/10.1007/s10856-020-06401-w>.

1544 [204] J.R. Clegg, K. Adebawale, Z. Zhao, S. Mitragotri, Hydrogels in the clinic: An update,
1545 *Bioeng. Transl. Med.* 9 (2024) e10680. <https://doi.org/10.1002/btm2.10680>.

1546

1547

1 **Hydrogels of Levan Polysaccharide: A Systematic Review**

2

3 Aybüke Tekin^a, Selay Tornacı^a, Defne Boyacı^b, Suming Li^c, Sonia Calligaris^d, Hana Maalej^e,
4 Ebru Toksoy Öner^{a*}

5 ^a IBSB, Marmara University, Department of Bioengineering, Istanbul, Turkey

6 ^b Uskudar American Academy, 34664, Uskudar, Istanbul, Turkey

7 ^c Institut Européen des Membranes, UMR CNRS 5635, Université de Montpellier, France

8 ^d Department of Agricultural, Food, Environmental and Animal Sciences, University of Udine,
9 Udine, 33100, Italy

10 ^e Laboratory of Biodiversity and Valorization of Arid Areas Bioresources (BVBA),
11 LR16ES36, Faculty of Sciences of Gabes, University of Gabes, Gabes 6072, Tunisia

12

13 *Corresponding author. E-mail: ebru.toksoy@marmara.edu.tr

14

15 **Abstract**

16 Levan is a fructose-based homopolysaccharide renowned for its unique properties, including
17 exceptional adhesive strength, self-assembly capability, low viscosity, and bioactivities such
18 as prebiotic, anti-cancer, anti-inflammatory, and anti-diabetic effects. These characteristics
19 have created increasing interest in levan-based biomaterials over the past decade, positioning
20 levan as a highly under-explored biopolymer for a wide range of applications, from medicine
21 to cosmetics. As a result, levan-based hydrogels have emerged as promising biomaterials in
22 drug delivery, tissue engineering, and cosmetic formulations, owing to their extracellular
23 matrix-mimicking structure, tunable mechanical properties, and controlled cargo release
24 capabilities. This review is the first to comprehensively examine the advancements in levan-
25 based hydrogel research, systematically analyzing their biomedical applications and
26 comparing them with other biopolymer-based hydrogels. Key questions regarding levan's
27 potential as an alternative to established hydrogel systems are explored, highlighting areas
28 requiring further research. By assessing trends and findings in the literature, this review
29 provides an overview of the advantages, limitations, and prospects of levan hydrogels. Our
30 analysis establishes a foundation for the continued development of levan-derived
31 biomaterials, fostering broader adoption in biomedical and industrial applications.

32

33 **Keywords**

34 Levan; Polysaccharide; Hydrogel; Biocompatibility; Biomaterials; Tissue Engineering

35

36

37

38

39 1. Introduction

40 Throughout history, significant milestones in humanity have been marked by
41 discoveries in human physiology, diseases and treatments. However, the search for solutions
42 to health problems dates back even further, as people have always relied on natural or
43 synthetic materials from their environment to facilitate wound healing, repair damaged tissues
44 and organs, and even enhance food preservation and safety [1]. Today, with increasing clinical
45 and industrial needs, there is a growing demand for materials, devices, and techniques not
46 only for diagnosing and treating diseases but also for ensuring safety, improving food quality,
47 extending shelf life, and enhancing health benefits [2,3]. Biomedical and food sciences have
48 emerged as multidisciplinary fields in response to these needs, aiming to improve human
49 health by addressing genetic, environmental, and dietary factors. The size of the biotechnology
50 market, which includes both biocompatible and functional, natural or synthetic materials that
51 meet the definition of "biocompatibility", is expected to increase from 1.75 trillion to
52 approximately 4.61 trillion USD from 2025 to 2034 [4]. This trend indicates growing interest in
53 the biomedical, food and cosmetic sectors, as well as in the development of biomaterials for
54 diverse applications.

55 Polysaccharides, the most common biocompatible polymers in nature, have been used
56 throughout human history for their nutritional and healing properties due to their structural and
57 functional characteristics that make them multifunctional bioactive materials [5]. Today, they
58 are widely utilized not only in diagnosis, regenerative medicine, gene therapy, drug targeting,
59 and tissue engineering, but also in food and nutrition sectors for enhancing food texture,
60 stability, and bioavailability, as well as for their prebiotic and health-promoting effects.
61 Polysaccharide-based hydrogels are three-dimensional colloidal solids that retain water in their
62 3D network structure. Compared to rigid scaffolds or dry polymeric systems, polysaccharide-
63 based hydrogels offer flexibility, soft structure, high porosity, and water-holding capacity that
64 promote cell viability, proliferation, matrix remodeling, and better resemblance to the native
65 living tissue. In hydrogel formation, polysaccharides with diverse functional groups enable both
66 chemical and physical crosslinking. Depending on application, this allows for the development
67 of covalently bonded hydrogels with enhanced chemical, mechanical, and dimensional
68 stability, as well as crosslinker-free hydrogels that are easier and faster to prepare [6]. Due to
69 their extracellular matrix-mimicking properties, biocompatibility, flexible synthesis methods,
70 and suitable physical properties, they have found broad applications as artificial soft tissue
71 biomaterials in various biomedical fields, such as controlled drug and cargo release,
72 biosensors, and tissue engineering and regenerative medicine [6, 7]. Furthermore, with a smart
73 hydrogel approach, polysaccharide-based hydrogels can be tuned to respond to environmental
74 stimuli such as pH, temperature, electrical and magnetic fields, ionic strength or light and can
75 change some of their properties such as their wettability, degradability, swelling, and
76 mechanical or surface properties. These tunable properties make them attractive especially
77 for smart drug delivery systems and personalized medicine [8, 9]. While chitosan [10], dextran
78 [11], and alginate [12] are common natural polysaccharides used in hydrogel formulations,
79 levan-based hydrogels have recently gained increasing attention in health-related applications
80 [13]. Levan, a natural homopolysaccharide of fructose, has been part of the human diet for
81 centuries. However, compared to inulin-type fructans, which have a well-established market
82 market as prebiotics, our knowledge of levan remains limited [14,15]. Despite this, levan's
83 remarkable properties, such as biocompatibility, biodegradability, antioxidant, immune
84 boosting, prebiotic, heparin-mimicking, anti-aging, and cryoprotectant effects, have piqued
85 scientific interest, leading to extensive research on its production, derivatives, and levan-based

86 biomaterials [16,17,18]. Challenges such as high production costs and limited commercial
87 availability, have hindered its widespread industrial use, promoting research into new
88 production systems [19]. This has led to the discovery of more affordable methods for
89 producing levan, opening up new avenues for its used in cosmetics, medicine,
90 pharmaceuticals, and the food sector [20]. However, further research is still needed before
91 levan can become a widely used product in these fields.

92 This review systematically examines trends and research on levan-based hydrogels and their
93 applications in various biomedical fields, such as drug delivery, tissue engineering, and
94 cosmetics. Several key questions are addressed, including why levan is an ideal biomaterial
95 for biomedical applications, whether levan-based hydrogels can compete with other
96 biomaterial-based hydrogels, and which sectors have extensively researched them. The
97 literature is compared with other biomaterial-based hydrogels, revealing the advantages and
98 limitations of levan-based hydrogels in various applications. This review aims to provide a solid
99 foundation for future research and development in levan-based hydrogel and biomaterial
100 applications.

101

102 2. State-of-the art

103 In order to gain insight into the current literature on levan-based hydrogels, a systematic
104 review was conducted following the Preferred Reporting Items for Systematic Reviews and
105 Meta-Analyses (PRISMA) protocol. The search strategy involved quering Scopus,
106 ScienceDirect, and other journal websites using keywords such as “Levan”, “Levan hydrogels”,
107 and “hydrogel”. No date or language restrictions were applied. To explore the sector-specific
108 uses, additional keywords, such as "drug delivery", "tissue engineering", "cosmetics", and
109 “food industry” were incorporated. From an initial set of 141 records, screening identified 15
110 relevant documents, after removing duplicates and out-of-scope articles. Further, a search on
111 the Web of Science (WoS) database revealed a total of 124,017 documents related to
112 hydrogels as of May 2025. Starting from the first studies with silica gels in 1946, the number
113 of documents increased exponentially after the 2000s, and according to the best model fit, a
114 total of 20,236 documents will be published in 2025 alone and an additional 182,458 reports
115 by the end of 2030. When the search was narrowed down to specific polysaccharides by
116 adding keywords, the total number of documents was 16,639 (chitosan), 13,508 (alginate),
117 8,884 (cellulose), and 6,666 (hyaluronic acid), followed by starch (1,946), dextran (1,837),
118 pectin (990), and xanthan (836). On the other hand, adding "levan" as a keyword reduced the
119 total number of documents to 21 that were only less than 0.02% of all hydrogel documents and
120 many orders of magnitude less than common polysaccharides like chitosan (13.4%) or alginate
121 (10.9%). While one of these 21 documents only cited levan and hence was discarded, another
122 one was a review article on the recent advancements in pharma and healthcare applications
123 of exopolysaccharide composites where authors also considered levan as a promising
124 biopolymer and briefly discussed a few levan-based biomaterials in a short paragraph [21].
125 The remaining 19 research articles also included those from the previous search, and they
126 were screened for their relevance. The first mention of levan as a hydrogel component
127 appeared in Castillo and López-Munguia’s 2004 study, which focused on the enzymatic
128 synthesis of high molecular weight levan by *Bacillus subtilis* levansucrase, resulting in a highly
129 viscous levan precipitate resembling a hydrogel [22]. Other early studies highlighted levan’s
130 hydrogel-like properties in *B. subtilis* biofilms [23] and *Erwinia tasmaniensis*-produced levan,
131 which formed sticky hydrogels at high concentrations [24]. The hydrogel’s swelling behavior

132 was also explored in enzymatically synthesized levan from *Erwinia amylovora* levansucrase
133 [25]. Another interesting study on encapsulating *Gluconobacter oxydans* cells in poly(vinyl
134 alcohol) (PVA) hydrogels reported interactions of the polymer network with bacterial
135 extracellular polysaccharide (EPS) components including levan as well as acetan, cellulose,
136 and dextran [26].

137 In 2018, Choi et al. introduced the first physically crosslinked levan hydrogels using
138 *Zymomonas mobilis* levan mixed with Pluronic F127 and carboxymethylcellulose (CMC) [27].
139 The group further incorporated hydroxyapatite to improve the hydrogel's injectability,
140 biocompatibility, and long-acting anti-wrinkle efficacy [28]. Similarly, blends of gellan and
141 *Erwinia herbicola* levan were ionically crosslinked to create shear-thinning hydrogels for tissue
142 engineering [29]. Other studies explored the use of *E. herbicola* levan mixed with CBD oil to
143 form sponges (rather than hydrogels) for wound healing applications [30]. Likewise, Maria et
144 al. (2021) reported that a *Bacillus* levan isolated from honey showed the capacity to form
145 emulsion hydrogels with omega-3 polyunsaturated fatty acids (PUFA) from ray liver oil and
146 chia oil [31].

147 In 2017, the first covalent use of levan in a hydrogel structure was reported, where
148 **carboxymethylated derivative of levan from *Halomonas smyrnensis*, *Halomonas levan***, was
149 employed as a cross-linker for temperature-responsive N-isopropyl acrylamide (pNIPA)
150 hydrogels [32]. Then, another group used the same procedure to obtain short
151 carboxymethylated *Zymomonas* levan, attached catechol, and then synthesized hydrogels
152 with high adhesivity [33].

153 Further advancements included the photochemical crosslinking of methacrylated
154 *Bacillus* levan to form covalent hydrogels, which were characterized for their structural and
155 mechanical features, biodegradability, and cytocompatibility [34]. These studies were followed
156 by the use of glutaraldehyde crosslinked *Zymomonas* levan/PVA hydrogels as pathogen-
157 capturing filters [35], chitosan crosslinked oxidized *Bacillus* levan hydrogels loaded with
158 curcumin for wound dressing applications [36], as well as 1,4-butanediol diglycidyl ether
159 (BDDE) crosslinked *Halomonas* levan hydrogels for controlled release of Amphotericin B
160 (AmB) [37], Resveratrol [38], *Plantago lanceolata* extracts [39], and as cryoprotectants for
161 probiotic bacteria [40]. These BDDE/*Halomonas* levan hydrogels were also integrated with
162 polyacrylamide to obtain interpenetrating hydrogel networks for uses in the conservation of
163 cultural heritage [41]. Most recently, these hydrogels also showed promise in guided bone
164 regeneration [42].

165 **A patent search was also conducted across four major databases, namely, World**
166 **Intellectual Property Organization (WIPO)'s Patentscope, Google Patents, Espacenet (by the**
167 **European Patent Office, EPO), and The Lens—using the keywords "levan" and "hydrogel."**
168 **The Lens, Google Patents, and Espacenet yielded 7,143, 4,518 and 448 hits, respectively. A**
169 **Frontpage search on Patentscope returned 4 results only (same search for chitosan and**
170 **alginate instead of levan yielded 2,969 and 2,412 hits, respectively). Two Korean patents**
171 **(KR1020190066936 and KR1020190041272) granted in 2019 focused on levan-based**
172 **hydrogels containing PF127 and CMC for cosmetic applications [27, 28]. In 2024, two Russian**
173 **patents (RU0002815367 and RU0002819701) described biocomposite hydrogels involving**
174 ***Paenibacillus polymyxa*-derived levan with one combined with alginate (RU0002815367), and**
175 **the other with *Komagataeibacter sucrofermentans* bacterial cellulose (RU0002819701) for**
176 **tissue engineering applications. The Cooperative Patent Classification (CPC) code A23V**

177 2250/5068, which pertains to fructans used in food applications, was identified as relevant to
178 levan but did not yield any hydrogel-related results.

179

180

181 3. Why levan?

182 Levan is a versatile, non-structural homopolysaccharide composed primarily of
183 fructose units linked by β -2,6 glycosidic bonds, with different degrees of branching at the β -
184 2,1 position. This unique structure allows levan to be synthesized naturally by a range of
185 microorganisms, including archaea, fungi, bacteria, and a few plants [43]. Due to the difficulty
186 of extracting levan from plants in large quantities, most of the levan used in current studies is
187 derived from microbial sources through cloning levan-related genes [44, 45].

188 Levan has several properties that make it extremely useful for use as a hydrogel
189 formulation in a variety of applications. First, it is an amphiphilic polymer soluble in both water
190 and oil, but insoluble in most organic solvents, except dimethyl sulfoxide (DMSO). Such
191 solubility profile gives levan the ability to self-assemble in water into densely packed spheres
192 with a diameter of 25-250 nm, resulting in a low viscosity of its aqueous solutions [46]. This
193 self-assembly behavior contributes to the formation of 3D networks, which are characteristic
194 of hydrogels, while maintaining low viscosity in solution. Although levan's low viscosity is
195 advantageous for injectable hydrogel systems, it can also hinder the development of
196 mechanically strong and stable hydrogels. This limitation can be addressed by optimizing
197 reaction conditions to relax the self-assembled structures, employing chemical crosslinking, or
198 forming composite hydrogels.


199 Another important feature of levan is its suitability for chemical derivatization methods,
200 such as sulfation, phosphonation, and oxidation [47]. Chemically-modified levan derivatives
201 exhibit distinct properties, such as the anticoagulant activity of sulfated *Halomonas* levan [48]
202 or the enhanced anticarcinogenic activity of oxidized *Halomonas* levan [49], which may
203 support the design of hydrogels with diverse properties tailored for specific applications.
204 Besides, a distinguishing feature of levan compared to other bioactive polymers is its
205 remarkable adhesive strength. This is due to the high number of interactions, such as hydrogen
206 bonds, Van der Waals forces, and interactions between the abundant hydroxyl groups within
207 the structure, which contribute to levan's strong adhesion properties [50]. This adhesive
208 strength is especially significant in the context of microbial biofilms, where levan serves not
209 only as a crucial structural component to protect the microbial community but also as a nutrient
210 reservoir, enabling survival under nutrient-deprived conditions [51].

211 There is growing interest in the use of bioactive polymers in hydrogel design across
212 diverse fields, from biomedicine to the food industry. Unlike traditional hydrogels that primarily
213 serve as passive carriers, these polymers can actively interact with biological systems, thereby
214 enhancing the material's functionality and biocompatibility depending on the application.
215 Levan, with its wide range of bioactivities, holds significant potential to confer additional
216 therapeutic or functional benefits when incorporated into hydrogel systems. Figure 1
217 summarizes various bioactivities of levan polysaccharide with the state of the art literature
218 discussed in the following sections.

219

220

221
222
223
224
225



226
227
228
229

Figure 1. Bioactivities of Levan polymer (Created with Canva.com).

230 3.1. *Levan as a Potential Prebiotic*

231 Prebiotics are non-digestible food ingredients that promote the growth or activity of
232 beneficial microbes in the body. Their degradation products, short-chain fatty acids (SCFAs),
233 have gained attention for influencing the microbiota and general health, including effects
234 beyond the gastrointestinal system [52, 53, 54]. In a study conducted with fructans of different
235 molecular weights, it was observed that high molecular weight levan was more effective than
236 low molecular weight fructooligosaccharides in terms of increasing the production of SCFAs
237 and contributing to the diversity of the intestinal microbiota [55]. For prebiotics to be used by
238 the beneficial microbiota, they must reach the colon without being digested in the upper
239 intestine [56]. Fructans, which meet this requirement, differ from glucans in that they are only
240 metabolized by the colon microbiota [51, 57]. Today, inulin-type fructans are the most
241 researched group for their effects on microbiota, immunity, and intestinal barrier function [58].
242 Although levan is less researched, there are studies on levan as a potential prebiotic [15, 59].
243 It has been reported that when chicken [59], pigs [60], or rats [61] were fed with levan, breast
244 meat and feed ratio increased, ammonia levels decreased, digestive abilities improved, and
245 beneficial bacteria were abundant. There are even studies where levans' prebiotic activity was
246 higher than inulin. For example, levan produced from *Erwinia* sp. significantly enhanced
247 microbial community growth compared to inulin, likely due to its higher degree of

248 polymerization (DP), which allowed for prolonged persistence in the colon [62]. Moreover,
249 levan from *Streptococcus salivarius* had higher or similar prebiotic activity scores against four
250 probiotic bacteria compared to inulin [63] while levan from *Bacillus siamensis* and *Bacillus*
251 *velezensis* supported the growth of *Streptococcus thermophilus* DKT-3 better than inulin [64].

252

253 3.2. *Anti-diabetic and Anti-obesogenic Activity of Levan*

254 Levan, unlike glucans such as cellulose and starch, is broken down into fructose rather
255 than glucose, making it a potentially more suitable option for diabetic patients [65]. Dahech et
256 al. (2011) demonstrated that orally administered levan reduced hyperglycemia and oxidative
257 stress in diabetic rats, also protecting against hepatic and pancreatic toxicity [66]. Further
258 studies reported that levan supplementation lowered blood sugar and serum cholesterol
259 levels—critical factors in diabetes management [67, 68, 69]. Moreover, in obese rats on a
260 high-fat diet, levan suppressed diet-induced obesity and hyperlipidemia, reducing total
261 cholesterol while increasing HDL levels [70]. Additionally, a combination of levan and
262 fermented ginseng was shown to reduce hyperlipidemia, fat accumulation, body weight gain,
263 and improve glucose homeostasis and leptin resistance [71]. These findings highlight the
264 biotherapeutic potential of levan in improving diabetes, diabetes-related metabolic
265 syndromes, and obesity.

266

267 3.3. *Anti-cancer, Antioxidant and Antiviral Activities of Levan*

268 Cancer, characterized by uncontrolled cell growth due to DNA mutations, remains a
269 significant health challenge due to the diversity in tumor types and treatment responses,
270 prompting growing interest in natural agents alongside traditional therapies like chemotherapy
271 and radiotherapy [72, 73]. Levan is one of the natural polymers that have been extensively
272 studied for their anticancer potential across various cancer types where the structural
273 properties of levan, such as its chain length and degree of branching, were found to play a
274 crucial role in its anticancer efficacy [74]. Recently, nanoparticles coated with *Zymomonas*
275 levan (Np-Lev) have shown significant antiproliferative activity against breast cancer and
276 melanoma cells [75], while levan combined with doxorubicin significantly reduced expression
277 of cancer-related genes in hepatocellular carcinoma cells [74]. Moreover, the combined use of
278 bacterial levan and benzimidazole derivative (BMPE) exhibited notable antimetastatic effects
279 in a triple-negative breast cancer mouse model via immunomodulation and redox regulation
280 [76].

281 Oxidative stress, caused by excessive accumulation of reactive oxygen species (ROS),
282 can result in cellular damage such as DNA disruption, protein misfolding, lipid peroxidation,
283 and membrane dysfunction, which in turn are associated with diseases like type 2 diabetes,
284 cardiovascular and neurodegenerative disorders, and ischemia [77]. In this context, levan has
285 been shown to effectively suppress peroxidation, donate electrons, and terminate free radical
286 chain reactions, acting as a potent antioxidant [78]. Studies have demonstrated that levan
287 derived from *Bacillus* strains and its sulfated forms possess strong antioxidant properties [64,
288 79, 80]. Similarly, levan isolated from *Acetobacter xylinum* and *Leuconostoc mesenteroides*
289 cultures have also been reported to exhibit strong antioxidant and anti-inflammatory effects
290 [44, 81].

291 Viruses with their complex structures and historical impact on pandemics, have driven

292 increased interest in antiviral agents, particularly following the global COVID-19 pandemic.
293 Levan has been studied for its antiviral properties, with *Bacillus levan* shown to affect
294 respiratory HPA1, H5N1, and enteric adenovirus type 40 [82]. More recently, same researchers
295 found that crude, dialyzed, and sulfated derivatives of levan produced from *Enterococcus*
296 *faecalis* cultures showed antiviral activity against Newcastle disease virus (NDV) [83].

297

298

299 3.4. Immunomodulatory Activity of Levan

300 The immune system plays a crucial role in defending against infections and cancer and
301 understanding its mechanisms is essential for recognizing its role in diseases, interactions with
302 other systems, and the development of new therapeutic strategies [84]. While traditional
303 treatments like corticosteroids and non-steroidal anti-inflammatory drugs (NSAIDs) are
304 commonly used to suppress inflammation [85], their long-term use is limited by significant side
305 effects [86], driving research into more selective and natural treatment approaches for immune
306 modulation with fewer adverse effects [87, 88].

307 There are numerous reports in the literature on the immunomodulatory activity of levan
308 polysaccharides from various sources, but only a few of them have investigated the related
309 molecular mechanism [89]. *In vivo* oral administration of *B. subtilis* natto levan was found to
310 reduce the serum level of ovalbumin-specific Immunoglobulin E (IgE), modulate the T helper
311 2 (Th2) cell response, and pattern recognition was found to be mediated by Toll-like receptor
312 (TLR) 4 [90]. TLR4 are receptors that recognize conserved pathogen-associated molecular
313 patterns (PAMPs) and thus constitute the first line of defense [91]. In addition, they recognize
314 lipopolysaccharide (LPS) glycolipids found in the outer membranes of both commensal and
315 pathogenic Gram-negative bacteria [92, 93]. A recent study showed that LPS is the actual
316 molecular determinant of the immunomodulatory property of levan toward TLR4 receptor-
317 expressing innate immune cells [94].

318 Some studies provide a better understanding of the changes in the immunomodulatory
319 properties of structurally different levan produced from different sources. For example, while
320 levan produced from *L. mesenteroides* increased the levels of interleukin-4 (IL-4), an important
321 anti-inflammatory cytokine [81], levan obtained from *Paenibacillus bovis* sp. did not cause any
322 modulation in IL-4 levels [95]. In addition, levan of different molecular weights from the same
323 species has been observed to have different effects on inflammation-related pathways. For
324 example, levan from *B. subtilis* altered iNOS, COX-2 gene expression [96] and nitric oxide
325 (NO) production [97] in RAW264.7 macrophages depending on molecular weight. Moreover, a
326 relatively recent study used methacrylated levan as a bio-ink for 3D bioprinting of bone tissue
327 scaffolds. In addition to good bioprintability, the samples supported the expression of the anti-
328 inflammatory marker CD206 [98]. These results suggest that the inherent immunomodulatory
329 effect may make levan an ideal polymer for hydrogels in tissue repair and regeneration
330 applications, as it will reduce the possibility of rejection by the body.

331


332 4. Synthesis of Levan-based hydrogels

333 Properties of hydrogels such as mechanical strength, self-healing ability, swelling
334 capacity, and biodegradability depend on cross-linking processes. Hydrogel synthesis is
335 generally achieved through chemical or physical crosslinking methods. **Chemical crosslinking**

336 involves the formation of covalent bonds between polymer chains, either directly or via low-
 337 molecular-weight crosslinkers, resulting in hydrogels with enhanced long-term stability and
 338 mechanical strength. In contrast, physical crosslinking relies on non-covalent interactions,
 339 often leading to heterogeneous polymer networks and hydrogels that are structurally less
 340 stable and mechanically brittle. Nevertheless, physically crosslinked hydrogels formed via
 341 weak interactions, such as ionic or electrostatic interactions, hydrophobic interactions,
 342 hydrogen bonding, or van der Waals forces, can exhibit advantageous properties, including
 343 self-healing capability and responsiveness to external stimuli [99].

344 The choice of cross-linking method depends on the physicochemical properties of the
 345 polymer. Due to its uncharged nature and water solubility, native levan does not readily form
 346 stable hydrogels without chemical or physical crosslinking or prior structural modification.
 347 Therefore, either levan or its chemical derivatives are mixed with other polymers to promote
 348 physical crosslinking, or chemical crosslinkers are used to establish covalent bonds and
 349 enhance hydrogel stability. Furthermore, the inherently fast biodegradation rate of levan can
 350 be tuned by chemical modifications or by integrating it into composite hydrogels, allowing for
 351 better control over its stability and degradation kinetics in various application environments.

352 In literature, there are reports on physically linked levan hydrogels such as injectable
 353 levan/ CMC /Pluronic F127 blends [27, 28]. In both studies, it was stated that there is
 354 hydrophobic association and hydrogen bonding between levan, Pluronic F127, and CMC, and
 355 especially that the poly(ethylene oxide) group of Pluronic F127 interacts with levan, and
 356 therefore levan is necessary for physical crosslinking. In another study, ionically crosslinked
 357 levan/gellan blends were examined, and it was hypothesized that under alkaline conditions,
 358 gellan interacts with levan via ionic crosslinking between hydroxyl and carboxyl groups to form
 359 a hydrogel network [29]. On the other hand, relatively more studies used chemical crosslinking
 360 to obtain better mechanical stability, including photo-polymerized methacrylated *Bacillus* levan
 361 [34] or chitosan crosslinked oxidized *Bacillus* levan [36]. In these studies, functional groups
 362 were introduced into levan to facilitate its reaction with crosslinkers or other polymers. For
 363 instance, methacrylate-modified levan enables covalent bonding with photoinitiated
 364 crosslinkers such as lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) or Irgacure 2959
 365 [34]. Similarly, the incorporation of aldehyde groups through oxidation allows levan to form
 366 Schiff base linkages with amine-containing polymers like chitosan [36]. However, there are
 367 also examples in which unmodified levan has been directly employed to form chemically
 368 crosslinked hydrogels such as glutaraldehyde crosslinked *Zymomonas* levan/PVA [35], and
 369 BDDE crosslinked *Halomonas* levan [37 - 42]. Figure 2 illustrates various types of chemically
 370 and physically crosslinked levan-based hydrogels while Figure 3 gives the classification of
 371 levan hydrogels.



380
 381
 382
 383
 384
 385
 386
 387
 388
 389
 390
 391
 392
 393
 394
 395
 396
 397
 398
 399
 400
 401
 402
 403
 404
 405
 406
 407
 408
 409
 410
 411
 412
 413
 414
 415
 416
 417

Figure 2. Physically and chemically crosslinked levan-based hydrogels (Created with Canva.com).

The good biocompatibility of hydrogels under physiological conditions, their degradability, and the low toxicity of the formed degradation products are important issues in the selection of the crosslinking agent [99]. Although hydrogels with good mechanical stability are formed by chemical crosslinking, crosslinking agents are generally synthetic and can cause toxic effects [100]. In a related study, levan was used to crosslink pNIPA hydrogels as an alternative to bis-acrylamide (BAAm), aiming to eliminate its potential toxic effects [32].

So far, mostly BDDE crosslinked levan hydrogels are reported where the formation of covalent bonds occurs as a result of the reaction between the epoxide groups of BDDE and the primary hydroxyl groups on the levan backbone. However, in a recent review by Wojtkiewicz et al. (2024) [101], it was noted that long-term use of BDDE-crosslinked hydrogels can lead to tissue hardening and redness in the application area after several years, potentially due to BDDE itself or its byproducts released during hydrogel disintegration, as indicated by clinical findings. On the other hand, physical crosslinking offers a valuable alternative to avoid the potential risks associated with chemical methods.




Figure 3. Classification of levan-based hydrogels (Created with Canva.com)

418

5. Applications of Levan Hydrogels

419

420 Levan-based hydrogels have emerged as promising biomaterials in various biomedical
 421 applications, particularly in drug delivery systems, tissue engineering, and regenerative
 422 medicine, as well as in cosmetics. Their unique physicochemical properties, including
 423 biocompatibility, biodegradability, and stimuli-responsiveness, make them suitable candidates
 424 for controlled and targeted drug release, offering improved stability, bioavailability, and efficacy.
 425 In Table 1 are summarized the key findings on levan-based hydrogels in various sectors to
 426 provide a general overview of their diverse applications.

427

428 **Table 1.** Hydrogels of Levan

Source of Levan	Hydrogel structure	Application	Reference
<i>Bacillus subtilis</i>	Levan was methacrylated and then photo-polymerized	Mechanically stable, slightly degradable and cytocompatible gels suitable as starting materials in common additive manufacturing processes like bioprinting or stereolithography	[34]
	Levan was oxidized with sodium metaperiodate and then mixed with chitosan for the gelation	Bio- and hemo-compatible drug delivery system and wound dressing material with sustained curcumin release	[36]
<i>Erwinia herbicola</i>	Levan/gellan blends crosslinked ionically with NaOH and CaCl ₂	Shear-thinning properties showed high potential of levan-gellan hydrogel for its use as an injectable material in medical and cosmetic industries	[29]
<i>Halomonas elongata</i>	BDDE crosslinked levan hydrogels loaded with liposomes containing <i>Plantago lanceolata</i> L. Extracts	Biocompatible and biodegradable levan-based herbal liposome-loaded hydrogels for acute wound healing	[39]
<i>Halomonas smyrnensis</i>	Hydrolyzed, carboxylated and then methacrylated levan crosslinked with <i>N</i> -isopropyl acrylamide (NIPA)	Thermoresponsive levan/pNIPA hydrogels for the controlled release of 5-ASA for the treatment of inflammatory bowel diseases	[32]
	BDDE crosslinked levan hydrogels	Amphotericin B release for exerting antifungal activity against <i>Candida albicans</i>	[37]
	Hydrolyzed and	Controlled release of resveratrol	[38]

	phosphonated levan crosslinked with BDDE	for skin tissue engineering	
	Levan, acrylamide and methylene-bis-acrylamide solution crosslinked with BDDE and Ammonium persulfate	IPN-based Levan/PA hydrogels for conservation of cultural heritage	[41]
	Hydrolyzed levan cross-linked with BDDE	Levan hydrogels for guided bone regeneration and bone tissue engineering	[42]
	Pluronic F127/CMC/levan mixture	Injectable hydrogels to be used as an alternative to hyaluronic acid (HA) based dermal fillers in soft tissue augmentation	[27]
	Hydroxyapatite containing Pluronic F127/CMC/levan hydrogels	<i>In vivo</i> stability of the composite hydrogel was enhanced with high anti-wrinkle efficacy maintained for 8 weeks and showing high collagen production	[28]
Zymomonas mobilis	Levan/PVA crosslinked with glutaldehyde	Virus capture efficiency of levan-PVA hydrogels was higher than that of commercial cotton swabs	[35]
	Catechol conjugated carboxymethylated levan hydrogels via oxidation-induced catechol/quinone (covalent) and Fe ³⁺ -(non-covalent) mediated coordinative crosslinking	Levan-catechol conjugate hydrogel for wound healing applications	[33]

429

430 5.1. Pharmaceutical Applications

431 Direct clinical use of active pharmaceutical ingredients (APIs) “as is” is limited since
432 drugs are sensitive chemicals and are adversely affected by body conditions (pH, temperature,
433 enzymes, etc.), low bioavailability, and low absorption [102]. Therefore, delivery systems that
434 transport therapeutics to relevant sites in the body in a controlled manner are necessary for
435 effective drug delivery. Traditional drug delivery systems require high and continuous doses
436 due to untargeted distribution and uncontrolled release of the drug. This is contrary to keeping
437 the plasma drug concentration above the minimum effective concentration (MEC) and below
438 the toxic concentration and may cause side effects [103]. There is increasing interest in
439 controlled and targeted drug delivery systems (DDS), designed to release the correct dose of
440 a therapeutic agent directly to the desired site and within the required period. These systems
441 maximize the effectiveness of the therapeutic agent and minimize possible side effects [104].

442 The conventional DDS methods, like oral tablets and injections, often suffer from limitations
443 like poor bioavailability, systemic side effects, and the need for frequent administration [105].
444 Advanced drug delivery systems have been developed to overcome these challenges, and so
445 many new options, such as liposomes, nanoparticles, microneedles, polymeric carriers, and
446 hydrogels offering unique advantages, improve health care day by day [106]. Among them,
447 hydrogels have gained considerable attention due to their cross-linked hydrophilic polymer
448 network that can retain large amounts of water. When loaded with drugs, they can hold the
449 drug inside and gradually release it in a controlled manner due to their porous structure and
450 swelling properties [107]. Nowadays, more specific versions of hydrogels, such as stimuli (pH,
451 temperature, enzymes, etc.) responsive, injectable, or nanogels, are being designed, thus
452 rapidly progressing towards more efficient and effective drug delivery systems [108,109].

453 The use of levan-based drug delivery systems may overcome, to a great extent, the
454 challenges of the conventional modes of drug administration. So far, various drugs have been
455 loaded into levan-based-drug delivery systems for targeted and controlled delivery. After levan
456 polysaccharide was first reported to be suitable for delivering peptides, proteins, and
457 macromolecular drugs [110], *Halomonas* levan was used for controlled release of vancomycin
458 [111], curcumin [112], paclitaxel [113], and resveratrol [114]. Additionally, levan derived from
459 *Bacillus licheniformis* has demonstrated high potential as a pharmaceutical excipient in topical
460 drug formulations [115]. Recent studies include *B. subtilis* levan-based nanoparticles loaded
461 with the antiretroviral drug - dolutegravir for potential use in HIV treatment [116] and levan-
462 shelled hydrophobic silica nanoclusters encapsulating doxorubicin as an ultrasound-
463 responsive drug delivery system for cancer treatment [117]. These studies reveal that levan is
464 a promising polymer for drug delivery strategies, not only as a carrier but also with its
465 bioactivity.

466 When designing drug delivery systems, some important issues should be considered.
467 The first one is the ability to provide targeted delivery. Hydrogels have been demonstrated as
468 the ideal pharmaceutical carrier in biomedicine due to their high porosity and water content
469 through their unique three-dimensional (3D) crosslinked network structure [118]. Stimuli-
470 responsive hydrogels, also known as smart or intelligent hydrogels, have become the most
471 studied systems for drug delivery [119]. They are able to respond to environmental changes
472 like temperature, pH, or magnetic fields, controlling not only drug administration but also the
473 timing and release profiles, with their sol-gel phase transition behavior influenced by their
474 sensor characteristics and surrounding conditions [120].

475 Examples of levan-based-stimuli-responsive hydrogels include thermoreactive
476 levan/N-isopropyl acrylamide (levan/pNIPA) hydrogels for controlled release of 5-
477 aminosalicylic acid (5-ASA) used in the treatment of inflammatory bowel diseases. Osman et
478 al. (2017) used methacrylated, hydrolyzed, and carboxymethylated forms of *Halomonas* levan
479 as crosslinkers to prepare levan-pNIPA hydrogel for the first time [32]. The biocompatibility of
480 the obtained hydrogels with L929 cells was evaluated, and data showed that the
481 biocompatibility was improved with higher levan percentage in hydrogels. Also, when different
482 concentrations and temperatures were tested, addition of levan brought the volume phase
483 transition temperature closer to the human body temperature.

484 Every drug delivery system, including hydrogels, has a limited residence time in the
485 targeted release region. This is between 2-5 hours for the stomach and 2-6 hours for the small
486 intestine, and at the end of this period, the content is transferred to the next step of the system,
487 such as the colon. Therefore, it is important to test how much and how quickly a hydrogel will

488 release the encapsulated drug. Since it is known that the type and content of crosslinker used
489 in hydrogel production change the drug release characteristics, the levan/pNIPA hydrogel
490 system [32] was compared with the same system where chitosan was used as a crosslinker
491 instead of levan [121]. It is observed that both hydrogels released approximately 90% of the
492 drug in 2 hours under the same conditions (37 °C, pH 7.4). Both hydrogels can release an
493 effective amount of the drug in a sufficient time. However, while 100% of the drug was released
494 in 4 hours in the chitosan hydrogel, this period was 6 hours in the levan hydrogel. This
495 difference can be attributed to the pH-sensitive structure of chitosan, suggesting that levan
496 may be a good alternative for medications that need to be released over a longer period.

497 The second important point to consider when designing drug-delivery hydrogels is the
498 swelling capacity. The reason is the high influence of swelling on drug loading efficiency (DLE)
499 and drug encapsulation efficiency (DEE), which are mandatory for an adequate drug delivery
500 system. It is worth noting that the swelling capacity of a hydrogel depends on the polymer used
501 and the degree of cross-linking. While high crosslinking causes lower water absorption
502 capacity, lower crosslinking degree leads to lower mechanical stability [38,122]. So, the
503 optimum cross-linking degree should be selected for enhanced drug delivery. Another essential
504 factor influencing swelling is the pH of the environment. Therefore, in a study by Demici et al.
505 (2020) to estimate swelling capacity, tests were performed with selected hydrogels that have
506 an optimum polymer/crosslinker ratio (*Halomonas* levan/BDDE) in different solutions [37]. The
507 results showed that the swelling capacity of the hydrogels was pH dependent, higher pH
508 leading to higher swelling, and the maximum equilibrium degree was reached in 1 hour.
509 Antifungal and cytotoxicity tests also revealed the high potential of levan hydrogels in the
510 transport of pH-sensitive drugs such as amphotericin B (AmB) [37].

511 The third and possibly most crucial factor is the biocompatibility of the drug delivery
512 system. Hydrogels, especially those produced from natural polymers, are known as
513 biocompatible since they are not toxic or injurious and do not cause immunological rejection in
514 living tissues [107]. Considering the need for more systematic studies on levan-based
515 hydrogels to widen their use in drug delivery systems and biomedical applications, chemically
516 modified forms were used to synthesize biocompatible hydrogels. Recently, levan produced
517 by *H. smyrnensis* and its hydrolyzed and phosphonated derivatives crosslinked with BDDE
518 were produced for the first time for resveratrol delivery [38]. Results revealed the superior *in*
519 *vitro* biocompatibility of levan hydrogels with a human keratinocyte cell line (HaCaT).
520 Additionally, cell attachment to phosphonated hydrogels was higher since phosphonate groups
521 affect cellular attachment via mimicking protein-protein and protein-natural polymer
522 interactions [123]. This finding proved that hydrogels produced from chemically modified forms
523 of levan polymer have superior potential in the pharmaceutical and cosmetic industries.

524

525 5.2. *Levan Hydrogels in Tissue Engineering*

526 Tissue engineering (TE), a rapidly growing field, is used to substitute diseased or
527 damaged tissues with functional ones, aiming to restore or enhance the function of the affected
528 tissues. Nowadays, hydrogels, due to their unique properties, have become an integral part
529 of tissue engineering, especially in enhancing tissue function and promoting cell growth,
530 differentiation, and regeneration [124,125]. When selecting biomaterials to form hydrogels,
531 several factors need to be considered, including mechanical properties, biocompatibility,
532 gelation time and swelling capacity [126]. The understanding that natural polymers, especially

533 polysaccharides, have the potential to meet these properties positions levan as an attractive
534 candidate for tissue engineering applications.

535 The first study on the synthesis of photo-crosslinkable levan derivatives and their use
536 for hydrogel production was reported by Berg et al. (2018) [34]. Levan from *B. subtilis* was
537 chemically modified via methacrylation with glycidyl methacrylate (GMA), methacrylic
538 anhydride (MAA), or 2-isocyanatoethyl methacrylate (IEM) and then photo-polymerized in the
539 presence of different photoinitiator systems and irradiation units. The resulting hydrogels were
540 mechanically stable and cytocompatible. Furthermore, it was shown that changing the type of
541 crosslinker and the crosslinking density altered the degradation rate of the hydrogels, thus
542 making these gels suitable candidates for both drug delivery and tissue engineering
543 applications. Considering the complexity and high cost of materials used in tissue engineering
544 in terms of preparation and application processes, there is a high need for new-generation
545 biomaterials that can be produced at low cost, have high bioactivity, and are sustainable [127].
546 The increasing use of natural polymers such as gelatin, hyaluronic acid, etc., in tissue
547 engineering applications has encouraged researchers to explore the potential of levan in this
548 area [128]. In a recent study, levan hydrogels were **incorporated** with Bio-Oss®, a traditional
549 xenograft used in guided bone regeneration applications (GPR), at different ratios. The results
550 showed that, in addition to higher biocompatibility, levan containing hydrogels exhibited higher
551 new bone formation, osteoblast density, and new vessel formation compared to the group
552 containing only Bio-Oss® [42].

553

554 5.3. *Applications in Wound Healing*

555 Wounds, which are pathological cases caused by various diseases and physical-
556 chemical damages, are classified as acute or chronic depending on the type of damage and
557 the duration of the healing process [129]. Wound healing is a complex biological process that
558 involves the coordination of various tissues and cell types, such as fibroblasts and
559 keratinocytes, to repair damaged skin or other tissues. Wound dressing materials play a critical
560 role in accelerating the healing process by providing an optimal environment for tissue
561 regeneration [130, 131]. A suitable and effective wound dressing material should possess key
562 properties, including biocompatibility, non-toxicity or non-allergenicity, mechanical strength, air
563 permeability, moisture retention, antimicrobial activity, and ease of removal [132, 133].
564 Conventional wound dressings often fail to meet these requirements, making biopolymer-
565 based hydrogels a promising alternative due to their morphological similarity to the
566 extracellular matrix and ability to mimic natural tissue structures [134, 135, 136, 137, 138].

567 Levan has gained attention for its wound healing potential. Its anti-inflammatory,
568 antibacterial and high adhesive properties, contribute significantly to tissue repair [139]. Levan
569 can support cell proliferation, particularly of fibroblasts and keratinocytes, which are essential
570 for wound closure and immune response regulation [140, 141]. Additionally, levan can enhance
571 the mechanical stability of wound healing systems, promoting faster recovery. As proof of that,
572 *Bacillus mojavensis* Levan-PVA nanofibers have been shown to accelerate wound healing due
573 to the water-holding properties of levan **combined** with the film-forming ability of PVA [142].
574 Increasing levan-PVA concentration further enhances tensile strength and cell viability, leading
575 to better healing outcomes [143] showed increasing levan-PVA concentration causes higher
576 tensile strength and improved cell viability. In addition, porous microbial levan-based sponges
577 loaded with cannabis oil (Lev@CBDs) exhibited a suitable swelling ratio and enough thermal
578 stability to use even after being exposed to harsh conditions for a long period. Also, produced

579 sponges exhibited antibacterial activity against *Staphylococcus aureus* and *Pseudomonas*
580 *aeruginosa*, the two most known bacteria that cause infection in wound areas [30]. In addition
581 to its bioactivity on the wound area, levan can also be used as a natural reducing and coating
582 material for microelement nanoparticles (NPs) [144] due to the presence of -OH groups on the
583 polymer chains [145].

584 In some cases, using more than one polymer for the synthesis of hydrogels called
585 hydrogel composites is preferred to obtain an effective drug delivery system, as they offer
586 excellent properties of contained biomaterials, which other drug delivery systems cannot
587 quickly achieve for the controlled release of drugs to specific sites. Basically, by cross-linking
588 through covalent bonding/ionic interactions/hydrogen bonding of levan with other polymers,
589 hydrogels with increased structural integrity can be formed. To improve wound healing, the
590 oxidized form of levan from *B. subtilis* was crosslinked with chitosan by Veerepandian et al.
591 (2023) [36]. Schiff's base reaction between oxidized levan and chitosan leads to formation of
592 hydrogels without need for an initiator such as UV light or chemical cross-linkers, making
593 hydrogels more biocompatible and suitable for wound healing. All the hydrogels had highly
594 interconnected porous networks due to the large number of functional groups in the structure
595 of levan and chitosan that help cell attachment, proliferation, and nutrient transfer. The
596 hydrogels showed better thermal stability than neat levan, and the presence of chitosan made
597 the swelling behavior of hydrogels pH-dependent (pH 2.6). The results from the
598 hemocompatibility tests via direct and indirect methods showed non-significant differences
599 compared to the control group. In another study, levan-catechol conjugate (LC) was
600 synthesized by combining the carboxyl group of CM-levan with the amino group of dopamine
601 using 1-ethyl-3-[3-dimethylaminopropyl] carbodiimide hydrochloride (EDC) chemistry. This
602 conjugation improves the produced hydrogels' water-proof ability as well as fast swelling over
603 the first 30 min of incubation, which makes these hydrogels good candidates for wound healing
604 applications. Furthermore, the increased blood clotting rate, low endotoxin levels, and faster
605 wound closure in the SD rat model compared to the control suggested that it can be used as
606 a biomedical adhesive in wound healing process [33]. Moreover, the wound healing efficacy of
607 the composite material developed by loading herbal liposomes into levan-based hydrogel
608 structures was investigated by Altıntaş and Çelik (2023) [39]. Hydrogel structures were
609 developed for the first time with levan produced by *Halomonas elongata* 153B halophilic
610 bacteria for wound healing. Extracts from *P. lanceolata* L., commonly known as a wound herb,
611 which has cell regeneration ability and anti-bacterial activity in the wound area, were obtained.
612 Then, extract-loaded liposomes were prepared, and were loaded into the levan-based
613 hydrogels for controlled release into the wound area. The wound healing efficacy of the herbal
614 liposome-loaded levan-based hydrogel was evaluated in an *in vitro* wound model. Results
615 indicated that the developed hydrogels are a promising therapeutic approach for the healing
616 of acute wounds [39].

617

618 5.4. Cosmetics

619 The skin, which is the largest organ of the body, has the basic functions of protecting
620 the body from pathogens and external environmental elements (radiation, impact, heat, etc.)
621 and maintaining homeostasis by maintaining body temperature and humidity [146]. Cosmetic
622 substances such as lotions, creams, masks, etc. are generally products used to maintain or
623 improve the current condition and can be produced from various raw materials [147]. However,
624 some cosmetic products contain several ingredients like parabens, which can harm the skin

625 and hair [148]. Recently, natural products are rapidly gaining attention due to their
626 biocompatibility, sustainability, and high contribution to skin health. Cosmetic product users
627 are more interested in skin and environment-friendly, biodegradable ingredients instead of
628 synthetic additives. For this reason, bioactive formulations are widely available in skincare,
629 haircare, and personal care items [149]. Levan, on the other hand, has remarkable properties
630 such as skin whitening, moisturizing, and reduction of skin irritants [150, 151].

631 While the selection of raw materials used in cosmetic formulas varies depending on
632 which area they will be applied in, today the cosmetic industry is showing much more interest
633 in hydrogel-based cosmetic products due to their properties such as biocompatibility, elasticity,
634 and the ability to hold excess water [152, 153, 154]. Hydrogels, which can be used to help
635 restore skin elasticity, softness, and moisture, can also facilitate drug penetration by loosening
636 the skin barrier [155]. Synthetic polymers and biopolymers are widely used in commercially
637 available cosmetic products. Biodegradable polymers, especially polysaccharides, have been
638 attracting much attention of scientists looking for new compounds with cosmetic properties
639 because they can be eliminated by normal metabolic pathways and do not cause toxicity and
640 accumulation in the body [156, 157].

641 The variety of properties of levan mentioned above makes it a useful and safe
642 biomaterial for cosmetics. In the literature, lots of research showed the suitability of using levan
643 in cosmetics. For example, the stimulation of human fibroblasts and keratinocytes by *Z. mobilis*
644 levan [158], as well as a whitening agent by inhibition of melanin production [159]. Lewińska
645 et al. (2022) [160] developed tonic, gel, and cream formulations containing surfactin-stabilized
646 *B. subtilis* levan nanoparticles (NP) and nanoemulsion (NE) nanosystems. They reported that
647 these formulations improved skin hydration, elasticity, wrinkle depth, and also skin
648 discoloration. In addition, levan, which also met the requirement of non-toxicity, did not show
649 cytotoxicity on human dermal fibroblasts (NHDF) [161]. In *in vitro* experiments with *Halomonas*
650 levan and its derivatives, increased cell proliferation, skin barrier function, and rapid wound
651 healing ability were observed [139]. In addition, the cosmetic product needs to maintain its
652 stability for a long time when the approximate period of use is evaluated. Da Silva et al. (2022)
653 [162] reported the maintenance of moisturizing, antioxidant activity, and stability of the product
654 consisting of *B. subtilis* natto levan and almond oil for 3 months. In a study, carboxymethyl
655 levan (CML)-hEGF nanoparticles designed to overcome the low stability of human epidermal
656 growth factor (hEGF) maintained over 100% cell proliferation activity for 6 weeks [163]. This is
657 one of the important studies supporting the potential use of levan as a cosmeceutical because
658 hEGF is a signaling molecule that stimulates the growth and motility of keratinocytes and
659 fibroblasts in epithelial tissues [164]. Moreover, in a study aimed at enhancing the effects of
660 levan with biocompatible actives such as natural compounds and vitamins, levan was
661 combined with natural compounds such as aloe vera extract, avocado oil, and vitamin E [165].
662 The cosmeceutical formulations were non-toxic and completely vegan, as well as showing
663 good stability. Another study also showed that levan-containing digestive extract reduces the
664 irritating effect of ionic surfactants and is therefore a suitable ingredient for the formulation of
665 harmless body wash cosmetics [166].

666 Soft tissue fillers are applications developed as an alternative to plastic surgery due to
667 reasons such as low life risk, fast recovery time, and instant effect. The material used for an
668 effective application should be biocompatible, non-allergenic, and stable [167, 168]. Fillers are
669 essentially divided into two categories: non-biodegradable and biodegradable, according to
670 the properties of the raw material used [169]. Non-biodegradable fillers are less tolerated in
671 the body than biodegradable ones and therefore can cause serious side effects. Hyaluronic

672 acid (HA) fillers are approved by Food and Drug Administration (FDA) and known for providing
673 the ideal features mentioned today and dominate the sector [167]. Choi [27] developed an
674 injectable levan-based hydrogel for use as a dermal filler for soft tissue augmentation and
675 reported that this system could be an alternative to hyaluronic acid (HA)-based dermal fillers.
676 The injectable hydrogels were formed by combining Pluronic F127, CMC, and levan derived
677 from *Z. mobilis* with hydrophobic and non-covalent interactions. The levan hydrogel and HA-
678 based hydrogels were tested in an animal disease model both *in vitro* and *in vivo*. Rheological
679 results showed that the elastic modulus of levan-based hydrogel (~6 kPa) was higher than that
680 of the HA-based hydrogel (~2.8 kPa), and the interconnected porous structures were similar
681 to each other. In addition, no cytotoxicity was observed in human adult dermal fibroblasts
682 (hADF) in the levan-treated group, and enhanced cell proliferation was observed. Since
683 collagen synthesis is another important factor in enhancing the anti-wrinkle effect [170],
684 hydrogels were also evaluated for their ability to improve collagen synthesis. hADF cells
685 treated with levan showed higher expression of the type I collagen gene and improved anti-
686 wrinkle efficacy in the wrinkle mouse model compared to HA. Later, by adding hydroxyapatite
687 to the prepared hydrogels, their *in vivo* stability was extended to maintain the anti-wrinkle effect
688 [28]. Levan hydrogel was biocompatible and stable longer *in vivo* than Pluronic F127 or HA,
689 indicating that levan has high potential as a new material for effective dermal filler compared
690 to HA *in vivo*. Therefore, levan-based dermal fillers are an up-and-coming, low-cost alternative
691 to overpriced HA-based hydrogels. Additionally, due to its surface morphology, thermal
692 behavior, rheological properties, and gel-forming features, enzymatically produced *E.*
693 *amylovora* levan was also proposed as a promising candidate for cosmeceutical applications
694 [25]. In this study, levan and other commercial hydrogels, such as carrageenan and guar gum,
695 showed similar rheological behavior, similar porous network microstructure, and endothermic
696 temperature.

697 Normally, shear-thinning hydrogels are mostly ideal for use in the cosmetic industry;
698 however, chemical modification, which is usually applied for synthesis, causes high gelation
699 time and chemical toxicity. Nair and Choudhury [29] produced levan/gellan composite
700 hydrogels using levan from the *E. herbicola* solution and low acyl gellan polysaccharide, aiming
701 to eliminate the problems caused by chemical modification by using natural polysaccharides.
702 The results showed that the composite hydrogels exhibited remarkable mechanical properties
703 and easy injectability. In addition, it was observed that when the ratio of levan or gellan
704 polysaccharide in the composite hydrogels was increased, the swelling percentage also
705 increased due to free hydroxyl groups compared to hydrogels consisting of equal amounts of
706 each polysaccharide [171]. In addition, it was shown that the hydrogels had 97% water
707 retention capacity and sufficient cross-linking with strong structures, revealing the significant
708 potential of levan-gellan hydrogel for use as an injectable material in the medical and cosmetic
709 industries.

710

711 5.5. Potential Applications in Food Science

712 Levan-based hydrogels hold significant promise in the food industry due to their natural
713 origin, biocompatibility, and functional properties such as antioxidant, antidiabetic, and anti-
714 obesogenic activity. Different authors proposed the use of levan in association with other
715 biopolymers to form films feasible as edible coatings. For instance, levan-gellan gum [172],
716 levan-chitosan [173], levan-vanillin [174], and oxidized levan-gelatin [175] films have been
717 proposed as a coating to be applied on the surface of food products to improve their shelf life.

718 Moreover, the gelling properties of levan could be exploited for the design of functional
719 foods with improved overall acceptability while delivering prebiotic levan. Being levan, able to
720 form hydrogels, its usage in all gel-based foods could be tested. However, to this aim, it would
721 be fundamental to have a deep understanding of structure-function relationships at different
722 lengths of scales (from nano to micro and macro scale). Today, the possible interactions of
723 levan with other biopolymers, such as proteins or other carbohydrates, in complex food
724 systems are still underexplored but highly demanded for the design of novel sustainable food
725 with designed health-improving capacity. In this context, Hundschell et al. (2022) [176] studied
726 the influence of levan on the thermally induced gel formation of β -lactoglobulin. The presence
727 of levan increased the water-binding capacity of the gel network. Besides, some studies
728 elucidated the structuring ability of levan produced by microbial fermentation in bread. The
729 exopolysaccharide levan is reported to be able to impact the bread quality [177]. *B. subtilis*
730 levan produced from coconut inflorescence extract was studied not only for its technological
731 properties but also as a sweetener [178]. The possibility of exploiting levan also as an
732 alternative and innovative sweetener is particularly interesting in the attempt to reduce the use
733 of artificial non-nutritive sweeteners, such as saccharin, cyclamate, and aspartame.
734 Considering both the health and technological functionalities of levan, it seems to be an ideal
735 polymer that can be used in many areas, from packaging to the food industry, as an ingredient
736 in many food formulations.

737 Furthermore, thinking about the possibility of converting hydrogels into oleogels, i.e.,
738 oil-based gels with macroscopic properties mimicking those of solid fats [179, 180], or into
739 aerogels, i.e., highly porous materials designed as delivery systems [181], it cannot be
740 underestimated the possibility to use levan hydrogels in the field of oleogelation or
741 aerogelation.

742

743 5.6. Other Applications

744 To minimize the health, economic, and social damage that epidemics can cause, it is
745 important to detect and capture the pathogens that cause them as soon as possible and many
746 strategies are applied in today's literature. Some of these are magnetic nanoparticles (MNPs)
747 for the detection of various infectious diseases [182], superparamagnetic iron oxide
748 nanoparticles (SPIONs) functionalized with peptides obtained from salivary protein, a
749 mesoporous PDMS sponge for foodborne pathogens [183], magnetic beads (MB) coated with
750 specific molecules for pathogen detection from blood samples [184], and a silk protein-based
751 microbial trap [185]. It is known that carbohydrates on the mucosal tissue surface act as
752 receptors for pathogens during infection and prevent invasion by preventing pathogens from
753 passing through the cell membrane [186]. With this approach, carbohydrate materials that will
754 be designed by taking inspiration from a natural process may be useful as pathogen trappers.
755 Li et al. (2011) [187] used carbohydrate-functional chitosan nanofibers to capture the influenza
756 virus. Moreover, carbohydrate-enriched graphene sheets [188] and glycosylated stimuli-
757 responsive polyacrylamide microspheres with AgNPs [189] not only selectively encapsulated
758 pathogens but also enabled the killing of captured bacteria.

759 Kim et al. (2020) [35] proposed hydrogels made of levan produced from *Z. mobilis* and
760 glutaraldehyde poly(vinyl alcohol) (PVA) as influenza virus capture and recovery materials. The
761 approach that levan would promote virus capture by effectively interacting with the lectin,
762 hemagglutinin and nucleoprotein (NP) of the virus was confirmed by RT-PCR and ELISA tests.
763 According to the results, the virus capture efficiency of levan-PVA hydrogels was higher than

764 commercial cotton swabs due to the lack of the lectin binding function of PVA alone. To test
765 the capture capacity of levan hydrogels in different transmission routes, the authors also
766 produced bioaerosols containing influenza viruses and tested their capture with a filter material
767 containing the hydrogels. RT-PCR analyses showed that levan hydrogels increased the
768 capture of virus droplets compared to the control group. This study showed that levan-based
769 hydrogels could be simple and cost-effective materials for pathogen capture and recovery.

770 Another interesting application is the use of levan hydrogels in conservation science.
771 Cultural heritages play a major role in ensuring the historical, social, and economic integrity of
772 the society. Even traditional restoration methods applied to protect them from destructive
773 environmental factors such as temperature, light, microorganisms, and erosion can damage
774 the heritage [190]. On the other hand, in recent years, new methods have been developed to
775 overcome the limitations of traditional restoration techniques and materials, and the interest in
776 sustainable, environmentally friendly, and non-toxic systems has increased. Recently, the
777 application of materials science and nanoscience to the preservation of works of art has led to
778 the development of advanced cleaning systems and approaches that are transforming the
779 preservation of cultural heritage [191]. The first suggestion of gels with their ability to provide
780 appropriate protection and cleaning due to the osmotic balance and flexibility they provide
781 [192], followed by the production of more advanced and responsive gels [193], inorganic
782 nanomaterials [194], microemulsions [195], biocomposite films [196], hybrids such as fibroin-
783 nanocellulose composite [197] and chitosan-based coatings [198] are among the materials
784 used in studies carried out to protect cultural heritage today, and it is noteworthy that
785 carbohydrates are frequently used in this sector due to their outstanding properties.

786 Based on the many important properties of levan-based hydrogels, a study was
787 conducted to investigate the potential use of levan polysaccharides in areas other than health
788 services, such as conservation. Saglam et al. (2023) [41] investigated the potential use of IPN-
789 based enzymatic levan-polyacrylamide hydrogels (EL-PA) in paper protection applications.
790 According to the results of hydrogel characterization in terms of structural, morphological,
791 rheological, and swelling kinetics, EL-PA hydrogels have larger specific surface areas
792 compared to PA-gel, and this is one of the properties sought in surface coating applications
793 [199]. In addition, in the FTIR analysis performed on the paper sample previously coated with
794 hydrogel, as a result of the separation of the hydrogel, only typical bands associated with
795 cellulose were observed, suggesting that the hydrogels successfully removed the
796 contaminants on the paper surface. The results showed that levan-based hydrogels have high
797 potential in conservation science thanks to their biocompatibility and easy applicability [41].

798

799 **6. Conclusion and Future Perspectives**

800 As the demand for natural, economical, biocompatible, and biodegradable materials
801 continues to rise, levan has emerged as a promising polysaccharide with a wide range of
802 applications in various fields, from medicine to cosmetics. Its properties, such as adhesive
803 strength, self-assembly, low viscosity, and its bioactivity, ranging from prebiotic and anti-cancer
804 to anti-inflammatory and anti-diabetic, distinguished it from other polysaccharides, making it a
805 polymer of significant interest for further research and development [15, 17]. Levan-based
806 hydrogels, with their 3D network structures, have proven to be ideal materials for biomedical
807 applications due to their superior biocompatibility, biodegradability, and nontoxicity.
808 Furthermore, Levan derivatives, such as methacrylated, phosphonated, and oxidized levan,

809 have shown potential as parent materials for hydrogel production. These hydrogels have
810 already been explored for applications in drug delivery, tissue engineering, cosmetics, and
811 beyond. However, challenges remain, including high production costs of levan and variability
812 in its properties, such as molecular weight, chain length, and branching patterns which depend
813 on the producing organisms and production conditions. These issues must be addressed to
814 optimize levan-based hydrogels for broader industrial applications [45].

815 In this systematic review, the physicochemical and functional properties of levan
816 polymers as ideal hydrogel raw materials are examined, together with the wide range of usage
817 areas of existing hydrogels from drug delivery to conservation science. In addition, in some
818 sections, an objective perspective is provided by comparing the hydrogel structures that are
819 currently accepted as gold standards with levan-based hydrogels. In light of the studies
820 conducted on levan hydrogels to date and in drug delivery, tissue engineering, cosmetics, and
821 other different fields, it can be expected that the potential usage areas of these hydrogels will
822 increase even more in the future. **One of these emerging areas is environmental science.**
823 **Levan hydrogels possess key features—such as high water absorption capacity, adjustable**
824 **porosity, biodegradability, and non-toxicity—that make them suitable for environmental uses.**
825 **These include their application as adsorbents in wastewater treatment and as carriers in**
826 **controlled-release systems for agricultural chemicals [200]. Moreover, a study by Phengnoi et**
827 **al. (2019) [201] demonstrated that blending levan with polyvinyl alcohol (PVA), a synthetic**
828 **polymer with low degradability, led to increased degradation rates with higher levan content,**
829 **further supporting their potential in eco-friendly materials.**

830 Despite the competitive properties of levan-based hydrogels with other natural polymer
831 hydrogels currently used, unfortunately, this is a relatively new field and there are still not
832 enough studies in the literature, **only a handful of patents have been issued.** Although most
833 studies have been in the fields focused on drug delivery and tissue engineering, hydrogel
834 studies in these areas are still insufficient.

835 A recently published article presenting a comprehensive bibliometric analysis of
836 hydrogel research suggested that future applications of hydrogels will predominantly focus on
837 wound healing, drug delivery, cell encapsulation, bioprinting, tissue engineering, electronic
838 devices, and environmental applications. Notably, in the field of drug delivery, the development
839 of responsive sustained-release nanocarriers, intelligent drug delivery systems, and targeted
840 delivery approaches are expected to be significant trends [202]. Also, in their analysis, “wound
841 healing”, “3D printing”, “antibacterial”, “strain”, “adhesive”, “tough”, “strain sensor”, and
842 “inflammation” were identified as hot spots.

843 Moving forward, levan-based hydrogels need to be developed further to enhance their
844 functionality and applicability. One important avenue of research is the investigation of levan’s
845 interaction with both synthetic and natural materials used in hydrogel production. The
846 properties of composite hydrogels, formed by combining levan with other materials, also
847 warrant further study.

848 **The regulatory framework for introducing hydrogels into practice depends on their**
849 **intended application—medical, cosmetic, food, or industrial. In medical and healthcare**
850 **contexts, hydrogels are regulated as medical devices or drug-device combinations by**
851 **authorities like the FDA in the US and under the EU Medical Device Regulation (MDR). These**
852 **require classification based on risk, biocompatibility testing (e.g., ISO 10993), sterility**
853 **validation, clinical evaluation, and compliance with manufacturing standards such as GMP or**

854 ISO 13485 [203]. For cosmetic uses, regulations focus on safety and proper labeling, with
855 notification procedures like the EU's Cosmetic Products Notification Portal (CPNP). In the food
856 sector, hydrogels must be approved as safe additives, such as GRAS substances in the US or
857 approved E numbers in the EU. Industrial applications are generally less tightly regulated but
858 may fall under environmental or chemical safety rules like EPA or REACH, especially if human
859 exposure is possible.

860 Levan hydrogels are not currently present in major regulatory or clinical databases such
861 as the FDA or European Database on Medical Devices (EUDAMED) and no approved or
862 clinically investigated levan-based hydrogel products have been identified [204]. This clearly
863 shows that they have not yet reached the stage of regulatory recognition or clinical translation
864 despite the broader clinical interest in hydrogel technologies. To advance the clinical and
865 commercial translation of levan-based hydrogels, future research should prioritize
866 comprehensive *in vivo* studies. While preliminary *in vivo* evaluations have demonstrated
867 promising biocompatibility, the current body of evidence remains limited and insufficient to fully
868 assess their behavior under complex physiological conditions. Systematic *in vivo* testing is
869 essential to evaluate not only biocompatibility but also immunogenicity, biodegradability,
870 mechanical stability, and therapeutic efficacy across diverse biomedical applications. Such
871 studies are critical for meeting the safety and efficacy standards set by regulatory agencies
872 such as the FDA and European Medicines Agency (EMA) and represent a necessary milestone
873 before progressing to human clinical trials and market adoption.

874 Despite the growing interest in levan-based hydrogels, there are only a limited number
875 of MSc and PhD theses dedicated to this topic worldwide, highlighting a significant gap in
876 academic research training that should be addressed through increased graduate-level
877 investigations across institutions globally. In conclusion, while levan hydrogels currently show
878 significant promise in several biomedical applications, their full potential has yet to be realized.
879 Future research will likely expand their use, not just as bioactive delivery systems, but also in
880 more diverse and functional areas, benefiting from their natural, biocompatible, and versatile
881 properties.

882

883 **Acknowledgements**

884 The authors sincerely acknowledge the financial support from the Partnership for Research
885 and Innovation in the Mediterranean Area (PRIMA) under the Valostones project. ETO also
886 gratefully acknowledges support from The Scientific and Technological Research Council of
887 Turkey (TÜBİTAK) through project 123N067.

888

889 **Declaration of generative AI and AI-assisted technologies in the writing** 890 **process**

891 During the preparation of this work the author(s) used ChatGPT in order to improve readability
892 and language of the work. After using this tool/service, the author(s) reviewed and edited the
893 content as needed and take(s) full responsibility for the content of the published article. Any
894 use of generative AI in this manuscript adheres to ethical guidelines for use and
895 acknowledgement of generative AI in academic research.

896

897 **References**

- 898 [1] B. Balakrishnan, P.A. Hassan, A.K. Tyagi, An introduction to biomaterials, *Engineered*
899 *Biomaterials: Progress and Prospects.* (2023) 1–57.
900 https://doi.org/10.1142/9789811272011_0001.
- 901 [2] S. Todros, M. Todesco, A. Bagnò, Biomaterials and Their Biomedical Applications: From
902 Replacement To Regeneration, Processes. 9 (2021) 1949. <https://doi.org/10.3390/pr9111949>.
- 903 [3] M. Ansari, A. Darvishi, A review of the current state of natural biomaterials in wound healing
904 applications, *Front. in Bioeng. and Biotechnol.* 12 (2024) 1309541.
905 <https://doi.org/10.3389/fbioe.2024.1309541>.
- 906 [4] P. Research, Biotechnology Market Size to Worth Around USD 4.25 Trillion by 2033.
907 <https://www.precedenceresearch.com/biotechnology-market>, 2024 (accessed 10 February
908 2025).
- 909 [5] I. Benalaya, G. Alves, J. Lopes, L.R. Silva, A review of natural polysaccharides: Sources,
910 characteristics, properties, food, and pharmaceutical applications, *Int. J. Mol. Sci.* 25(2) (2024)
911 1322. <https://doi.org/10.3390/ijms25021322>.
- 912 [6] Q. Yang, J. Peng, H. Xiao, X. Xu, Z. Qian, Polysaccharide hydrogels: Functionalization,
913 construction and served as scaffold for tissue engineering, *Carbohydr. Polym.* 278 (2022)
914 118952. <https://doi.org/10.1016/j.carbpol.2021.118952>.
- 915 [7] P.M. Junaid, A.H. Dar, K.K. Dash, S. Rohilla, R. Islam, R. Shams, V.K. Pandey, S.
916 Srivastava, P. S. Panesar, S. Zaidi, Polysaccharide-based hydrogels for microencapsulation of
917 bioactive compounds: A review, *J. Agric. Food Res.* 15 (2024) 101038.
918 <https://doi.org/10.1016/j.jafr.2024.101038>.
- 919 [8] M.U.A. Khan, G.M. Stojanović, M.F.B. Abdullah, A. Dolatshahi-Pirouz, H.E. Marei, N.
920 Ashammakhi, A. Hasan, Fundamental properties of smart hydrogels for tissue engineering
921 applications: A review, *Int. J. Biol. Macromol.* 254 (2024) 127882.
922 <https://doi.org/10.1016/j.ijbiomac.2023.127882>.
- 923 [9] A. Bordbar-Khiabani, M. Gasik, Smart hydrogels for advanced drug delivery systems, *Int.*
924 *J. Mol. Sci.* 23 (2022) 3665. <https://doi.org/10.3390/ijms23073665>.
- 925 [10] D. Tahir, A. Ardiansyah, H. Heryanto, E.E.M. Noor, M.A. Mohamed, Chitosan-based
926 hydrogels: A comprehensive review of transdermal drug delivery, *Int. J. Biol. Macromol.* 298
927 (2025) 140010. <https://doi.org/10.1016/j.ijbiomac.2025.140010>.
- 928 [11] N. Maqbool, Z. Ali, S. Batool, M.U. Rehman, A.H. Alamri, A.A. Fatease, A.A. Lahiq, S.T.
929 Alsharif, F.U. Din, Improved wound care via novel dextran and boric acid loaded wound healing
930 gel in excision mice wound model, *J. Drug Deliv. Sci. Technol.* (2025) 106586.
931 <https://doi.org/10.1016/j.jddst.2024.106586>.
- 932 [12] J. Singh, N. Vishavnath, V. Sharma, B. Singh, Development of agar-alginate marine
933 polysaccharides-based hydrogels for agricultural applications to reduce environmental
934 hazards, *Int. J. Biol. Macromol.* 295 (2025) 139659.
935 <https://doi.org/10.1016/j.ijbiomac.2025.139659>.
- 936 [13] Akan G. & Toksoy Öner E. (2021) Gel Properties of Microbial Polysaccharides. In: Oliveira
937 J., Radhouani H., Reis R.L. (eds) *Polysaccharides of Microbial Origin*. Springer, Cham.
938 https://doi.org/10.1007/978-3-030-35734-4_34-1.

- 939 [14] D. Ni, S. Zhang, X. Liu, Y. Zhu, W. Xu, W. Zhang, W. Mu, Production, effects, and
940 applications of fructans with various molecular weights, *Food Chem.* 437 (2024) 137895.
941 <https://doi.org/10.1016/j.foodchem.2023.137895>.
- 942 [15] E. Toksoy Öner, J. Hernández, J. Combie, Review of levan polysaccharide: from a century
943 of past experiences to future prospects, *Biotechnol. Adv.* 34 (2016) 827–844.
944 <https://doi.org/10.1016/j.biotechadv.2016.05.002>.
- 945 [16] B. Veerapandian, S. Krishnan, S. Sivaraman, A. Immanuel, S.R. Shanmugam, E.T. Öner,
946 P. Venkatachalam, V. Ulaganathan, *Bacillus* spp. as microbial factories for levan and
947 fructooligosaccharide production – Recent trends, *Int. J. Biol. Macromol.* (2025) 252.
948 <https://doi.org/10.1016/j.ijbiomac.2025.140252>.
- 949 [17] E.T. Öner, Levan as a Functional Polymer for Biomedical Applications, In Elsevier eBooks.
950 (2023) pp. 257–274. <https://doi.org/10.1016/b978-0-323-85410-8.00008-9>.
- 951 [18] S. Tornacı, M. Erginer, B. Gökalsın, A. Aysan, M. Çetin, M. Sadauki, N. Fındıklı, S. Genç,
952 C. Sesal, E. Toksoy Öner, Investigating the cryoprotective efficacy of fructans in mammalian
953 cell systems via a structure-functional perspective, *Carbohydr. Polym.* 328 (2024) 121704.
954 <https://doi.org/10.1016/j.carbpol.2023.121704>.
- 955 [19] E.C. de Siqueira, E. Toksoy Öner, Co-production of levan with other high-value
956 bioproducts: A Review, *Int. J. Biol. Macromol.* 235 (2023) 123800.
957 <https://doi.org/10.1016/j.ijbiomac.2023.123800>.
- 958 [20] M. González-Torres, F. Hernández-Rosas, N. Pacheco, J. Salinas-Ruiz, J.A. Herrera-
959 Corredor, R. Hernández-Martínez, Levan production by *Suhomyces kilbournensis* using
960 sugarcane molasses as a carbon source in submerged fermentation, *Molecules* 29(5) (2024)
961 1105. <https://doi.org/10.3390/molecules29051105>.
- 962 [21] V. Ahuja, A.K. Bhatt, J.R. Banu, V. Kumar, G. Kumar, Y.-H. Yang, S.K. Bhatia, Microbial
963 Exopolysaccharide Composites in Biomedicine and Healthcare: Trends and Advances,
964 *Polymers* 15 (2023) 1801. <https://doi.org/10.3390/polym15071801>.
- 965 [22] E. Castillo, A. López–Munguía, Synthesis of levan in water–miscible organic solvents, *J.*
966 *Biotechnol.* 114 (2004) 209–217. <https://doi.org/10.1016/j.jbiotec.2004.06.003>.
- 967 [23] N. Ido, A. Lybman, S. Hayet, D.N. Azulay, M. Ghayeb, S. Liddawieh, L. Chai, *Bacillus*
968 *subtilis* biofilms characterized as hydrogels. insights on water uptake and water binding in
969 biofilms, *Soft Matter* 16(26) (2020) 6180–6190. <https://doi.org/10.1039/d0sm00581a>.
- 970 [24] C. Charoenwongphaibun, C. Lorthongpanich, P. Septham, K. Wangpaiboon, P. Panpetch,
971 R. Pichyangkura, T. Charoenwongpaiboon, K. Kuttiyawong, Synthesis of Cationic Quaternized
972 Nanolevan Derivative for Small Molecule and Nucleic Acid Delivery, *Gels* 9(3) (2023) 188.
973 <https://doi.org/10.3390/gels9030188>.
- 974 [25] J. Peng, W. Xu, D. Ni, W. Zhang, T. Zhang, C. Guang, W. Mu, Preparation of a novel water-
975 soluble gel from *Erwinia amylovora* levan, *Int. J. Biol. Macromol.* 122 (2019) 469–478.
976 <https://doi.org/10.1016/j.ijbiomac.2018.10.093>.
- 977 [26] V.K. Truong, C.M. Bhadra, A.J. Christofferson, I. Yarovsky, M. Al Kobaisi, C.J. Garvey, O.N.
978 Ponamoreva, S.V. Alferov, V.A. Alferov, P.G. Tharushi Perera, D.H. Nguyen, R. Buividas, S.
979 Juodkakis, R.J. Crawford, E.P. Ivanova, Three-dimensional organization of self-encapsulating
980 *Gluconobacter oxydans* bacterial cells, *ACS Omega* 2(11) (2017) 8099–8107.
981 <https://doi.org/10.1021/acsomega.7b01282>.

- 982 [27] W.I. Choi, Y. Hwang, A. Sahu, K. Min, D. Sung, G. Tae, J.H. Chang, An injectable and
983 physical levan-based hydrogel as a dermal filler for soft tissue augmentation, *Biomater. Sci.*
984 6(10) (2018) 2627–2638. <https://doi.org/10.1039/c8bm00524a>.
- 985 [28] Y. Hwang, J.S. Lee, H. An, H. Oh, D. Sung, G. Tae, W.I. Choi, Hydroxyapatite-embedded
986 levan composite hydrogel as an injectable dermal filler for considerable enhancement of
987 biological efficacy, *J. Ind. Eng. Chem.* 104 (2021) 491–499.
988 <https://doi.org/10.1016/j.jiec.2021.08.040>.
- 989 [29] R. Nair, A.R. Choudhury, Synthesis and rheological characterization of a novel shear
990 thinning levan gellan hydrogel, *Int. J. Biol. Macromol.* 159 (2020) 922–930.
991 <https://doi.org/10.1016/j.ijbiomac.2020.05.119>.
- 992 [30] R. Hama, A. Ulziibayar, J.W. Reinhardt, T. Watanabe, J. Kelly, T. Shinoka, Recent
993 developments in biopolymer-based hydrogels for tissue engineering applications,
994 *Biomolecules* 13 (2023) 280. <https://doi.org/10.3390/biom13020280>.
- 995 [31] S.V. María, G.D.C. Katia, A. Florencia, M.L. María, G. Gerardo, V. Nancy, R.C. Mariana,
996 Biopolymer production by bacteria isolated from native stingless bee honey, *Scaptotrigona*
997 *jujuyensis*, *Food Biosci.* 42 (2021) 101077. <https://doi.org/10.1016/j.fbio.2021.101077>
- 998 [32] A. Osman, E. Toksoy Öner, M.S. Eroglu, Novel levan and pNIPA temperature sensitive
999 hydrogels for 5-ASA controlled release, *Carbohydr. Polym.* 165 (2017) 61–70.
1000 <https://doi.org/10.1016/j.carbpol.2017.01.097>.
- 1001 [33] A. Osman, E. Lin, D.S. Hwang, A sticky carbohydrate meets a mussel adhesive: Catechol-
1002 conjugated levan for hemostatic and wound healing applications, *Carbohydr. Polym.* 299
1003 (2022) 120172. <https://doi.org/10.1016/j.carbpol.2022.120172>.
- 1004 [34] A. Berg, E. Toksoy Öner, J. Combie, B. Schneider, R. Ellinger, J. Weisser, R. Wyrwa, M.
1005 Schnabelrauch, Formation of new, cytocompatible hydrogels based on photochemically
1006 crosslinkable levan methacrylates, *Int. J. Biol. Macromol.* 107 (2018) 2312–2319.
1007 <https://doi.org/10.1016/j.ijbiomac.2017.10.120>.
- 1008 [35] S.-J. Kim, P.K. Bae, M. Choi, J.O. Keem, Y. Shin, Fabrication and Application of Levan–
1009 PVA Hydrogel for Effective Influenza Virus Capture, *ACS Appl. Mater. Interfaces* 12 (2020)
1010 29103–29109. <https://doi.org/10.1021/acsami.0c08333>.
- 1011 [36] B. Veerapandian, T.K.R. Selvaraj, S.R. Shanmugam, K.K. Sarwareddy, K.P. Mani, P.
1012 Venkatachalam, In-vitro drug release and stability assessment of tailored levan–chitosan
1013 biocomposite hydrogel, *Iran. Polym. J.* (2023) 1–13. <https://doi.org/10.1007/s13726-023-01229-x>.
- 1015 [37] T. Demirci, M. Erginer Hasköylü, M.S. Eroğlu, J. Hemberger, E. Toksoy Öner, Levan-based
1016 hydrogels for controlled release of Amphotericin B for dermal local antifungal therapy of
1017 Candidiasis, *Eur. J. Pharm. Sci.* 145 (2020) 105255.
1018 <https://doi.org/10.1016/j.ejps.2020.105255>.
- 1019 [38] S.S. Selvi, M. Erginer Hasköylü, S. Genç, E. Toksoy Öner, Synthesis and characterization
1020 of levan hydrogels and their use for resveratrol release, *J. Bioact. Compat. Polym.* 36(6) (2021)
1021 464–480. <https://doi.org/10.1177/08839115211055725>.
- 1022 [39] Ö.E. Altıntaş, P.A. Çelik, Levan-based bioactive hydrogels containing herbal liposome in
1023 treating acute wounds, *J. Bioact. Compat. Polym.* 38 (2023) 437–457.
1024 <https://doi.org/10.1177/08839115231198528>.

- 1025 [40] M. Yavuz, M. Erginer, C. Kasavi, E. Toksoy Öner, Enhanced preservation of viability and
1026 species stratification in *Lactocaseibacillus* group using levan-fortified skim milk as a
1027 cryoprotectant during freeze-drying, *Food Sci. Biotechnol.* (2024).
1028 <https://doi.org/10.1007/s10068-024-01802-x>.
- 1029 [41] R.O. Saglam, S.U. Yıldırım, F.N. Oktar, S. Genc, G. Erdem, E.T. Oner, Synthesis and
1030 characterization of interpenetrating network (IPN) based levan-polyacrylamide hydrogels and
1031 their application in conservation of Cultural Heritage, *J. Cult. Herit.* 64 (2023) 255–265.
1032 <https://doi.org/10.1016/j.culher.2023.10.013>.
- 1033 [42] C.Y. Akkulah, M. Erginer, A. Cumbul, O. Kirtel, F. Bayram, E. Toksoy Öner, Enhanced
1034 effects of levan hydrogels and bovine grafts on guided bone regeneration: In-vitro and in-vivo
1035 analysis, *Int. J. Biol. Macromol.* 292 (2025) 139129.
1036 <https://doi.org/10.1016/j.ijbiomac.2024.139129>.
- 1037 [43] O. Kirtel, M. Menéndez, M. Versluys, W. Van den Ende, L. Hernández, E. Toksoy Öner,
1038 Levansucrase from *Halomonas smyrnensis* AAD6T: first halophilic GH-J clan enzyme
1039 recombinantly expressed, purified, and characterized, *Appl. Microbiol. Biotechnol.*
1040 102(21)(2018) 9207–9220. <https://doi.org/10.1007/s00253-018-9311-z>.
- 1041 [44] R. Srikanth, G. Siddartha, C.H.S.S. Sundhar Reddy, B.S. Harish, M. Janaki Ramaiah, K.B.
1042 Uppuluri, Antioxidant and anti-inflammatory levan produced from *Acetobacter xylinum*
1043 NCIM2526 and its statistical optimization, *Carbohydr. Polym.* 123 (2015) 8–16.
1044 <https://doi.org/10.1016/j.carbpol.2014.12.079>.
- 1045 [45] J. Combie, E. Toksoy Öner, Fructan Production Processes, *The Book of Fructans* (2023)
1046 187–199. <https://doi.org/10.1016/b978-0-323-85410-8.00009-0>.
- 1047 [46] G. Gojgic-Cvijovic, D. Jakovljevic, B. Loncarevic, N. Todorovic, M. Pergal, J. Ciric, K. Loos,
1048 V. Beskoski, M. Vrvic, Production of levan by *Bacillus licheniformis* NS032 in sugar beet
1049 molasses-based medium, *Int. J. Biol. Macromol.* 121 (2018) 142–151.
1050 <https://doi.org/10.1016/j.ijbiomac.2018.10.019>.
- 1051 [47] O. Kirtel, E.T. Öner, Levan polysaccharide for biomedical applications, *Soft Matter Biomed.*
1052 *Appl.* (2021) 134–154. <https://doi.org/10.1039/9781839161124-00134>.
- 1053 [48] M. Erginer, A. Akcay, B. Coskuncan, T. Morova, D. Rende, S. Bucak, N. Baysal, R. Özişik,
1054 M.S. Eroğlu, M. Agirbasli, E. Toksoy Öner, Sulfated levan from *Halomonas smyrnensis* as a
1055 bioactive, heparin-mimetic glycan for cardiac tissue engineering applications, *Carbohydr.*
1056 *Polym.* 149 (2016) 289–296. <https://doi.org/10.1016/j.carbpol.2016.04.092>.
- 1057 [49] H.K. Sarilmiser, E. Toksoy Öner, Investigation of anti-cancer activity of linear and
1058 aldehyde-activated levan from *Halomonas smyrnensis* AAD6T, *Biochem. Eng. J.* 92 (2014)
1059 28–34. <https://doi.org/10.1016/j.bej.2014.06.020>.
- 1060 [50] J. Combie, E.T. Öner, From healing wounds to resorbable electronics, Levan can fill
1061 bioadhesive roles in scores of Markets, *Bioinspir. Biomim.* 14(1) (2018) 011001.
1062 <https://doi.org/10.1088/1748-3190/aaed92>.
- 1063 [51] M. Versluys, O. Kirtel, E. Toksoy Öner, W. Van den Ende, The Fructan Syndrome:
1064 Evolutionary Aspects and Common Themes Among Plants and Microbes, *Plant Cell Environ.*
1065 41(1) (2017) 16–38. <https://doi.org/10.1111/pce.13070>.

- 1066 [52] S. Yoo, S. Jung, K. Kwak, J. Kim, The Role of Prebiotics in Modulating Gut Microbiota:
1067 Implications for Human Health, *International Journal of Molecular Sciences*. 25(9) (2024) 4834.
1068 <https://doi.org/10.3390/ijms25094834>.
- 1069 [53] D. Davani-Davari, M. Negahdaripour, I. Karimzadeh, M. Seifan, M. Mohkam, S. Masoumi,
1070 A. Berenjian, Y. Ghasemi, Prebiotics: Definition, Types, Sources, Mechanisms, and Clinical
1071 Applications, *Foods* 8(3) (2019) 92. <https://doi.org/10.3390/foods8030092>.
- 1072 [54] M. Arapović, L. Puljić, N. Kajić, B. Kartalović, K. Habschied, K. Mastanjević, New insights
1073 in prebiotic utilization: A systematic review, *Processes* 12(5) (2024) 867.
1074 <https://doi.org/10.3390/pr12050867>.
- 1075 [55] Y. Xiao, Q. Zhao, D. Ni, X. Zhang, W. Hao, Q. Yuan, W. Xu, W. Mu, D. Wu, X. Wu, S.
1076 Wang, Polymerization of dietary fructans differentially affects interactions among intestinal
1077 microbiota of colitis mice, *The ISME J.* (2025). <https://doi.org/10.1093/ismejo/wrae262>.
- 1078 [56] Y. Jia, Y. Liu, Y. Wu, F. Ren, H. Liu, From Diet to microbiota: How fruits and vegetables
1079 influence gut microbiota, *Int. J. Food Sci. Technol.* 60(1) (2025).
1080 <https://doi.org/10.1093/ijfood/vvae008>.
- 1081 [57] S.S. Selvi, E. Eminagic, M.Y. Kandur, E. Ozcan, C. Kasavi, E.T. Toksoy Öner, Ch. 10 -
1082 Research and Production of Microbial Polymers for Food Industry, in: G. Molina, V.K. Gupta,
1083 B.N. Singh, N. Gathergood (Eds.), *Bioprocessing for Biomolecules Production*, 2019, pp. 211–
1084 231, ISBN 1119434327, 9781119434320.
- 1085 [58] L. Li, Z. Qiu, Y. Qiao, X. Bai, W. Zhu, Z. Li, Z. Zheng, Immunomodulatory effects of inulin-
1086 type fructans from *Arctium Lappa* L. by targeting gut microbiota and their metabolites, *Food*
1087 *Chem.* 467 (2025) 142308. <https://doi.org/10.1016/j.foodchem.2024.142308>.
- 1088 [59] P. Zhao, J. Wang, I. Kim, Evaluation of dietary fructan supplementation on growth
1089 performance, nutrient digestibility, meat quality, fecal microbial flora, and fecal noxious gas
1090 emission in finishing pigs, *J. Anim. Sci.* 91(11) (2013) 5280–5286.
1091 <https://doi.org/10.2527/jas.2012-5393>.
- 1092 [60] X.J. Lei, Y.M. Kim, J.H. Park, D.H. Baek, C.M. Nyachoti, I.H. Kim, Effects of levan-type
1093 fructan on growth performance, nutrient digestibility, diarrhea scores, faecal shedding of total
1094 lactic acid bacteria and coliform bacteria, and faecal gas emission in weaning pigs, *J. Sci. Food*
1095 *Agric.* 98(4) (2017) 1539–1544. <https://doi.org/10.1002/jsfa.8625>.
- 1096 [61] A.A. Hamdy, N.A. Elattal, M.A. Amin, A.E. Ali, N.M. Mansour, G.E. Awad, A.R.H. Farrag,
1097 M.A. Esawy, *In vivo* assessment of possible probiotic properties of *Bacillus subtilis* and
1098 prebiotic properties of levan, *Biocatal. Agric. Biotechnol.* 13 (2018) 190–197.
1099 <https://doi.org/10.1016/j.bcab.2017.12.001>.
- 1100 [62] C. Liu, S. Kolida, D. Charalampopoulos, R.A. Rastall, An evaluation of the prebiotic
1101 potential of microbial levans from *Erwinia* sp. 10119, *J. Funct. Foods* 64 (2020) 103668.
1102 <https://doi.org/10.1016/j.jff.2019.103668>.
- 1103 [63] J. Ju, S. Heo, H. Kim, M. Jo, S. Jeon, D. Park, C. Kim, B. Oh, Selective production of two
1104 prebiotic extracellular polysaccharides from an oral probiotic lactic acid bacterium,
1105 *Streptococcus salivarius* SY511, *LWT* 198 (2024) 116051.
1106 <https://doi.org/10.1016/j.lwt.2024.116051>.

- 1107 [64] R. Wannasutta, S. Laopeng, S. Yuensuk, S. McCloskey, N. Riddech, W. Mongkolthanaruk,
1108 Biopolymer-Levan Characterization in *Bacillus* Species Isolated from Traditionally Fermented
1109 Soybeans (Thua Nao), ACS Omega (2025). <https://doi.org/10.1021/acsomega.4c09641>.
- 1110 [65] P. Zambelli, L. Tamborini, S. Cazzamalli, A. Pinto, S. Arioli, S. Balzaretto, F.J. Plou, L.
1111 Fernandez-Arrojo, F. Molinari, P. Conti, D. Romano, An efficient continuous flow process for
1112 the synthesis of a non-conventional mixture of fructooligosaccharides, Food Chem. 190 (2016)
1113 607–613. <https://doi.org/10.1016/j.foodchem.2015.06.002>.
- 1114 [66] I. Dahech, K.S. Belghith, K. Hamden, A. Feki, H. Belghith, H. Mejdoub, Antidiabetic activity
1115 of levan polysaccharide in alloxan-induced diabetic rats, Int. J. Biol. Macromol. 49(4) (2011)
1116 742–746. <https://doi.org/10.1016/j.ijbiomac.2011.07.007>.
- 1117 [67] K.S. Belghith, I. Dahech, K. Hamden, A. Feki, H. Mejdoub, H. Belghith, Hypolipidemic
1118 effect of diet supplementation with bacterial levan in cholesterol-fed rats, Int. J. Biol. Macromol.
1119 50(4) (2012) 1070–1074. <https://doi.org/10.1016/j.ijbiomac.2012.02.024>.
- 1120 [68] S. Bahroudi, B. Shabanpour, J. Combie, A. Shabani, M. Salimi, Levan Exerts Health
1121 Benefit Effect through Alteration in Bifidobacteria Population, Iranian Biomed. J. 24(1) (2020)
1122 54–59. <https://doi.org/10.29252/ibj.24.1.54>.
- 1123 [69] W. Ahmad, A. Nasir, S. Prakash, A. Hayat, M.U. Rehman, S. Khaliq, K. Akhtar, M.A. Anwar,
1124 N. Munawar, *In vitro* and *in vivo* interventions reveal the health benefits of levan-type
1125 exopolysaccharide produced by a fish gut isolate *Lactobacillus reuteri* FW2, Life 15(1) (2025)
1126 89. <https://doi.org/10.3390/life15010089>.
- 1127 [70] S.A. Kang, K. Hong, K. Jang, S. Kim, K.H. Lee, B.I. Chang, C. Kim, R. Choue, Anti-obesity
1128 and hypolipidemic effects of dietary levan in high fat diet-induced obese rats, J. Microbiol.
1129 Biotechnol. 14 (2004) 796–804.
- 1130 [71] J.S. Oh, S.R. Lee, K.T. Hwang, G.E. Ji, The anti-obesity effects of the dietary combination
1131 of fermented red ginseng with levan in high fat diet mouse model, Phytother. Res. 28(4) (2013)
1132 617–622. <https://doi.org/10.1002/ptr.5042>.
- 1133 [72] J. Wang, Y. Jiang, Natural compounds as anticancer agents: Experimental evidence,
1134 World J. Exp. Med. 2(3) (2012) 45. <https://doi.org/10.5493/wjem.v2.i3.45>.
- 1135 [73] P. Marino, G. Pepe, M.G. Basilicata, V. Vestuto, S. Marzocco, G. Autore, A. Procino, I.M.
1136 Gomez-Monterrey, M. Manfra, P. Campiglia, Potential role of natural antioxidant products in
1137 oncological diseases, Antioxidants 12 (2023) 704. <https://doi.org/10.3390/antiox12030704>.
- 1138 [74] W.A. Wahab, H.I. Shafey, K.F. Mahrous, M.A. Esawy, S.A. Saleh, Coculture of bacterial
1139 levans and evaluation of its anti-cancer activity against hepatocellular carcinoma cell lines, Sci.
1140 Rep. 14 (2024). <https://doi.org/10.1038/s41598-024-52699-9>.
- 1141 [75] A.T. De Aguiar Silva, I.D.L. Cavalcanti, M. De Araújo Sobral, G.M. De Souza Lima, O.D.L.
1142 Pessoa, N.S.S. Magalhães, C.G.O. Coimbra, M.C. De Britto Lira Nogueira, Development of
1143 levan-coated PIBCA nanoparticles and their antiproliferative activity against MDA-MB-231 and
1144 B16F10 cells, Colloids Surf. A 670 (2023) 131567.
1145 <https://doi.org/10.1016/j.colsurfa.2023.131567>.
- 1146 [76] H. Shawky, D.B. Fayed, S.S.A. El-Karim, H. Rezk, M.A. Esawy, E.K. Farrag,
1147 Immunotherapeutic effects of de novo benzimidazole derivative and prebiotic bacterial levan
1148 against triple-negative breast tumors by harnessing the immune landscape to intercept the

- 1149 oncogenic transcriptome, *Int. J. Biol. Macromol.* 289 (2024) 138844.
1150 <https://doi.org/10.1016/j.ijbiomac.2024.138844>.
- 1151 [77] S. Chen, Q. Li, H. Shi, F. Li, Y. Duan, Q. Guo, New insights into the role of mitochondrial
1152 dynamics in oxidative stress-induced diseases, *Biomed. Pharm.* 178 (2024) 117084.
1153 <https://doi.org/10.1016/j.biopha.2024.117084>.
- 1154 [78] G. Mummaleti, C. Sarma, S. Yarrakula, R. Urla, H. Gazula, Production, properties and
1155 applications of levan polysaccharide, *Food Hum.* 100369 (2024).
1156 <https://doi.org/10.1016/j.foohum.2024.100369>.
- 1157 [79] A.M. Abdel-Fattah, A.M. Gamal-Eldeen, W.A. Helmy, M.A. Esawy, Antitumor and
1158 antioxidant activities of levan and its derivative from the isolate *Bacillus subtilis* NRC1aza,
1159 *Carbohydr. Polym.* 89 (2012) 314–322. <https://doi.org/10.1016/j.carbpol.2012.02.041>.
- 1160 [80] I. Dahech, B. Harrabi, K. Hamden, A. Feki, H. Mejdoub, H. Belghith, K.S. Belghith,
1161 Antioxidant effect of nondigestible levan and its impact on cardiovascular disease and
1162 atherosclerosis, *Int. J. Biol. Macromol.* 58 (2013) 281–286.
1163 <https://doi.org/10.1016/j.ijbiomac.2013.04.058>.
- 1164 [81] O. Taylan, M.T. Yilmaz, E. Dertli, Partial characterization of a levan type exopolysaccharide
1165 (EPS) produced by *Leuconostoc mesenteroides* showing immunostimulatory and antioxidant
1166 activities, *Int. J. Biol. Macromol.* 136 (2019) 436–444.
1167 <https://doi.org/10.1016/j.ijbiomac.2019.06.078>.
- 1168 [82] M.A. Esawy, E.F. Ahmed, W.A. Helmy, N.M. Mansour, W.M. El-Senousy, M.M. El-Safty,
1169 Production of levansucrase from novel honey *Bacillus subtilis* isolates capable of producing
1170 antiviral levans, *Carbohydr. Polym.* 86 (2011) 823–830.
1171 <https://doi.org/10.1016/j.carbpol.2011.05.035>.
- 1172 [83] A.A. Gamal, A.M. Hashem, M.M. El-Safty, R.A. Soliman, M.A. Esawy, Evaluation of the
1173 antiviral activity of *Enterococcus faecalis* Esawy levan and its sulfated form, *Biocatal. Agric.*
1174 *Biotechnol.* 28 (2020) 101735. <https://doi.org/10.1016/j.bcab.2020.101735>.
- 1175 [84] K. Foo, D. Roofeh, Inflammatory diseases, in: N. Liao, J. Mahan, S. Misra, R. Scherzer, J.
1176 Schiller (Eds.), *Pediatric Rotations*, Springer, Cham, 2024. https://doi.org/10.1007/978-3-031-59873-9_26.
- 1177
- 1178 [85] Y. Sharma, M. Arora, K. Bala, The potential of immunomodulators in shaping the future of
1179 healthcare, *Deleted J.* 1 (2024) 1–1. <https://doi.org/10.1007/s44337-024-00029-3>.
- 1180 [86] M. Strzelec, J. Detka, P. Mieszczak, M.K. Sobocińska, M. Majka, Immunomodulation—a
1181 general review of the current state-of-the-art and new therapeutic strategies for targeting the
1182 immune system, *Front. Immunol.* 14 (2023). <https://doi.org/10.3389/fimmu.2023.1127704>.
- 1183 [87] M. Arfeen, A. Srivastava, N. Srivastava, R.A. Khan, S.A. Almahmoud, H.A. Mohammed,
1184 Design, classification, and adverse effects of NSAIDs: A review on recent advancements,
1185 *Bioorg. Med. Chem.* 112 (2024) 117899. <https://doi.org/10.1016/j.bmc.2024.117899>.
- 1186 [88] Y. Qian, J. Ding, R. Zhao, Y. Song, J. Yoo, H. Moon, S. Koo, J.S. Kim, J. Shen, Intrinsic
1187 immunomodulatory hydrogels for chronic inflammation, *Chem. Soc. Rev.* (2024).
1188 <https://doi.org/10.1039/d4cs00450g>.
- 1189 [89] I.D. Young, D. Latousakis, N. Juge, The immunomodulatory properties of β -2,6 fructans:
1190 A comprehensive review, *Nutrients* 13 (2021) 1309. <https://doi.org/10.3390/nu13041309>.

1191 [90] Q. Xu, T. Yajima, W. Li, K. Saito, Y. Ohshima, Y. Yoshikai, Levan (β -2,6-fructan), a major
1192 fraction of fermented soybean mucilage, displays immunostimulating properties via Toll-like
1193 receptor 4 signaling: induction of interleukin-12 production and suppression of T-helper type 2
1194 response and immunoglobulin E production, *Clin. Exp. Allergy* 36 (2006) 94-101.
1195 <https://doi.org/10.1111/j.1365-2222.2006.02401.x>.

1196 [91] M. Molteni, S. Gemma, C. Rossetti, The role of toll-like receptor 4 in infectious and
1197 noninfectious inflammation, *Mediators Inflamm.* (2016) 1-9.
1198 <https://doi.org/10.1155/2016/6978936>.

1199 [92] B.W. Simpson, M.S. Trent, Pushing the envelope: LPS modifications and their
1200 consequences, *Nat. Rev. Microbiol.* 17 (2019) 403-416. [https://doi.org/10.1038/s41579-019-](https://doi.org/10.1038/s41579-019-0201-x)
1201 [0201-x](https://doi.org/10.1038/s41579-019-0201-x).

1202 [93] E. Gerber-Tichet, F.P. Blanchet, K. Majzoub, E.J. Kremer, Toll-like receptor 4 – a
1203 multifunctional virus recognition receptor, *Trends Microbiol.* 33 (2024) 34–47.
1204 <https://doi.org/10.1016/j.tim.2024.07.001>.

1205 [94] I.D. Young, S.A. Nepogodiev, I.M. Black, G. Le Gall, A. Wittmann, D. Latousakis, T.
1206 Visnapuu, P. Azadi, R.A. Field, N. Juge, N. Kawasaki, Lipopolysaccharide associated with β -
1207 2,6 fructan mediates TLR4-dependent immunomodulatory activity *in vitro*, *Carbohydr. Polym.*
1208 277 (2022) 118606. <https://doi.org/10.1016/j.carbpol.2021.118606>.

1209 [95] X. Xu, C. Gao, Z. Liu, J. Wu, J. Han, M. Yan, Z. Wu, Characterization of the levan produced
1210 by *Paenibacillus bovis* sp. nov. BD3526 and its immunological activity, *Carbohydr. Polym.* 144
1211 (2016) 178–186. <https://doi.org/10.1016/j.carbpol.2016.02.049>.

1212 [96] P. Aramsangtienchai, W. Raksachue, S. Pechroj, K. Srisook, The immunomodulatory
1213 activity of levan in RAW264.7 macrophage varies with its molecular weights, *Food Biosci.* 53
1214 (2023) 102721. <https://doi.org/10.1016/j.fbio.2023.102721>.

1215 [97] P. Aramsangtienchai, T. Kongmon, S. Pechroj, K. Srisook, Enhanced production and
1216 immunomodulatory activity of levan from the acetic acid bacterium, *Tanticharoenia*
1217 *sakaeratensis*, *Int. J. Biol. Macromol.* 163 (2020) 574–581.
1218 <https://doi.org/10.1016/j.ijbiomac.2020.07.001>.

1219 [98] Y.O. Waidi, V.S. Wagh, S. Mishra, S. Jhunjhunwala, S.G. Dastager, K. Chatterjee, Vat-
1220 Based 3D-bioprinted scaffolds from photocurable bacterial levan for osteogenesis and
1221 immunomodulation, *Biomacromolecules* (2025). <https://doi.org/10.1021/acs.biomac.4c01264>.

1222 [99] C.N. Munyiri, E.S. Madivoli, J. Kisato, J. Gichuki, P.G. Kareru, Biopolymer based
1223 hydrogels: crosslinking strategies and their applications, *Int. J. Polym. Mater. Polym. Biomater.*
1224 74 (2025) 625–640. <https://doi.org/10.1080/00914037.2024.2356603>.

1225 [100] S. Maiti, B. Maji, H. Yadav, Progress on green crosslinking of polysaccharide hydrogels
1226 for drug delivery and tissue engineering applications, *Carbohydr. Polym.* 326 (2023) 121584.
1227 <https://doi.org/10.1016/j.carbpol.2023.121584>.

1228 [101] M. Wojtkiewicz, A. Stachura, B. Roszkowski, N. Winiarska, K. Kazimierska, K. Stachura,
1229 Are we overlooking harms of BDDE-cross-linked dermal fillers? A scoping review, *Aesthet.*
1230 *Plast. Surg.* (2024). <https://doi.org/10.1007/s00266-024-01995-0>.

1231 [102] S. Adepu, S. Ramakrishna, Controlled drug delivery systems: Current status and future
1232 directions, *Molecules* 26 (2021) 5905. <https://doi.org/10.3390/molecules26195905>.

- 1233 [103] M. Hamidi, M.S. Tabatabaei, M. Moslehi, M. Barati, Introduction to novel drug delivery
1234 systems, *Novel Drug Delivery Systems* (2024) 1–34.
1235 <https://doi.org/10.1002/9781119852476.ch1>.
- 1236 [104] U.E. Ewii, A.L. Onugwu, V.C. Nwokpor, I. Akpaso, T.E. Ogbulie, B. Aharanwa, C. Chijioke,
1237 N. Verla, C. Iheme, C. Ujowundu, C. Anyiam, A.A. Attama, Novel drug delivery systems: Insight
1238 into self-powered and nano-enabled drug delivery systems, *Nano TransMed* 3 (2024) 100042.
1239 <https://doi.org/10.1016/j.ntm.2024.100042>.
- 1240 [105] A.C. Anselmo, S. Mitragotri, An overview of clinical and commercial impact of drug
1241 delivery systems, *J. Controlled Release* 190 (2014) 15–28.
1242 <https://doi.org/10.1016/j.jconrel.2014.03.053>.
- 1243 [106] R. Sharma, S. Kumar, R. Malviya, B.G. Prajapati, D. Puri, S. Limmatvapirat, P.
1244 Sriamornsak, Recent advances in biopolymer-based mucoadhesive drug delivery systems for
1245 oral application, *J. Drug Delivery Sci. Technol.* 91 (2024) 105227.
1246 <https://doi.org/10.1016/j.jddst.2023.105227>.
- 1247 [107] N.H. Thang, T.B. Chien, D.X. Cuong, Polymer-based hydrogels applied in drug delivery:
1248 An overview, *Gels* 9 (2023) 523. <https://doi.org/10.3390/gels9070523>.
- 1249 [108] Y. Guo, M. Wang, Y. Zhang, Z. Zhao, J. Li, Advanced hydrogel material for colorectal
1250 cancer treatment, *Drug Delivery* 32 (2024) 1. <https://doi.org/10.1080/10717544.2024.2446552>.
- 1251 [109] X. Xuan, Y. Li, X. Xu, Z. Pan, Y. Li, Y. Luo, L. Sun, Three-dimensional printable magnetic
1252 hydrogels with adjustable stiffness and adhesion for magnetic actuation and magnetic
1253 hyperthermia applications, *Gels* 11 (2025) 67. <https://doi.org/10.3390/gels11010067>.
- 1254 [110] A.D. Sezer, H. Kazak, E. Toksoy Öner, J. Akbuğa, Levan-based nanocarrier system for
1255 peptide and protein drug delivery: Optimization and influence of experimental parameters on
1256 the nanoparticle characteristics, *Carbohydr. Polym.* 84 (2011) 358–363.
1257 <https://doi.org/10.1016/j.carbpol.2010.11.046>.
- 1258 [111] A.D. Sezer, H. Kazak Sarılmışer, E. Rayaman, A. Çevikbaş, E. Toksoy Öner, J. Akbuğa,
1259 Development and characterization of vancomycin-loaded levan-based microparticulate system
1260 for drug delivery, *Pharm. Dev. Technol.* 22 (2017) 627–634.
1261 <https://doi.org/10.3109/10837450.2015.1116564>.
- 1262 [112] F. Bahadori, Z. Eskandari, N. Ebrahimi, M.S. Bostan, M.S. Eroğlu, E.T. Oner,
1263 Development and optimization of a novel PLGA-Levan based drug delivery system for
1264 curcumin, using a quality-by-design approach, *Eur. J. Pharm. Sci.* 138 (2019) 105037.
1265 <https://doi.org/10.1016/j.ejps.2019.105037>.
- 1266 [113] E.C. Mutlu, F. Bahadori, M.S. Bostan, H.K. Sarilmiser, E. ToksoyOner, M.S. Eroğlu,
1267 *Halomonas* levan-coated phospholipid based nano-carrier for active targeting of A549 lung
1268 cancer cells, *Eur. Polym. J.* 144 (2020) 110239.
1269 <https://doi.org/10.1016/j.eurpolymj.2020.110239>.
- 1270 [114] E. Cinan, S. Cesur, M. Erginer Haskoylu, O. Gunduz, E. Toksoy Öner, Resveratrol-loaded
1271 levan nanoparticles produced by electrohydrodynamic atomization technique, *Nanomaterials*
1272 11 (2021) 2582. <https://doi.org/10.3390/nano11102582>.
- 1273 [115] I. Pantelić, M. Lukić, G. Gojgić-Cvijović, D. Jakovljević, I. Nikolić, D.J. Lunter, R. Daniels,
1274 S. Savić, *Bacillus licheniformis* levan as a functional biopolymer in topical drug dosage forms:

1275 From basic colloidal considerations to actual pharmaceutical application, *Eur. J. Pharm. Sci.*
1276 142 (2020) 105109. <https://doi.org/10.1016/j.ejps.2019.105109>.

1277 [116] S.L. Sadhana, K.P. Dharshini, D.R. Devi, V.H.B. Naryanan, B. Veerapandian, R. Luo, J.
1278 Yang, S.R. Shanmugam, V. Ponnusami, M. Brzezinski, Y. Zheng, Investigation of levan-derived
1279 nanoparticles of dolutegravir: A promising approach for the delivery of anti-HIV drug as milk
1280 admixture, *J. Pharm. Sci.* 113 (2024) 2513–2523. <https://doi.org/10.1016/j.xphs.2024.05.019>.

1281 [117] Y.H. Song, H.M. Cho, Y.C. Ryu, B.H. Hwang, J.H. Seo, Electro-sprayable levan-coated
1282 nanoclusters and ultrasound-responsive drug delivery for cancer therapy, *ACS Appl. Mater.*
1283 *Interfaces* 16 (2024) 21509–21521. <https://doi.org/10.1021/acsami.3c18774>.

1284 [118] T. Ho, C. Chang, H. Chan, T. Chung, C. Shu, K. Chuang, T. Duh, M. Yang, Y. Tyan,
1285 Hydrogels: Properties and applications in biomedicine, *Molecules* 27 (2022) 2902.
1286 <https://doi.org/10.3390/molecules27092902>.

1287 [119] Y. Li, X. Ding, H. Hu, F. Xu, Stimulus-responsive polysaccharide-based hydrogels: From
1288 design to biomedical applications, *Precision Med. Eng.* 1 (2024) 100001.
1289 <https://doi.org/10.1016/j.preme.2024.100001>.

1290 [120] I.S. Protsak, Y.M. Morozov, Fundamentals and advances in stimuli-responsive hydrogels
1291 and their applications: A review, *Gels* 11 (2025) 30. <https://doi.org/10.3390/gels11010030>.

1292 [121] M.S. Bostan, M. Senol, T. Cig, I. Peker, A.C. Goren, T. Ozturk, M.S. Eroglu, Controlled
1293 release of 5-aminosalicylic acid from chitosan based pH and temperature sensitive hydrogels,
1294 *Int. J. Biol. Macromol.* 52 (2012) 177–183. <https://doi.org/10.1016/j.ijbiomac.2012.09.018>.

1295 [122] H. Nasution, H. Harahap, N.F. Dalimunthe, M.H.S. Ginting, M. Jaafar, O.O.H. Tan, H.K.
1296 Aruan, A.L. Herfananda, Hydrogel and effects of crosslinking agent on cellulose-based
1297 hydrogels: A review, *Gels* 8 (2022) 568. <https://doi.org/10.3390/gels8090568>.

1298 [123] R.A. Gemeinhart, C.M. Bare, R.T. Haasch, E.J. Gemeinhart, Osteoblast-like cell
1299 attachment to and calcification of novel phosphonate-containing polymeric substrates, *J.*
1300 *Biomed. Mater. Res. Part A* 78A (2006) 433–440. <https://doi.org/10.1002/jbm.a.30788>.

1301 [124] A. Revete, A. Aparicio, B.A. Cisterna, J. Revete, L. Luis, E. Ibarra, E.A.S. González, J.
1302 Molino, D. Reginensi, Advancements in the use of hydrogels for regenerative medicine:
1303 Properties and biomedical applications, *Int. J. Biomater.* 2022 (2022) 1–16.
1304 <https://doi.org/10.1155/2022/3606765>.

1305 [125] S. Dutta, P. Bansal, Hydrogel-based bio-inks: Current progress and future directions in
1306 3D printing, *Indian J. Chem. Technol.* (2025). <https://doi.org/10.56042/ijct.v32i1.12274>.

1307 [126] F. Ali, I. Khan, J. Chen, K. Akhtar, E.M. Bakhsh, S.B. Khan, Emerging fabrication
1308 strategies of hydrogels and its applications, *Gels* 8 (2022) 205.
1309 <https://doi.org/10.3390/gels8040205>.

1310 [127] M.P. Ferraz, An overview on the big players in bone tissue engineering: Biomaterials,
1311 scaffolds and cells, *Int. J. Mol. Sci.* 25(7) (2024) 3836. <https://doi.org/10.3390/ijms25073836>.

1312 [128] S. Pramanik, S. Kharche, N. More, D. Ranglani, G. Singh, G. Kapusetti, Natural
1313 biopolymers for bone tissue engineering: A brief review, *Eng. Regener.* 4(2) (2023) 193–204.
1314 <https://doi.org/10.1016/j.engreg.2022.12.002>.

1315 [129] C. Ding, X. Liu, S. Zhang, S. Sun, J. Yang, G. Chai, N. Wang, S. Ma, Q. Ding, W. Liu,
1316 Multifunctional hydrogel bioscaffolds based on polysaccharide to promote wound healing: A

- 1317 review, Int. J. Biol. Macromol. 259 (2024) 129356.
1318 <https://doi.org/10.1016/j.ijbiomac.2024.129356>.
- 1319 [130] G. Sandri, S. Rossi, M.C. Bonferoni, C. Caramella, F. Ferrari, Electrospinning
1320 technologies in wound dressing applications, in: *Therapeutic Dressings and Wound Healing*
1321 *Applications*, Wiley, 2020, pp. 315–336. <https://doi.org/10.1002/9781119433316.ch14>.
- 1322 [131] M.G. Nur, M. Rahman, T.M. Dip, M.H. Hossain, N.B. Hossain, S. Baratchi, R. Padhye, S.
1323 Houshyar, Recent advances in bioactive wound dressings, *Wound Repair Regen.* 33(1)
1324 (2024). <https://doi.org/10.1111/wrr.13233>.
- 1325 [132] M. Farahani, A. Shafiee, Wound healing: From passive to smart dressings, *Adv.*
1326 *Healthcare Mater.* 10(16) (2021). <https://doi.org/10.1002/adhm.202100477>.
- 1327 [133] S. Kaya, S. Derman, Properties of ideal wound dressing, *Ankara Univ. Eczacilik Fak.*
1328 *Dergisi* 47(3) (2023) 5. <https://doi.org/10.33483/jfpau.1253376>.
- 1329 [134] R. Hama, J.W. Reinhardt, A. Ulziibayar, T. Watanabe, J. Kelly, T. Shinoka, Recent tissue
1330 engineering approaches to mimicking the extracellular matrix structure for skin regeneration,
1331 *Biomimetics* 8(1) (2023) 130. <https://doi.org/10.3390/biomimetics8010130>.
- 1332 [135] A. Gaspar-Pintiliescu, A. Stanciuc, O. Craciunescu, Natural composite dressings based
1333 on collagen, gelatin and plant bioactive compounds for wound healing: A review, *Int. J. Biol.*
1334 *Macromol.* 138 (2019) 854–865. <https://doi.org/10.1016/j.ijbiomac.2019.07.155>.
- 1335 [136] J. Su, J. Li, J. Liang, K. Zhang, J. Li, Hydrogel preparation methods and biomaterials for
1336 wound dressing, *Life* 11(10) (2021) 1016. <https://doi.org/10.3390/life11101016>.
- 1337 [137] M.L. Del Prado-Audelo, I.H. Caballero-Florán, N. Mendoza-Muñoz, D. Giraldo-Gomez,
1338 J. Sharifi-Rad, J.K. Patra, M. González-Torres, B. Florán, H. Cortes, G. Leyva-Gómez, Current
1339 progress of self-healing polymers for medical applications in tissue engineering, *Iran. Polym.*
1340 *J.* 31 (2022) 7–29. <https://doi.org/10.1007/s13726-021-00943-8>.
- 1341 [138] B.F. Far, L. Jameie, P. Taromi, R. Nahavndi, E. Jamshidi, Dermal and oral wound healing,
1342 in: *ACS Symp. Ser.* (2025) 297–329. <https://doi.org/10.1021/bk-2025-1497.ch009>.
- 1343 [139] C. Sturzoiu, M. Petrescu, B. Galateanu, M. Anton, C. Nica, G.I. Simionca, G. Stoian,
1344 *Zymomonas mobilis* levan is involved in metalloproteinases activation in healing of wounded
1345 and burned tissues, *Sci. Pap. Anim. Sci. Biotechnol.* 44(1) (2011) 453–458.
- 1346 [140] M. Erginer, B. Gökalsin, S. Tornaci, C. Sesal, E.T. Öner, Exploring the potential of
1347 *Halomonas* levan and its derivatives as active ingredients in cosmeceutical and skin
1348 regenerating formulations, *Int. J. Biol. Macromol.* 240 (2023) 124418.
1349 <https://doi.org/10.1016/j.ijbiomac.2023.124418>.
- 1350 [141] E. Peled, S. Tornaci, I. Zlotver, A. Dubnika, E.T. Öner, A. Sosnik, First transcriptomic
1351 insight into the reprogramming of human macrophages by levan-type fructans, *Carbohydr.*
1352 *Polym.* 320 (2023) 121203. <https://doi.org/10.1016/j.carbpol.2023.121203>.
- 1353 [142] A. Haddar, E. Ben Ayed, A. Sila, J.-L. Putaux, A. Bougatef, S. Boufi, Hybrid levan–
1354 Ag/AgCl nanoparticles produced by UV-irradiation: Properties, antibacterial efficiency, and
1355 application in bioactive poly(vinyl alcohol) films, *RSC Adv.* 11(62) (2021) 38990–39003.
1356 <https://doi.org/10.1039/d1ra07852f>.
- 1357 [143] N. Ismayilova, M.K. Zia, H.S. Akkaya, S. Ulag, Y. Guldorum, E.T. Öner, E. Ince,
1358 Development and Evaluation of Fucoidan-Loaded Electrospun Polyvinyl Alcohol/Levan

- 1359 Nanofibers for Wound Dressing Applications, *Biomimetics* 9(9) (2024) 1–14.
1360 <https://doi.org/10.3390/biomimetics9090508>.
- 1361 [144] O.M. Bondarenko, A. Ivask, A. Kahru, H. Vija, T. Titma, M. Visnapuu, U. Joost, K. Pudova,
1362 S. Adamberg, T. Visnapuu, T. Alamäe, Bacterial polysaccharide levan as stabilizing, non-toxic
1363 and functional coating material for microelement-nanoparticles, *Carbohydr. Polym.* 136 (2016)
1364 710–720. <https://doi.org/10.1016/j.carbpol.2015.09.093>.
- 1365 [145] Á. González-Garcinuño, R. Masa, M. Hernández, Á. Domínguez, A. Taberner, E.M. Del
1366 Valle, Levan-Capped Silver Nanoparticles for Bactericidal Formulations: Release and Activity
1367 Modelling, *Int. J. Mol. Sci.* 20(6) (2019) 1502. <https://doi.org/10.3390/ijms20061502>.
- 1368 [146] R.D. Kasai, D. Radhika, S. Archana, H. Shanavaz, R. Koutavarapu, D.Y. Lee, J. Shim, A
1369 review on hydrogels classification and recent developments in biomedical applications, *Int. J.*
1370 *Polym. Mater. Polym. Biomater.* 72(13) (2022) 1059–1069.
1371 <https://doi.org/10.1080/00914037.2022.2075872>.
- 1372 [147] S. Mitura, A. Sionkowska, A. Jaiswal, Biopolymers for hydrogels in cosmetics: review, *J.*
1373 *Mater. Sci. Mater. Med.* 31 (2020) 50. <https://doi.org/10.1007/s10856-020-06390-w>.
- 1374 [148] S.K. Bhatia, P.S. Panesar, S. Mehariya, Microbial Exopolysaccharides: Production and
1375 applications, CRC Press (2024).
- 1376 [149] J.K. Liu, Natural products in cosmetics, *Nat. Prod. Bioprospect.* 12(1) (2022) 40.
- 1377 [150] M.E. Hasköylü, E.T. Öner, Fructans in Personal Care Products, in: *The Book of Fructans*
1378 (2023) 275–294. Academic Press.
- 1379 [151] K.H. Kim, C.B. Chung, Y.H. Kim, K.S. Kim, C.S. Han, C.H. Kim, Cosmeceutical properties
1380 of levan produced by *Zymomonas mobilis*, *J. Cosmet. Sci.* 56 (2005) 395–406.
- 1381 [152] M.E. Parente, A.O. Andrade, G. Ares, F. Russo, Á. Jiménez-Kairuz, Bioadhesive
1382 hydrogels for cosmetic applications, *Int. J. Cosmet. Sci.* 37 (2015) 511–518.
1383 <https://doi.org/10.1111/ics.12227>.
- 1384 [153] E. Manousi, A. Chatzitaki, E. Vakirlis, C. Karavasili, D.G. Fatouros, Development and *in*
1385 *vivo* evaluation of 3D printed hydrogel patches for personalized cosmetic use based on skin
1386 type, *J. Drug Deliv. Sci. Technol.* 92 (2023) 105306.
1387 <https://doi.org/10.1016/j.jddst.2023.105306>.
- 1388 [154] M.A. Waqar, N. Mubarak, A.M. Khan, F. Shaheen, M.A. Mustafa, T. Riaz, Recent
1389 advances in polymers, preparation techniques, applications, and future perspectives of
1390 hydrogels, *Int. J. Polym. Mater.* 1–20 (2024). <https://doi.org/10.1080/00914037.2024.2335163>.
- 1391 [155] M. Tamimi, S. Bagheri-Khoulenjani, R. Narain, S. Rajabi, Hydrogels for wound dressing,
1392 in: Elsevier eBooks (2025) 531–562. <https://doi.org/10.1016/b978-0-443-16168-1.00019-2>.
- 1393 [156] Q. Wu, N. Cheng, D. Fang, H. Wang, F. Rahman, H. Hao, Y. Zhang, Recent advances
1394 on application of polysaccharides in cosmetics, *Deleted J.* 1(1) (2024) 100004.
1395 <https://doi.org/10.1016/j.jdsct.2024.100004>.
- 1396 [157] B.G. Prajapati, S.R. Shah, S. Singh, Natural Biopolymer, Smart Ways of Biomaterial
1397 Designing Synthesis and Characterization: Prospects of Enhanced Application From Labs to
1398 Clinics, 63 (2025).

- 1399 [158] K.H. Kim, C.B. Chung, Y.H. Kim, K.S. Kim, C.S. Han, C.H. Kim, Cosmeceutical properties
1400 of levan produced by *Zymomonas mobilis*, *Int. J. Cosmet. Sci.* 28(3) (2006) 231.
1401 <https://doi.org/10.1111/j.1467-2494.2006.00314.2.x>.
- 1402 [159] F. Masayo, T. Takayuki, Beautifully Whitening Agent, JP2006052146A (2006), Patent,
1403 February 23.
- 1404 [160] A. Lewińska, M. Domżał-Kędzia, M. Łukaszewicz, Self-assembly levan, as a natural
1405 active bio-nanocarrier, *Sustainable Chem. Pharm.* 31 (2022) 100936.
1406 <https://doi.org/10.1016/j.scp.2022.100936>.
- 1407 [161] M. Domżał-Kędzia, A. Lewińska, A. Jaromin, M. Weselski, R. Pluskota, M. Łukaszewicz,
1408 Fermentation parameters and conditions affecting levan production and its potential
1409 applications in cosmetics, *Bioorg. Chem.* 93 (2019) 102787.
1410 <https://doi.org/10.1016/j.bioorg.2019.02.012>.
- 1411 [162] R.T. Da Silva, G.T. Bersaneti, B.G. Bigotto, V.A.I. Silveira, A.A.S.G. Lonni, D. Borsato,
1412 M.A.P.C. Celligoi, Development of a facial biocosmetic containing levan, almond, and
1413 cinnamon oils with antioxidant and moisturizing properties, *Acta Sci. Biol. Sci.* 44 (2022)
1414 e58869. <https://doi.org/10.4025/actasciobiolsci.v44i1.58869>.
- 1415 [163] H. Ko, B.H. Sung, M. Kim, H.J. Park, J. Sohn, J. Bae, Dual-functional carboxymethyl
1416 levan-based protein carrier for cosmeceutical application of human epidermal growth factor,
1417 *Int. J. Biol. Macromol.* 229 (2022) 181–187. <https://doi.org/10.1016/j.ijbiomac.2022.12.278>.
- 1418 [164] M.A. Seeger, A.S. Paller, The roles of growth factors in keratinocyte migration, *Adv.*
1419 *Wound Care* 4(4) (2014) 213–224. <https://doi.org/10.1089/wound.2014.0540>.
- 1420 [165] J.K. Helenas, G.T. Bersaneti, R.T. Da Silva, B.G. Bigotto, A.A.S.G. Lonni, D. Borsato, C.
1421 Baldo, M.A.P.C. Celligoi, Development of facial cosmetic formulations using microbial levan in
1422 association with plant-derived compounds using simple lattice design, *Braz. Arch. Biol.*
1423 *Technol.* 66 (2022). <https://doi.org/10.1590/1678-4324-2023220275>.
- 1424 [166] T. Wasilewski, A. Seweryn, D. Pannert, K. Kierul, M. Domżał-Kędzia, Z. Hordyjewicz-
1425 Baran, M. Łukaszewicz, A. Lewińska, Application of Levan-Rich Digestate Extract in the
1426 Production of Safe-to-Use and Functional Natural Body Wash Cosmetics, *Molecules* 27(9)
1427 (2022) 2793. <https://doi.org/10.3390/molecules27092793>.
- 1428 [167] A. Fallacara, E. Durini, S. Vertuani, S. Manfredini, Hyaluronic acid fillers in soft tissue
1429 regeneration, *Facial Plast. Surg.* 33(01) (2017) 87–96. <https://doi.org/10.1055/s-0036-1597685>.
- 1430
- 1431 [168] D. Hamrah, B. Aleman, Injectable soft tissue fillers and their use in facial rejuvenation,
1432 in: Springer eBooks (2024) 301–313. https://doi.org/10.1007/978-3-031-47307-4_42.
- 1433 [169] D. Cassuto, G. Bellia, C. Schiraldi, An overview of soft tissue fillers for cosmetic
1434 dermatology: From filling to regenerative medicine, *Clin. Cosmet. Investig. Dermatol.* 14 (2021)
1435 1857–1866. <https://doi.org/10.2147/ccid.s276676>.
- 1436 [170] X. He, X. Gao, Y. Guo, W. Xie, Research progress on bioactive factors against skin aging,
1437 *Int. J. Mol. Sci.* 25(7) (2024) 3797. <https://doi.org/10.3390/ijms25073797>.
- 1438 [171] A.M. Romyantsev, A. Pan, S.G. Roy, P. De, E.Y. Kramarenko, Polyelectrolyte gel swelling
1439 and conductivity vs counterion type, cross-linking density, and solvent polarity,
1440 *Macromolecules* 49(17) (2016) 6630–6643. <https://doi.org/10.1021/acs.macromol.6b00911>.

- 1441 [172] N. Agarwal, N. Jyoti, M. Thakur, B.B. Mishra, S.P. Singh, Preparation and characterization
1442 of biodegradable films based on levan polysaccharide blended with gellan gum, Environ.
1443 Technol. Innov. 31 (2023) 103231. <https://doi.org/10.1016/j.eti.2023.103231>.
- 1444 [173] Y. Wang, Z. Zhou, Y. Han, Levan-chitosan blend films: Preparation, structural, physical
1445 properties and application in pork packaging, Int. J. Biol. Macromol. 217 (2022) 624–632.
1446 <https://doi.org/10.1016/j.ijbiomac.2022.07.049>.
- 1447 [174] M. Xu, L. Zhang, Y. Zeng, Z. Zhou, Y. Han, Preparation and characterization of Levan
1448 composite film incorporating vanillin for use as a potential edible coating for peony seed oil,
1449 Int. J. Biol. Macromol. (2024) 138732. <https://doi.org/10.1016/j.ijbiomac.2024.138732>.
- 1450 [175] W. Hong, H. Xiao, Z. Zhang, M. Xu, Z. Yi, Z. Zhou, Y. Han, A composite film of oxidized
1451 levan crosslinked with gelatin: Strong hydrophobic and mechanical properties and effective
1452 preservation of fresh mozzarella cheese, Int. J. Biol. Macromol. 284 (2024) 137701.
1453 <https://doi.org/10.1016/j.ijbiomac.2024.137701>.
- 1454 [176] C.S. Hundschell, J. Brühhan, T. Anzmann, R. Kohlus, A.M. Wagemans, Influence of levan
1455 on the thermally induced gel formation of β -lactoglobulin, Gels 8(4) (2022) 228.
1456 <https://doi.org/10.3390/gels8040228>.
- 1457 [177] T. Ua-Arak, F. Jakob, R.F. Vogel, Fermentation pH modulates the size distributions and
1458 functional properties of *Gluconobacter albidus* TMW 2.1191 levan, Front. Microbiol. 8 (2017)
1459 807. <https://doi.org/10.3389/fmicb.2017.00807>.
- 1460 [178] G. Mummaleti, C. Sarma, S.K. Kalakandan, H. Gazula, V. Sivanandham, A. Anandharaj,
1461 Characterization of levan produced from coconut inflorescence sap using *Bacillus subtilis* and
1462 its application as a sweetener, LWT 154 (2021) 112697.
1463 <https://doi.org/10.1016/j.lwt.2021.112697>.
- 1464 [179] F. Ciuffarin, S. Plazzotta, K. Rondou, F. Van Bockstaele, K. Dewettinck, L. Manzocco, S.
1465 Calligaris, Oil structuring using whey protein-based cryogel particles: Effect of gelation pH and
1466 feasibility as an ingredient in low-saturated fat cocoa spreads, Food Res. Int. 196 (2024)
1467 115029. <https://doi.org/10.1016/j.foodres.2024.115029>.
- 1468 [180] S. Plazzotta, S. Calligaris, L. Manzocco, Innovative bioaerogel-like materials from fresh-
1469 cut salad waste via supercritical-CO₂-drying, Innov. Food Sci. Emerg. Technol. 47 (2018) 485–
1470 492.
- 1471 [181] L. De Berardinis, S. Plazzotta, M. Magnan, L. Manzocco, Hybrid aerogels of spirulina
1472 and whey proteins as novel cellular solids, LWT 213 (2024) 117078.
1473 <https://doi.org/10.1016/j.lwt.2024.117078>.
- 1474 [182] B.H. Elwakil, M.H. Elsabrouty, N. Yousef, M. El-Khatib, Functionalized magnetic
1475 nanosystems for the detection and control of infectious diseases, Elsevier eBooks (2024) 475–
1476 503. <https://doi.org/10.1016/b978-0-443-19012-4.00017-5>.
- 1477 [183] S. Azinheiro, K. Kant, M. Shahbazi, A. Garrido-Maestu, M. Prado, L. Dieguez, A smart
1478 microfluidic platform for rapid multiplexed detection of foodborne pathogens, Food Control 114
1479 (2020) 107242. <https://doi.org/10.1016/j.foodcont.2020.107242>.
- 1480 [184] S. David, R. Munteanu, A. Tițoiu, I. Petcu, I. Cernat, C. Leancu, M. Gheorghiu, E.
1481 Gheorghiu, Direct, rapid detection of pathogens from urine samples, Materials 15(21) (2022)
1482 7640. <https://doi.org/10.3390/ma15217640>.

- 1483 [185] S. Wu, J. Chen, H. Wu, Biofabricating a silk scaffold as a functional microbial trap, ACS
1484 Biomater. Sci. Eng. 6(12) (2020) 7041–7050.
1485 <https://doi.org/10.1021/acsbiomaterials.0c01232>.
- 1486 [186] K. Kato, A. Ishiwa, The role of carbohydrates in infection strategies of enteric pathogens,
1487 Trop. Med. Health 43(1) (2014) 41–52. <https://doi.org/10.2149/tmh.2014-25>.
- 1488 [187] X. Li, P. Wu, G.F. Gao, S. Cheng, Carbohydrate-functionalized chitosan fiber for influenza
1489 virus capture, Biomacromolecules 12(11) (2011) 3962–3969.
1490 <https://doi.org/10.1021/bm200970x>.
- 1491 [188] Z. Qi, P. Bharate, C. Lai, B. Ziem, C. Böttcher, A. Schulz, F. Beckert, B. Hatting, R.
1492 Mülhaupt, P.H. Seeberger, R. Haag, Multivalency at interfaces: Supramolecular carbohydrate-
1493 functionalized graphene derivatives for bacterial capture, release, and disinfection, Nano Lett.
1494 15(9) (2015) 6051–6057. <https://doi.org/10.1021/acs.nanolett.5b02256>.
- 1495 [189] J.K. Ajish, P.N. Rao, S. Bhakta, S. Kota, K.A. Kumar, Glycosylated stimuli-responsive
1496 polyacrylamide microspheres with in-situ formed AgNPs for bacterial capture, detection and
1497 killing, Colloids Surf. A Physicochem. Eng. Asp. 696 (2024) 134305.
1498 <https://doi.org/10.1016/j.colsurfa.2024.134305>.
- 1499 [190] D. Chelazzi, P. Baglioni, From nanoparticles to gels: A breakthrough in art conservation
1500 science, Langmuir 39(31) (2023) 10744–10755.
1501 <https://doi.org/10.1021/acs.langmuir.3c01324>.
- 1502 [191] N. Khaksar-Baghan, A. Koochakzai, Y. Hamzavi, An overview of gel-based cleaning
1503 approaches for art conservation, Heritage Sci. 12(1) (2024). [https://doi.org/10.1186/s40494-](https://doi.org/10.1186/s40494-024-01369-0)
1504 [024-01369-0](https://doi.org/10.1186/s40494-024-01369-0).
- 1505 [192] A. Burnstock, R. Wolbers, Cleaning painted surfaces: Aqueous methods, Stud. Conserv.
1506 46(3) (2001) 221. <https://doi.org/10.2307/1506812>.
- 1507 [193] E. Carretti, M. Bonini, L. Dei, B.H. Berrie, L.V. Angelova, P. Baglioni, R.G. Weiss, New
1508 frontiers in materials science for art conservation: Responsive gels and beyond, Acc. Chem.
1509 Res. 43(6) (2010) 751–760. <https://doi.org/10.1021/ar900282h>.
- 1510 [194] D. Chelazzi, G. Poggi, Y. Jaidar, N. Toccafondi, R. Giorgi, P. Baglioni, Hydroxide
1511 nanoparticles for cultural heritage: Consolidation and protection of wall paintings and
1512 carbonate materials, J. Colloid Interface Sci. 392 (2012) 42–49.
1513 <https://doi.org/10.1016/j.jcis.2012.09.069>.
- 1514 [195] D. Chelazzi, R. Giorgi, P. Baglioni, Microemulsions, micelles, and functional gels: How
1515 colloids and soft matter preserve works of art, Angew. Chem. Int. Ed. 57(25) (2017) 7296–
1516 7303. <https://doi.org/10.1002/anie.201710711>.
- 1517 [196] G. Infurna, G. Cavallaro, G. Lazzara, S. Milioto, N.T. Dintcheva, Bionanocomposite films
1518 containing halloysite nanotubes and natural antioxidants with enhanced performance and
1519 durability as promising materials for cultural heritage protection, Polymers 12(9) (2020) 1973.
1520 <https://doi.org/10.3390/polym12091973>.
- 1521 [197] C. Cianci, D. Chelazzi, G. Poggi, F. Modi, R. Giorgi, M. Laurati, Hybrid fibroin-
1522 nanocellulose composites for the consolidation of aged and historical silk, Colloids Surf. A
1523 Physicochem. Eng. Asp. 634 (2021) 127944. <https://doi.org/10.1016/j.colsurfa.2021.127944>.

1524 [198] C.H.M. Camargos, G. Poggi, D. Chelazzi, P. Baglioni, C.A. Rezende, Protective coatings
1525 based on cellulose nanofibrils, cellulose nanocrystals, and lignin nanoparticles for the
1526 conservation of cellulosic artifacts, *ACS Appl. Nano Mater.* 5(9) (2022) 13245–13259.
1527 <https://doi.org/10.1021/acsanm.2c02968>.

1528 [199] S. Croll, Surface roughness profile and its effect on coating adhesion and corrosion
1529 protection: A review, *Prog. Org. Coat.* 148 (2020) 105847.
1530 <https://doi.org/10.1016/j.porgcoat.2020.105847>.

1531 [200] Y. Dong, M. Ghasemzadeh, Z. Khorsandi, R. Sheibani, M. Nasrollahzadeh, Starch-based
1532 hydrogels for environmental applications: A review, *Int. J. Biol. Macromol.* 269 (2024) 131956.
1533 <https://doi.org/10.1016/j.ijbiomac.2024.131956>.

1534 [201] P. Phengnoi, K. Thongmee, S. Tiptipakorn, B. Boekfa, K. Kuttitawong, Biodegradation of
1535 levan polymer / poly(lactic acid) (PLA) blend, *IOP Conf. Ser. Mater. Sci. Eng.* 526 (2019)
1536 012025. <https://doi.org/10.1088/1757-899X/526/1/012025>.

1537 [202] Z.-Z. Yuan, Y.-Z. Fan, S.-J. Cheng, F.-J. Wei, J. Gao, C.-X. Wang, B.-S. Song, S.-L. Tan,
1538 S.-L. Gao, J.-J. Kang, Y. Liu, S.-H. Li, A bibliometric analysis of hydrogel research in various
1539 fields: The trends and evolution of Hydrogel Application, *J. Nanobiotechnol.* 23(1) (2025)
1540 <https://doi.org/10.1186/s12951-025-03090-x>.

1541 [203] M.C. Catoira, J. González-Payo, L. Fusaro, et al., Natural hydrogels R&D process:
1542 technical and regulatory aspects for industrial implementation, *J. Mater. Sci. Mater. Med.* 31
1543 (2020) 64. <https://doi.org/10.1007/s10856-020-06401-w>.

1544 [204] J.R. Clegg, K. Adebowale, Z. Zhao, S. Mitragotri, Hydrogels in the clinic: An update,
1545 *Bioeng. Transl. Med.* 9 (2024) e10680. <https://doi.org/10.1002/btm2.10680>.

1546

1547




Figure 1. Bioactivities of Levan polymer (Created with Canva.com)




Figure 2. Physically and chemically crosslinked levan-based hydrogels (Created with Canva.com)




Figure 3. Classification of Levan-based hydrogels (Created with Canva.com)

Table 1. Hydrogels of Levan

Source of Levan	Hydrogel structure	Application	Reference
<i>Bacillus subtilis</i>	Levan was methacrylated and then photo-polymerized	Mechanically stable, slightly degradable and cytocompatible gels suitable as starting materials in common additive manufacturing processes like bioprinting or stereolithography	[34]
	Levan was oxidized with sodium metaperiodate and then mixed with chitosan for the gelation	Bio- and hemo-compatible drug delivery system and wound dressing material with sustained curcumin release	[36]
<i>Erwinia herbicola</i>	Levan/gellan blends crosslinked ionically with NaOH and CaCl ₂	Shear-thinning properties showed high potential of levan-gellan hydrogel for its use as an injectable material in medical and cosmetic industries	[29]
<i>Halomonas elongata</i>	BDDE crosslinked levan hydrogels loaded with liposomes containing <i>Plantago lanceolata</i> L. Extracts	Biocompatible and biodegradable levan-based herbal liposome-loaded hydrogels for acute wound healing	[39]
<i>Halomonas smyrnensis</i>	Hydrolyzed, carboxylated and then methacrylated levan crosslinked with <i>N</i> -isopropyl acrylamide (NIPA)	Thermoresponsive levan/pNIPA hydrogels for the controlled release of 5-ASA for the treatment of inflammatory bowel diseases	[32]
	BDDE crosslinked levan hydrogels	Amphotericin B release for exerting antifungal activity against <i>Candida albicans</i>	[37]
	Hydrolyzed and phosphonated levan crosslinked with BDDE	Controlled release of resveratrol for skin tissue engineering	[38]
	Levan, acrylamide and methylene-bis-acrylamide solution crosslinked with	IPN-based Levan/PA hydrogels for conservation of cultural heritage	[41]

	BDDE and Ammonium persulfate		
	Hydrolyzed levan cross-linked with BDDE	Levan hydrogels for guided bone regeneration and bone tissue engineering	[42]
	Pluronic F127/CMC/levan mixture	Injectable hydrogels to be used as an alternative to hyaluronic acid (HA) based dermal fillers in soft tissue augmentation	[27]
	Hydroxyapatite containing Pluronic F127/CMC/levan hydrogels	<i>In vivo</i> stability of the composite hydrogel was enhanced with high anti-wrinkle efficacy maintained for 8 weeks and showing high collagen production	[28]
Zymomonas mobilis	Levan/PVA crosslinked with glutaldehyde	Virus capture efficiency of levan-PVA hydrogels was higher than that of commercial cotton swabs	[35]
	Catechol conjugated carboxymethylated levan hydrogels via oxidation-induced catechol/quinone (covalent) and Fe ³⁺ -(non-covalent) mediated coordinative crosslinking	Levan-catechol conjugate hydrogel for wound healing applications	[33]